{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "%load_ext autoreload\n",
    "%autoreload 2"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "import sys\n",
    "import requests\n",
    "import time\n",
    "import math\n",
    "import hashlib\n",
    "from lxml import html\n",
    "import pickle\n",
    "import pandas as pd\n",
    "import numpy as np\n",
    "from bs4 import BeautifulSoup \n",
    "\n",
    "sys.setrecursionlimit(25000)\n",
    "# sys.path.append('../python')\n",
    "# import monitor_url as murl"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Company</th>\n",
       "      <th>Yahoo Listed Co.</th>\n",
       "      <th>Symbol</th>\n",
       "      <th>Exchange</th>\n",
       "      <th>Market Cap</th>\n",
       "      <th>Company Size</th>\n",
       "      <th>Is American</th>\n",
       "      <th>Home URL</th>\n",
       "      <th>Press Release URL</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>AstraZeneca</td>\n",
       "      <td>AstraZeneca PLC</td>\n",
       "      <td>AZN</td>\n",
       "      <td>NYSE</td>\n",
       "      <td>$140,554,649,600</td>\n",
       "      <td>v-large</td>\n",
       "      <td>Y</td>\n",
       "      <td>http://www.astrazeneca.com</td>\n",
       "      <td>https://www.astrazeneca.com/media-centre/press...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>CanSino Biological Inc.</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Beijing Institute of Biotechnology</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Moderna</td>\n",
       "      <td>Moderna, Inc.</td>\n",
       "      <td>MRNA</td>\n",
       "      <td>NASDAQ</td>\n",
       "      <td>$21,742,589,952</td>\n",
       "      <td>medium</td>\n",
       "      <td>Y</td>\n",
       "      <td>http://www.modernatx.com</td>\n",
       "      <td>https://investors.modernatx.com/news-releases/</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NIAID</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Wuhan Institute of Biological Products</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Sinopharm</td>\n",
       "      <td>Sinopharm Group Co., Ltd.</td>\n",
       "      <td>SHTDY</td>\n",
       "      <td>OTC Markets</td>\n",
       "      <td>$8,092,427,776</td>\n",
       "      <td>small</td>\n",
       "      <td>N</td>\n",
       "      <td>http://www.sinopharmgroup.com.cn</td>\n",
       "      <td>http://ir.sinopharmgroup.com.cn/</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Beijing Institute of Biological Products</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Sinovac</td>\n",
       "      <td>Sinovac Biotech Ltd.</td>\n",
       "      <td>SVA</td>\n",
       "      <td>NASDAQ</td>\n",
       "      <td>$460,249,280</td>\n",
       "      <td>small</td>\n",
       "      <td>Y</td>\n",
       "      <td>http://www.sinovacbio.com</td>\n",
       "      <td>http://www.sinovacbio.com/?optionid=754</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>Novavax</td>\n",
       "      <td>Novavax, Inc.</td>\n",
       "      <td>NVAX</td>\n",
       "      <td>NASDAQ</td>\n",
       "      <td>$4,791,271,936</td>\n",
       "      <td>small</td>\n",
       "      <td>Y</td>\n",
       "      <td>http://www.novavax.com</td>\n",
       "      <td>https://ir.novavax.com/press-releases</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>BioNTech</td>\n",
       "      <td>BioNTech SE</td>\n",
       "      <td>BNTX</td>\n",
       "      <td>NASDAQ</td>\n",
       "      <td>$14,348,370,944</td>\n",
       "      <td>medium</td>\n",
       "      <td>Y</td>\n",
       "      <td>http://www.biontech.de</td>\n",
       "      <td>https://investors.biontech.de/press-releases/</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>Fosun Pharma</td>\n",
       "      <td>Shanghai Fosun Pharmaceutical (Group) Co., Ltd.</td>\n",
       "      <td>SFOSF</td>\n",
       "      <td>OTC Markets</td>\n",
       "      <td>$11,733,709,824</td>\n",
       "      <td>medium</td>\n",
       "      <td>N</td>\n",
       "      <td>http://www.fosunpharma.com</td>\n",
       "      <td>https://www.fosunpharma.com/en/news/mediaRepor...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Pfizer Inc.</td>\n",
       "      <td>PFE</td>\n",
       "      <td>NYSE</td>\n",
       "      <td>$191,697,174,528</td>\n",
       "      <td>v-large</td>\n",
       "      <td>Y</td>\n",
       "      <td>http://www.pfizer.com</td>\n",
       "      <td>https://www.pfizer.com/news/press-release/pres...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>Inovio Pharmaceuticals</td>\n",
       "      <td>Inovio Pharmaceuticals, Inc.</td>\n",
       "      <td>INO</td>\n",
       "      <td>NASDAQ</td>\n",
       "      <td>$3,391,159,296</td>\n",
       "      <td>small</td>\n",
       "      <td>Y</td>\n",
       "      <td>http://www.inovio.com</td>\n",
       "      <td>http://ir.inovio.com/news-releases/default.aspx</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>Genexine Consortium</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>Gamaleya Research Institute</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>Clover Biopharmaceuticals Inc.</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>GSK</td>\n",
       "      <td>GlaxoSmithKline plc</td>\n",
       "      <td>GSK</td>\n",
       "      <td>NYSE</td>\n",
       "      <td>$103,150,575,616</td>\n",
       "      <td>v-large</td>\n",
       "      <td>Y</td>\n",
       "      <td>http://www.gsk.com</td>\n",
       "      <td>https://www.gsk.com/en-gb/media/press-releases/</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>Dynavax</td>\n",
       "      <td>Dynavax Technologies Corporation</td>\n",
       "      <td>DVAX</td>\n",
       "      <td>NASDAQ</td>\n",
       "      <td>$943,261,312</td>\n",
       "      <td>small</td>\n",
       "      <td>Y</td>\n",
       "      <td>http://www.dynavax.com</td>\n",
       "      <td>http://investors.dynavax.com/press-releases</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>Anhui Zhifei Longcom Biopharmaceutical</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>Curevac</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>Walvax Biotech.</td>\n",
       "      <td>Walvax Biotechnology Co., Ltd.</td>\n",
       "      <td>300142.SZ</td>\n",
       "      <td>Shenzhen</td>\n",
       "      <td>$79,193,530,368</td>\n",
       "      <td>v-large</td>\n",
       "      <td>N</td>\n",
       "      <td>http://www.walvax.com</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                     Company  \\\n",
       "0                                AstraZeneca   \n",
       "1                    CanSino Biological Inc.   \n",
       "2         Beijing Institute of Biotechnology   \n",
       "3                                    Moderna   \n",
       "4                                      NIAID   \n",
       "5     Wuhan Institute of Biological Products   \n",
       "6                                  Sinopharm   \n",
       "7   Beijing Institute of Biological Products   \n",
       "8                                    Sinovac   \n",
       "9                                    Novavax   \n",
       "10                                  BioNTech   \n",
       "11                              Fosun Pharma   \n",
       "12                                    Pfizer   \n",
       "13                    Inovio Pharmaceuticals   \n",
       "14                       Genexine Consortium   \n",
       "15               Gamaleya Research Institute   \n",
       "16            Clover Biopharmaceuticals Inc.   \n",
       "17                                       GSK   \n",
       "18                                   Dynavax   \n",
       "19    Anhui Zhifei Longcom Biopharmaceutical   \n",
       "20                                   Curevac   \n",
       "21                           Walvax Biotech.   \n",
       "\n",
       "                                   Yahoo Listed Co.     Symbol     Exchange  \\\n",
       "0                                   AstraZeneca PLC        AZN         NYSE   \n",
       "1                                               NaN        NaN          NaN   \n",
       "2                                               NaN        NaN          NaN   \n",
       "3                                     Moderna, Inc.       MRNA       NASDAQ   \n",
       "4                                               NaN        NaN          NaN   \n",
       "5                                               NaN        NaN          NaN   \n",
       "6                         Sinopharm Group Co., Ltd.      SHTDY  OTC Markets   \n",
       "7                                               NaN        NaN          NaN   \n",
       "8                              Sinovac Biotech Ltd.        SVA       NASDAQ   \n",
       "9                                     Novavax, Inc.       NVAX       NASDAQ   \n",
       "10                                      BioNTech SE       BNTX       NASDAQ   \n",
       "11  Shanghai Fosun Pharmaceutical (Group) Co., Ltd.      SFOSF  OTC Markets   \n",
       "12                                      Pfizer Inc.        PFE         NYSE   \n",
       "13                     Inovio Pharmaceuticals, Inc.        INO       NASDAQ   \n",
       "14                                              NaN        NaN          NaN   \n",
       "15                                              NaN        NaN          NaN   \n",
       "16                                              NaN        NaN          NaN   \n",
       "17                              GlaxoSmithKline plc        GSK         NYSE   \n",
       "18                 Dynavax Technologies Corporation       DVAX       NASDAQ   \n",
       "19                                              NaN        NaN          NaN   \n",
       "20                                              NaN        NaN          NaN   \n",
       "21                   Walvax Biotechnology Co., Ltd.  300142.SZ     Shenzhen   \n",
       "\n",
       "          Market Cap Company Size Is American  \\\n",
       "0   $140,554,649,600      v-large           Y   \n",
       "1                NaN          NaN         NaN   \n",
       "2                NaN          NaN         NaN   \n",
       "3    $21,742,589,952       medium           Y   \n",
       "4                NaN          NaN         NaN   \n",
       "5                NaN          NaN         NaN   \n",
       "6     $8,092,427,776        small           N   \n",
       "7                NaN          NaN         NaN   \n",
       "8       $460,249,280        small           Y   \n",
       "9     $4,791,271,936        small           Y   \n",
       "10   $14,348,370,944       medium           Y   \n",
       "11   $11,733,709,824       medium           N   \n",
       "12  $191,697,174,528      v-large           Y   \n",
       "13    $3,391,159,296        small           Y   \n",
       "14               NaN          NaN         NaN   \n",
       "15               NaN          NaN         NaN   \n",
       "16               NaN          NaN         NaN   \n",
       "17  $103,150,575,616      v-large           Y   \n",
       "18      $943,261,312        small           Y   \n",
       "19               NaN          NaN         NaN   \n",
       "20               NaN          NaN         NaN   \n",
       "21   $79,193,530,368      v-large           N   \n",
       "\n",
       "                            Home URL  \\\n",
       "0         http://www.astrazeneca.com   \n",
       "1                                NaN   \n",
       "2                                NaN   \n",
       "3           http://www.modernatx.com   \n",
       "4                                NaN   \n",
       "5                                NaN   \n",
       "6   http://www.sinopharmgroup.com.cn   \n",
       "7                                NaN   \n",
       "8          http://www.sinovacbio.com   \n",
       "9             http://www.novavax.com   \n",
       "10            http://www.biontech.de   \n",
       "11        http://www.fosunpharma.com   \n",
       "12             http://www.pfizer.com   \n",
       "13             http://www.inovio.com   \n",
       "14                               NaN   \n",
       "15                               NaN   \n",
       "16                               NaN   \n",
       "17                http://www.gsk.com   \n",
       "18            http://www.dynavax.com   \n",
       "19                               NaN   \n",
       "20                               NaN   \n",
       "21             http://www.walvax.com   \n",
       "\n",
       "                                    Press Release URL  \n",
       "0   https://www.astrazeneca.com/media-centre/press...  \n",
       "1                                                 NaN  \n",
       "2                                                 NaN  \n",
       "3      https://investors.modernatx.com/news-releases/  \n",
       "4                                                 NaN  \n",
       "5                                                 NaN  \n",
       "6                    http://ir.sinopharmgroup.com.cn/  \n",
       "7                                                 NaN  \n",
       "8             http://www.sinovacbio.com/?optionid=754  \n",
       "9               https://ir.novavax.com/press-releases  \n",
       "10      https://investors.biontech.de/press-releases/  \n",
       "11  https://www.fosunpharma.com/en/news/mediaRepor...  \n",
       "12  https://www.pfizer.com/news/press-release/pres...  \n",
       "13    http://ir.inovio.com/news-releases/default.aspx  \n",
       "14                                                NaN  \n",
       "15                                                NaN  \n",
       "16                                                NaN  \n",
       "17    https://www.gsk.com/en-gb/media/press-releases/  \n",
       "18        http://investors.dynavax.com/press-releases  \n",
       "19                                                NaN  \n",
       "20                                                NaN  \n",
       "21                                                NaN  "
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df = pd.read_csv('../datasets/compiled_company_info.csv')\n",
    "df = df.drop_duplicates()\n",
    "df.head(len(df))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Monitoring for changes\n",
    "~~ As a starting point, looking into leveraging the URLWATCH package:\n",
    "https://github.com/thp/urlwatch ~~\n",
    "\n",
    "~~ To do from scratch, here are some references: ~~\n",
    "- ~~https://chrisalbon.com/python/web_scraping/monitor_a_website/ ~~\n",
    "- ~~https://www.adventuresintechland.com/detect-when-a-webpage-changes-with-python/~~\n",
    "- ~~https://www.codementor.io/@gergelykovcs/how-and-why-i-built-a-simple-web-scrapig-script-to-notify-us-about-our-favourite-food-fcrhuhn45 ~~\n",
    "\n",
    "Went the BeautifulSoup route"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<body class=\"body-sidebars-none nir-node nir-node--type-nir-landing-page nir-node--5816 path-node page-node-type-nir-landing-page\">\n",
      "<div id=\"skip\">\n",
      "<a class=\"visually-hidden focusable skip-link\" href=\"#main-menu\">\n",
      "        Skip to main navigation\n",
      "      </a>\n",
      "</div>\n",
      "<div class=\"dialog-off-canvas-main-canvas\" data-off-canvas-main-canvas=\"\">\n",
      "<div class=\"body-page\">\n",
      "<header class=\"header-v1\" id=\"header\">\n",
      "<div class=\"topbar\">\n",
      "<div class=\"topbar-inner\">\n",
      "<div class=\"container\">\n",
      "<div class=\"content\">\n",
      "<h2 class=\"visually-hidden\">Topbar Nav</h2>\n",
      "<nav aria-labelledby=\"block-topbarmenu-menu\" class=\"topBarMenu block block-menu navigation menu--top-bar-menu\" id=\"block-topbarmenu\" role=\"navigation\">\n",
      "<div class=\"block-content\">\n",
      "<ul class=\"gva_menu\">\n",
      "<li class=\"menu-item menu-item--active-trail\">\n",
      "<a class=\"is-active\" href=\"/investors-media\" target=\"\" title=\"Investors &amp; Media\">Investors &amp; Media</a>\n",
      "</li>\n",
      "<li class=\"menu-item\">\n",
      "<a href=\"https://biontech.de/careers\" target=\"\" title=\"Careers\">Careers</a>\n",
      "</li>\n",
      "<li class=\"menu-item\">\n",
      "<a href=\"https://biontech.de/connect\" target=\"\" title=\"Connect\">Connect</a>\n",
      "</li>\n",
      "</ul>\n",
      "</div>\n",
      "</nav>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "<div class=\"header-main\">\n",
      "<div class=\"container header-content-layout\">\n",
      "<div class=\"header-main-inner p-relative\">\n",
      "<div class=\"row\">\n",
      "<div class=\"col-md-3 col-sm-6 col-xs-8 branding\">\n",
      "<div class=\"clearfix text-formatted field field--name-field-nir-global-block-body field--type-text-long field--label-hidden field__item\"><p>\n",
      "<a class=\"site-branding-logo\" href=\"https://biontech.de/\" rel=\"home\" title=\"Home\">\n",
      "<img alt=\"Home\" data-entity-type=\"file\" data-entity-uuid=\"1837ee17-6885-4f93-a877-76ed83809177\" src=\"/system/files-encrypted/nasdaq_kms/inline-images/logo_0.png\"/></a>\n",
      "</p></div>\n",
      "</div>\n",
      "<div class=\"col-md-9 col-sm-6 col-xs-4 p-static\">\n",
      "<div class=\"header-inner clearfix\">\n",
      "<div class=\"main-menu\">\n",
      "<div class=\"area-main-menu\">\n",
      "<div class=\"area-inner\">\n",
      "<div class=\"search-mobile-cont\">\n",
      "<div class=\"search-input-dup-cont\">\n",
      "<input class=\"earch-input-dup\" id=\"search-input-dup\" placeholder=\"Search\"/>\n",
      "</div>\n",
      "</div>\n",
      "<div class=\"gva-offcanvas-mobile\">\n",
      "<div class=\"close-offcanvas hidden\">\n",
      "<i class=\"gv-icon-8\"></i>\n",
      "</div>\n",
      "<nav aria-labelledby=\"block-gavias-tico-main-menu-menu\" class=\"block block-menu navigation menu--main\" id=\"block-gavias-tico-main-menu\" role=\"navigation\">\n",
      "<h2 class=\"visually-hidden block-title\" id=\"block-gavias-tico-main-menu-menu\">\n",
      "<span>Main navigation</span>\n",
      "</h2>\n",
      "<div class=\"block-content\">\n",
      "<div class=\"gva-navigation\">\n",
      "<div class=\"arr-slide\">\n",
      "<a href=\"#\"> </a>\n",
      "</div>\n",
      "<h2 class=\"visually-hidden\">Main navigation</h2>\n",
      "<ul class=\"clearfix gva_menu gva_menu_main\">\n",
      "<li class=\"menu-item menu-item--expanded gva-mega-menu megamenu menu-grid menu-columns-4 levelOneWithChildren\">\n",
      "<a href=\"https://biontech.de/our-dna/vision\" target=\"\">\n",
      "                Our DNA\n",
      "                <span class=\"icaret nav-plus fa fa-angle-down\"></span>\n",
      "</a>\n",
      "<ul class=\"menu sub-menu\">\n",
      "<li class=\"menu-item menu-item--expanded levelTwoWithChildren\">\n",
      "<a href=\"/\" target=\"\">\n",
      "                Our DNA - Child\n",
      "                <span class=\"icaret nav-plus fa fa-angle-down\"></span>\n",
      "</a>\n",
      "<ul class=\"menu sub-menu\">\n",
      "<li class=\"item-child levelTwoNoChildren\">\n",
      "<a href=\"https://biontech.de/our-dna/vision\" target=\"\">Our vision</a>\n",
      "</li>\n",
      "<li class=\"item-child levelTwoNoChildren\">\n",
      "<a href=\"https://biontech.de/our-dna/leadership\" target=\"\">Leadership</a>\n",
      "</li>\n",
      "<li class=\"item-child levelTwoNoChildren\">\n",
      "<a href=\"https://biontech.de/our-dna/collaborators\" target=\"\">Collaborators</a>\n",
      "</li>\n",
      "<li class=\"item-child levelTwoNoChildren\">\n",
      "<a href=\"https://biontech.de/our-dna/services\" target=\"\">Services</a>\n",
      "</li>\n",
      "<li class=\"item-child levelTwoNoChildren\">\n",
      "<a href=\"https://biontech.de/our-dna/locations\" target=\"\">Our locations</a>\n",
      "</li>\n",
      "</ul>\n",
      "</li>\n",
      "<li class=\"cont-box-article-menu\" id=\"cont-box-article-1\"></li>\n",
      "</ul>\n",
      "</li>\n",
      "<li class=\"menu-item menu-item--expanded gva-mega-menu megamenu menu-grid menu-columns-4 levelOneWithChildren\">\n",
      "<a href=\"https://biontech.de/how-we-translate/biontech-approach\" target=\"\">\n",
      "                How we translate\n",
      "                <span class=\"icaret nav-plus fa fa-angle-down\"></span>\n",
      "</a>\n",
      "<ul class=\"menu sub-menu\">\n",
      "<li class=\"menu-item menu-item--expanded levelTwoWithChildren\">\n",
      "<a href=\"/\" target=\"\">\n",
      "                How we translate - Child\n",
      "                <span class=\"icaret nav-plus fa fa-angle-down\"></span>\n",
      "</a>\n",
      "<ul class=\"menu sub-menu\">\n",
      "<li class=\"item-child levelTwoNoChildren\">\n",
      "<a href=\"https://biontech.de/how-we-translate/biontech-approach\" target=\"\">The BionTech Approach</a>\n",
      "</li>\n",
      "<li class=\"item-child levelTwoNoChildren\">\n",
      "<a href=\"https://biontech.de/how-we-translate/mrna-therapeutics\" target=\"\">mRNA Therapeutics</a>\n",
      "</li>\n",
      "<li class=\"item-child levelTwoNoChildren\">\n",
      "<a href=\"https://biontech.de/how-we-translate/engineered-cell-therapies\" target=\"\">Engineered Cell Therapies</a>\n",
      "</li>\n",
      "<li class=\"item-child levelTwoNoChildren\">\n",
      "<a href=\"https://biontech.de/how-we-translate/antibodies\" target=\"\">Antibodies</a>\n",
      "</li>\n",
      "<li class=\"item-child levelTwoNoChildren\">\n",
      "<a href=\"https://biontech.de/how-we-translate/small-molecule-immunomodulators\" target=\"\">Small Molecule Immunomodulators</a>\n",
      "</li>\n",
      "<li class=\"item-child levelTwoNoChildren\">\n",
      "<a href=\"https://biontech.de/how-we-translate/manufacturing\" target=\"\">Manufacturing</a>\n",
      "</li>\n",
      "<li class=\"item-child levelTwoNoChildren\">\n",
      "<a href=\"https://biontech.de/how-we-translate/intellectual-property\" target=\"\">Intellectual property</a>\n",
      "</li>\n",
      "</ul>\n",
      "</li>\n",
      "<li class=\"cont-box-article-menu\" id=\"cont-box-article-2\"></li>\n",
      "</ul>\n",
      "</li>\n",
      "<li class=\"menu-item menu-item--expanded gva-mega-menu megamenu menu-grid menu-columns-4 levelOneWithChildren\">\n",
      "<a href=\"https://biontech.de/science/individualized-cancer-medicine\" target=\"\">\n",
      "                Science\n",
      "                <span class=\"icaret nav-plus fa fa-angle-down\"></span>\n",
      "</a>\n",
      "<ul class=\"menu sub-menu\">\n",
      "<li class=\"menu-item menu-item--expanded levelTwoWithChildren\">\n",
      "<a href=\"/\" target=\"\">\n",
      "                Science - Child\n",
      "                <span class=\"icaret nav-plus fa fa-angle-down\"></span>\n",
      "</a>\n",
      "<ul class=\"menu sub-menu\">\n",
      "<li class=\"item-child levelTwoNoChildren\">\n",
      "<a href=\"https://biontech.de/science/individualized-cancer-medicine\" target=\"\">Individualized cancer medicine</a>\n",
      "</li>\n",
      "<li class=\"item-child levelTwoNoChildren\">\n",
      "<a href=\"https://biontech.de/science/pipeline\" target=\"\">Pipeline</a>\n",
      "</li>\n",
      "<li class=\"item-child levelTwoNoChildren\">\n",
      "<a href=\"https://biontech.de/science/platforms\" target=\"\">Platforms</a>\n",
      "</li>\n",
      "<li class=\"item-child levelTwoNoChildren\">\n",
      "<a href=\"https://biontech.de/science/publications\" target=\"\">Publications</a>\n",
      "</li>\n",
      "</ul>\n",
      "</li>\n",
      "<li class=\"cont-box-article-menu\" id=\"cont-box-article-3\"></li>\n",
      "</ul>\n",
      "</li>\n",
      "<li class=\"menu-item menu-item--expanded gva-mega-menu megamenu menu-grid menu-columns-4 levelOneWithChildren\">\n",
      "<a href=\"https://biontech.de/for-patients/info-resources\" target=\"\">\n",
      "                For patients\n",
      "                <span class=\"icaret nav-plus fa fa-angle-down\"></span>\n",
      "</a>\n",
      "<ul class=\"menu sub-menu\">\n",
      "<li class=\"menu-item menu-item--expanded levelTwoWithChildren\">\n",
      "<a href=\"/\" target=\"\">\n",
      "                For patients - Child\n",
      "                <span class=\"icaret nav-plus fa fa-angle-down\"></span>\n",
      "</a>\n",
      "<ul class=\"menu sub-menu\">\n",
      "<li class=\"item-child levelTwoNoChildren\">\n",
      "<a href=\"https://biontech.de/for-patients/info-resources\" target=\"\">Info &amp; Resources</a>\n",
      "</li>\n",
      "<li class=\"item-child levelTwoNoChildren\">\n",
      "<a href=\"https://biontech.de/for-patients/clinical-trials\" target=\"\">Clinical trials</a>\n",
      "</li>\n",
      "</ul>\n",
      "</li>\n",
      "<li class=\"cont-box-article-menu\" id=\"cont-box-article-4\"></li>\n",
      "</ul>\n",
      "</li>\n",
      "</ul>\n",
      "<div class=\"generic-mob-menu\">\n",
      "<div class=\"separator-generic-mob-menu\"></div>\n",
      "<h2 class=\"visually-hidden\">Topbar Nav</h2>\n",
      "<li class=\"menu-mob-other\">\n",
      "<a href=\"/investors-media\" target=\"\">Investors &amp; Media</a>\n",
      "</li>\n",
      "<li class=\"menu-mob-other\">\n",
      "<a href=\"https://biontech.de/careers\" target=\"\">Careers</a>\n",
      "</li>\n",
      "<li class=\"menu-mob-other\">\n",
      "<a href=\"https://biontech.de/connect\" target=\"\">Connect</a>\n",
      "</li>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</nav>\n",
      "</div>\n",
      "</div>\n",
      "<div class=\"menu-bar hidden-lg hidden-md\" id=\"menu-bar\">\n",
      "<span class=\"one\"></span>\n",
      "<span class=\"two\"></span>\n",
      "<span class=\"three\"></span>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</header>\n",
      "<div class=\"main main-page\" role=\"main\">\n",
      "<div class=\"clearfix\"></div>\n",
      "<div class=\"help show\">\n",
      "<div class=\"container\">\n",
      "<div class=\"control-panel\">\n",
      "<i class=\"fa fa-cogs\"></i>\n",
      "</div>\n",
      "<div class=\"content-inner\"></div>\n",
      "</div>\n",
      "</div>\n",
      "<div class=\"clearfix\"></div>\n",
      "<div class=\"clearfix\"></div>\n",
      "<div class=\"content content-full\" id=\"content\">\n",
      "<div>\n",
      "<div class=\"content-main-inner\">\n",
      "<div class=\"main-content\" id=\"page-main-content\">\n",
      "<div class=\"main-content-inner\">\n",
      "<div class=\"content-main\">\n",
      "<div>\n",
      "<div class=\"block block-system block-system-main-block no-title\" id=\"block-gavias-tico-content--4\">\n",
      "<div class=\"content block-content\">\n",
      "<div class=\"hero-conainer gbb-row bg-size-cover\" style=\"background-image:url('/sites/g/files/knoqqb50866/themes/site/nir_pid3469/client/images/banner-ir.png'); background-repeat:no-repeat; background-position:center bottom\">\n",
      "<div class=\"bb-inner default\">\n",
      "<div class=\"bb-container container\">\n",
      "<div class=\"row\">\n",
      "<div class=\"row-wrapper clearfix\">\n",
      "<div class=\"gsc-column col-lg-12 col-md-12 col-sm-12 col-xs-12 hero-title\">\n",
      "<div class=\"column-inner bg-size-cover\">\n",
      "<div class=\"column-content-inner\">\n",
      "<div class=\"column-content h1-title\">\n",
      "<h1 class=\"banner-header\">\n",
      "                                                                                                                                                                            Press Releases\n",
      "                                                                                                                                                                    </h1>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "<article class=\"node node--type-index-news node--promoted node--view-mode-full clearfix\" data-history-node-id=\"38\" role=\"article\">\n",
      "<div class=\"node__content clearfix\">\n",
      "<div class=\"bg-greyx ndq-5816\" id=\"ndq-content\">\n",
      "<div class=\"container cont-control-fixed\">\n",
      "<div class=\"row\">\n",
      "<div class=\"col-xs-12 col-sm-12 col-md-12 col-lg-9 ir-content-area\">\n",
      "<div class=\"language-switcher\">\n",
      "<div class=\"language-switcher-language-url block--language-blocklanguage-content block--language-blocklanguage-content--5816 block--lang-switcher--language-block--language-content block--lang-switcher--language-block--language-content--5816 block--a85dfc23-f45a-46c4-b028-39d90ffdabad block--a85dfc23-f45a-46c4-b028-39d90ffdabad--5816 block block-language block-language-blocklanguage-content\" id=\"block-languageswitchercontent\" role=\"navigation\">\n",
      "<ul class=\"inline-links\" data-block-uuid=\"a85dfc23-f45a-46c4-b028-39d90ffdabad\"><li class=\"en inline-links__item is-active\" data-drupal-link-system-path=\"node/5816\" hreflang=\"en\"><a class=\"language-link is-active\" data-drupal-link-system-path=\"node/5816\" href=\"/press-releases\" hreflang=\"en\">English</a></li><li class=\"de inline-links__item\" data-drupal-link-system-path=\"node/5816\" hreflang=\"de\"><a class=\"language-link\" data-drupal-link-system-path=\"node/5816\" href=\"/de/press-releases\" hreflang=\"de\">German</a></li></ul>\n",
      "</div>\n",
      "</div>\n",
      "<div class=\"block--website-notice-block block--website-notice-block--5816 block--content--website-notice-block block--content--website-notice-block--5816 block--f47281d2-4f1a-4c92-9f81-37b6f8578261 block--f47281d2-4f1a-4c92-9f81-37b6f8578261--5816 block block-nir-website-notices block-website-notice-block\" id=\"block-nir-pid3469-websitenoticeblock\">\n",
      "</div>\n",
      "<div class=\"hidden\" data-drupal-messages-fallback=\"\"></div>\n",
      "<div class=\"block--system-main-block block--system-main-block--5816 block--content--system-main-block block--content--system-main-block--5816 block--21e6a44c-bbd1-4ffe-9f57-453eacfc3740 block--21e6a44c-bbd1-4ffe-9f57-453eacfc3740--5816 block block-system block-system-main-block\" id=\"block-nir-pid3469-content\">\n",
      "<article class=\"node node--type-nir_landing_page node--view-mode-full clearfix\">\n",
      "<h1>\n",
      "              Press Releases\n",
      "          </h1>\n",
      "<div>\n",
      "<div class=\"mb30\">\n",
      "<div class=\"block-region-contentmain\"><div class=\"block--search-form block--search-form--5816 block--contentmain--search-form block--contentmain--search-form--5816 block--790c808c-22fd-47e2-8995-87170c7aa1b9 block--790c808c-22fd-47e2-8995-87170c7aa1b9--5816 block block-nir-search block-search-form\">\n",
      "<form accept-charset=\"UTF-8\" action=\"/search\" data-block-uuid=\"790c808c-22fd-47e2-8995-87170c7aa1b9\" method=\"get\">\n",
      "<div class=\"js-form-item form-item js-form-type-search form-item-query js-form-item-query form-no-label\">\n",
      "<input aria-required=\"true\" class=\"form-search required\" maxlength=\"128\" name=\"query\" placeholder=\"Search\" required=\"required\" size=\"60\" type=\"search\"/>\n",
      "</div>\n",
      "<input name=\"f[0]\" type=\"hidden\" value=\"type:nir_news\"/>\n",
      "<input class=\"button button--primary js-form-submit form-submit\" name=\"op\" type=\"submit\" value=\"Search\"/>\n",
      "</form>\n",
      "</div>\n",
      "<div class=\"block--news-tbl block--nir-news__widget block--nir-news__widget--5816 block--contentmain--nir-news__widget block--contentmain--nir-news__widget--5816 block--14d5a2ff-a238-42f2-a643-56492d05b291 block--14d5a2ff-a238-42f2-a643-56492d05b291--5816 block block-nir-news block-nir-news__widget\">\n",
      "<div class=\"nir-widget\">\n",
      "<div class=\"nir-widget--content\">\n",
      "<div class=\"nir-widget--form\">\n",
      "<form accept-charset=\"UTF-8\" action=\"/press-releases/\" data-drupal-selector=\"widget-form-base\" id=\"widget-form-base\" method=\"get\">\n",
      "<div class=\"nir-widgets--field-container js-form-wrapper form-wrapper\" data-drupal-selector=\"edit-a9d908dd-field-nir-news-category\" id=\"edit-a9d908dd-field-nir-news-category\"><div class=\"js-form-item form-item js-form-type-select form-item-a9d908dd-field-nir-news-category-value js-form-item-a9d908dd-field-nir-news-category-value\">\n",
      "<label for=\"edit-a9d908dd-field-nir-news-category-value\">News Category</label>\n",
      "<select class=\"two-col-field form-select\" data-drupal-selector=\"edit-a9d908dd-field-nir-news-category-value\" id=\"edit-a9d908dd-field-nir-news-category-value\" multiple=\"multiple\" name=\"a9d908dd_field_nir_news_category[value][]\"><option value=\"4016\">All</option><option value=\"3981\">Clinical</option><option value=\"3986\">Collaborators</option><option value=\"4001\">Events</option><option value=\"3976\">Financial</option><option value=\"3991\">HR</option><option value=\"4006\">Other</option><option value=\"3996\">Science</option></select>\n",
      "</div>\n",
      "</div>\n",
      "<div class=\"nir-widgets--field-container nir-widgets--field-container--yeartimezone js-form-wrapper form-wrapper\" data-drupal-selector=\"edit-a9d908dd-year\" id=\"edit-a9d908dd-year\"><div class=\"two-col-field form-item js-form-item js-form-type-select form-type-select form-item-a9d908dd-year-value js-form-item-a9d908dd-year-value\">\n",
      "<label for=\"edit-a9d908dd-year-value\">Year</label>\n",
      "<select class=\"form-select\" data-drupal-selector=\"edit-a9d908dd-year-value\" id=\"edit-a9d908dd-year-value\" name=\"a9d908dd_year[value]\"><option value=\"_none\">None</option><option selected=\"selected\" value=\"2020\">2020</option><option value=\"2019\">2019</option><option value=\"2018\">2018</option><option value=\"2017\">2017</option><option value=\"2016\">2016</option><option value=\"2015\">2015</option></select>\n",
      "</div>\n",
      "</div>\n",
      "<input class=\"button button--primary js-form-submit form-submit\" data-drupal-selector=\"edit-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Filter\"/>\n",
      "<input data-drupal-selector=\"edit-a9d908dd-widget-id\" name=\"a9d908dd_widget_id\" type=\"hidden\" value=\"a9d908dd\"/>\n",
      "<input autocomplete=\"off\" data-drupal-selector=\"form-gaaaqygdp5fx-ctjozlax7ubqxxvlyick6sw-xoim4k\" name=\"form_build_id\" type=\"hidden\" value=\"form-gAaaqygDP5FX-CtJOZLAX7UBQXxvlYICk6sW-Xoim4k\"/>\n",
      "<input data-drupal-selector=\"edit-widget-form-base\" name=\"form_id\" type=\"hidden\" value=\"widget_form_base\"/>\n",
      "</form>\n",
      "</div>\n",
      "<div class=\"nir-widget--list\">\n",
      "<table class=\"nirtable collapse-table\">\n",
      "<thead>\n",
      "<tr>\n",
      "<th class=\"views-field-field-nir-date\" scope=\"col\">Date</th>\n",
      "<th class=\"views-field-field-nir-title\" scope=\"col\">Title</th>\n",
      "<th class=\"views-field-field-nir-document\" scope=\"col\"></th>\n",
      "</tr>\n",
      "</thead>\n",
      "<tbody>\n",
      "<tr>\n",
      "<td class=\"views-field-field-nir-date\">\n",
      "    1 July 2020\n",
      "  </td>\n",
      "<td class=\"views-field-field-nir-title\">\n",
      "<a class=\"skip-me\" href=\"/news-releases/news-release-details/biontech-hold-webcast-present-early-positive-data-ongoing-phase\">BioNTech to Hold Webcast to Present Early Positive Data from Ongoing Phase 1/2 Study of mRNA-based Vaccine Candidate Against SARS-CoV-2</a>\n",
      "</td>\n",
      "<td class=\"views-field-field-nir-document\">\n",
      "<div class=\"nir-widget--field nir-widget--news--addl-formats\">\n",
      "<div class=\"nir-widgets-file-link\">\n",
      "<a href=\"/node/8016/pdf\" target=\"_blank\"><span class=\"file-icon widget-file--application-pdf\"></span></a>\n",
      "</div>\n",
      "</div>\n",
      "</td>\n",
      "</tr>\n",
      "<tr>\n",
      "<td class=\"views-field-field-nir-date\">\n",
      "    1 July 2020\n",
      "  </td>\n",
      "<td class=\"views-field-field-nir-title\">\n",
      "<a class=\"skip-me\" href=\"/news-releases/news-release-details/pfizer-and-biontech-announce-early-positive-data-ongoing-phase\">Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 Study of mRNA-based Vaccine Candidate Against SARS-CoV-2</a>\n",
      "</td>\n",
      "<td class=\"views-field-field-nir-document\">\n",
      "<div class=\"nir-widget--field nir-widget--news--addl-formats\">\n",
      "<div class=\"nir-widgets-file-link\">\n",
      "<a href=\"/node/8011/pdf\" target=\"_blank\"><span class=\"file-icon widget-file--application-pdf\"></span></a>\n",
      "</div>\n",
      "</div>\n",
      "</td>\n",
      "</tr>\n",
      "<tr>\n",
      "<td class=\"views-field-field-nir-date\">\n",
      "    29 June 2020\n",
      "  </td>\n",
      "<td class=\"views-field-field-nir-title\">\n",
      "<a class=\"skip-me\" href=\"/news-releases/news-release-details/biontech-raise-usd-250-million-private-placement\">BioNTech to Raise USD 250 Million in Private Placement</a>\n",
      "</td>\n",
      "<td class=\"views-field-field-nir-document\">\n",
      "<div class=\"nir-widget--field nir-widget--news--addl-formats\">\n",
      "<div class=\"nir-widgets-file-link\">\n",
      "<a href=\"/node/7981/pdf\" target=\"_blank\"><span class=\"file-icon widget-file--application-pdf\"></span></a>\n",
      "</div>\n",
      "</div>\n",
      "</td>\n",
      "</tr>\n",
      "<tr>\n",
      "<td class=\"views-field-field-nir-date\">\n",
      "    11 June 2020\n",
      "  </td>\n",
      "<td class=\"views-field-field-nir-title\">\n",
      "<a class=\"skip-me\" href=\"/news-releases/news-release-details/investment-plan-europe-european-investment-bank-provide-biontech\">Investment Plan for Europe: European Investment Bank to provide BioNTech with up to €100 million in debt financing for COVID-19 vaccine development and manufacturing</a>\n",
      "</td>\n",
      "<td class=\"views-field-field-nir-document\">\n",
      "<div class=\"nir-widget--field nir-widget--news--addl-formats\">\n",
      "<div class=\"nir-widgets-file-link\">\n",
      "<a href=\"/node/7896/pdf\" target=\"_blank\"><span class=\"file-icon widget-file--application-pdf\"></span></a>\n",
      "</div>\n",
      "</div>\n",
      "</td>\n",
      "</tr>\n",
      "<tr>\n",
      "<td class=\"views-field-field-nir-date\">\n",
      "    12 May 2020\n",
      "  </td>\n",
      "<td class=\"views-field-field-nir-title\">\n",
      "<a class=\"skip-me\" href=\"/news-releases/news-release-details/biontech-announces-first-quarter-2020-financial-results-and\">BioNTech Announces First Quarter 2020 Financial Results and Corporate Progress</a>\n",
      "</td>\n",
      "<td class=\"views-field-field-nir-document\">\n",
      "<div class=\"nir-widget--field nir-widget--news--addl-formats\">\n",
      "<div class=\"nir-widgets-file-link\">\n",
      "<a href=\"/node/7561/pdf\" target=\"_blank\"><span class=\"file-icon widget-file--application-pdf\"></span></a>\n",
      "</div>\n",
      "</div>\n",
      "</td>\n",
      "</tr>\n",
      "<tr>\n",
      "<td class=\"views-field-field-nir-date\">\n",
      "    6 May 2020\n",
      "  </td>\n",
      "<td class=\"views-field-field-nir-title\">\n",
      "<a class=\"skip-me\" href=\"/news-releases/news-release-details/biontech-completes-acquisition-neon-therapeutics\">BioNTech Completes Acquisition of Neon Therapeutics</a>\n",
      "</td>\n",
      "<td class=\"views-field-field-nir-document\">\n",
      "<div class=\"nir-widget--field nir-widget--news--addl-formats\">\n",
      "<div class=\"nir-widgets-file-link\">\n",
      "<a href=\"/node/7551/pdf\" target=\"_blank\"><span class=\"file-icon widget-file--application-pdf\"></span></a>\n",
      "</div>\n",
      "</div>\n",
      "</td>\n",
      "</tr>\n",
      "<tr>\n",
      "<td class=\"views-field-field-nir-date\">\n",
      "    5 May 2020\n",
      "  </td>\n",
      "<td class=\"views-field-field-nir-title\">\n",
      "<a class=\"skip-me\" href=\"/news-releases/news-release-details/pfizer-and-biontech-dose-first-participants-us-part-global-covid\">Pfizer and BioNTech Dose First Participants in the U.S. as Part of Global COVID-19 mRNA Vaccine Development Program</a>\n",
      "</td>\n",
      "<td class=\"views-field-field-nir-document\">\n",
      "<div class=\"nir-widget--field nir-widget--news--addl-formats\">\n",
      "<div class=\"nir-widgets-file-link\">\n",
      "<a href=\"/node/7536/pdf\" target=\"_blank\"><span class=\"file-icon widget-file--application-pdf\"></span></a>\n",
      "</div>\n",
      "</div>\n",
      "</td>\n",
      "</tr>\n",
      "<tr>\n",
      "<td class=\"views-field-field-nir-date\">\n",
      "    5 May 2020\n",
      "  </td>\n",
      "<td class=\"views-field-field-nir-title\">\n",
      "<a class=\"skip-me\" href=\"/news-releases/news-release-details/biontech-report-first-quarter-2020-financial-results-and\">BioNTech to Report First Quarter 2020 Financial Results and Operational Update on May 12, 2020</a>\n",
      "</td>\n",
      "<td class=\"views-field-field-nir-document\">\n",
      "<div class=\"nir-widget--field nir-widget--news--addl-formats\">\n",
      "<div class=\"nir-widgets-file-link\">\n",
      "<a href=\"/node/7531/pdf\" target=\"_blank\"><span class=\"file-icon widget-file--application-pdf\"></span></a>\n",
      "</div>\n",
      "</div>\n",
      "</td>\n",
      "</tr>\n",
      "<tr>\n",
      "<td class=\"views-field-field-nir-date\">\n",
      "    29 April 2020\n",
      "  </td>\n",
      "<td class=\"views-field-field-nir-title\">\n",
      "<a class=\"skip-me\" href=\"/news-releases/news-release-details/biontech-and-pfizer-announce-completion-dosing-first-cohort\">BioNTech and Pfizer announce completion of dosing for first cohort of Phase 1/2 trial of COVID-19 vaccine candidates in Germany</a>\n",
      "</td>\n",
      "<td class=\"views-field-field-nir-document\">\n",
      "<div class=\"nir-widget--field nir-widget--news--addl-formats\">\n",
      "<div class=\"nir-widgets-file-link\">\n",
      "<a href=\"/node/7486/pdf\" target=\"_blank\"><span class=\"file-icon widget-file--application-pdf\"></span></a>\n",
      "</div>\n",
      "</div>\n",
      "</td>\n",
      "</tr>\n",
      "<tr>\n",
      "<td class=\"views-field-field-nir-date\">\n",
      "    22 April 2020\n",
      "  </td>\n",
      "<td class=\"views-field-field-nir-title\">\n",
      "<a class=\"skip-me\" href=\"/news-releases/news-release-details/biontech-and-pfizer-announce-regulatory-approval-german\">BioNTech and Pfizer announce regulatory approval from German authority Paul-Ehrlich-Institut to commence first clinical trial of COVID-19 vaccine candidates</a>\n",
      "</td>\n",
      "<td class=\"views-field-field-nir-document\">\n",
      "<div class=\"nir-widget--field nir-widget--news--addl-formats\">\n",
      "<div class=\"nir-widgets-file-link\">\n",
      "<a href=\"/node/7431/pdf\" target=\"_blank\"><span class=\"file-icon widget-file--application-pdf\"></span></a>\n",
      "</div>\n",
      "</div>\n",
      "</td>\n",
      "</tr>\n",
      "<tr>\n",
      "<td class=\"views-field-field-nir-date\">\n",
      "    9 April 2020\n",
      "  </td>\n",
      "<td class=\"views-field-field-nir-title\">\n",
      "<a class=\"skip-me\" href=\"/news-releases/news-release-details/pfizer-and-biontech-announce-further-details-collaboration\">Pfizer and BioNTech Announce Further Details on Collaboration to Accelerate Global COVID-19 Vaccine Development</a>\n",
      "</td>\n",
      "<td class=\"views-field-field-nir-document\">\n",
      "<div class=\"nir-widget--field nir-widget--news--addl-formats\">\n",
      "<div class=\"nir-widgets-file-link\">\n",
      "<a href=\"/node/7416/pdf\" target=\"_blank\"><span class=\"file-icon widget-file--application-pdf\"></span></a>\n",
      "</div>\n",
      "</div>\n",
      "</td>\n",
      "</tr>\n",
      "<tr>\n",
      "<td class=\"views-field-field-nir-date\">\n",
      "    31 March 2020\n",
      "  </td>\n",
      "<td class=\"views-field-field-nir-title\">\n",
      "<a class=\"skip-me\" href=\"/news-releases/news-release-details/biontech-announces-full-year-2019-financial-results-and\">BioNTech Announces Full Year 2019 Financial Results and Corporate Update</a>\n",
      "</td>\n",
      "<td class=\"views-field-field-nir-document\">\n",
      "<div class=\"nir-widget--field nir-widget--news--addl-formats\">\n",
      "<div class=\"nir-widgets-file-link\">\n",
      "<a href=\"/node/7356/pdf\" target=\"_blank\"><span class=\"file-icon widget-file--application-pdf\"></span></a>\n",
      "</div>\n",
      "</div>\n",
      "</td>\n",
      "</tr>\n",
      "<tr>\n",
      "<td class=\"views-field-field-nir-date\">\n",
      "    23 March 2020\n",
      "  </td>\n",
      "<td class=\"views-field-field-nir-title\">\n",
      "<a class=\"skip-me\" href=\"/news-releases/news-release-details/biontech-report-full-year-financial-results-2019-and-provide\">BioNTech to report full year financial results for 2019  and provide corporate update on the fourth quarter  on March 31, 2020</a>\n",
      "</td>\n",
      "<td class=\"views-field-field-nir-document\">\n",
      "<div class=\"nir-widget--field nir-widget--news--addl-formats\">\n",
      "<div class=\"nir-widgets-file-link\">\n",
      "<a href=\"/node/7346/pdf\" target=\"_blank\"><span class=\"file-icon widget-file--application-pdf\"></span></a>\n",
      "</div>\n",
      "</div>\n",
      "</td>\n",
      "</tr>\n",
      "<tr>\n",
      "<td class=\"views-field-field-nir-date\">\n",
      "    17 March 2020\n",
      "  </td>\n",
      "<td class=\"views-field-field-nir-title\">\n",
      "<a class=\"skip-me\" href=\"/news-releases/news-release-details/pfizer-and-biontech-co-develop-potential-covid-19-vaccine\">Pfizer and BioNTech to Co-develop Potential COVID-19 Vaccine</a>\n",
      "</td>\n",
      "<td class=\"views-field-field-nir-document\">\n",
      "<div class=\"nir-widget--field nir-widget--news--addl-formats\">\n",
      "<div class=\"nir-widgets-file-link\">\n",
      "<a href=\"/node/7321/pdf\" target=\"_blank\"><span class=\"file-icon widget-file--application-pdf\"></span></a>\n",
      "</div>\n",
      "</div>\n",
      "</td>\n",
      "</tr>\n",
      "<tr>\n",
      "<td class=\"views-field-field-nir-date\">\n",
      "    16 March 2020\n",
      "  </td>\n",
      "<td class=\"views-field-field-nir-title\">\n",
      "<a class=\"skip-me\" href=\"/news-releases/news-release-details/biontech-reports-rapid-progress-covid-19-vaccine-program-address\">BioNTech reports rapid progress on COVID-19 vaccine program to address global public health threat</a>\n",
      "</td>\n",
      "<td class=\"views-field-field-nir-document\">\n",
      "<div class=\"nir-widget--field nir-widget--news--addl-formats\">\n",
      "<div class=\"nir-widgets-file-link\">\n",
      "<a href=\"/node/7296/pdf\" target=\"_blank\"><span class=\"file-icon widget-file--application-pdf\"></span></a>\n",
      "</div>\n",
      "</div>\n",
      "</td>\n",
      "</tr>\n",
      "<tr>\n",
      "<td class=\"views-field-field-nir-date\">\n",
      "    16 March 2020\n",
      "  </td>\n",
      "<td class=\"views-field-field-nir-title\">\n",
      "<a class=\"skip-me\" href=\"/news-releases/news-release-details/biontech-and-fosun-pharma-form-covid-19-vaccine-strategic\">BioNTech and Fosun Pharma form COVID-19 vaccine strategic alliance in China</a>\n",
      "</td>\n",
      "<td class=\"views-field-field-nir-document\">\n",
      "<div class=\"nir-widget--field nir-widget--news--addl-formats\">\n",
      "<div class=\"nir-widgets-file-link\">\n",
      "<a href=\"/node/7301/pdf\" target=\"_blank\"><span class=\"file-icon widget-file--application-pdf\"></span></a>\n",
      "</div>\n",
      "</div>\n",
      "</td>\n",
      "</tr>\n",
      "<tr>\n",
      "<td class=\"views-field-field-nir-date\">\n",
      "    3 February 2020\n",
      "  </td>\n",
      "<td class=\"views-field-field-nir-title\">\n",
      "<a class=\"skip-me\" href=\"/news-releases/news-release-details/biontech-announces-commencement-public-offering-american\">BioNTech Announces Commencement of Public Offering of American Depositary Shares</a>\n",
      "</td>\n",
      "<td class=\"views-field-field-nir-document\">\n",
      "<div class=\"nir-widget--field nir-widget--news--addl-formats\">\n",
      "<div class=\"nir-widgets-file-link\">\n",
      "<a href=\"/node/7166/pdf\" target=\"_blank\"><span class=\"file-icon widget-file--application-pdf\"></span></a>\n",
      "</div>\n",
      "</div>\n",
      "</td>\n",
      "</tr>\n",
      "<tr>\n",
      "<td class=\"views-field-field-nir-date\">\n",
      "    16 January 2020\n",
      "  </td>\n",
      "<td class=\"views-field-field-nir-title\">\n",
      "<a class=\"skip-me\" href=\"/news-releases/news-release-details/biontech-acquire-neon-strengthen-global-leadership-position-t\">BioNTech to acquire Neon to strengthen global leadership position in T cell therapies</a>\n",
      "</td>\n",
      "<td class=\"views-field-field-nir-document\">\n",
      "<div class=\"nir-widget--field nir-widget--news--addl-formats\">\n",
      "<div class=\"nir-widgets-file-link\">\n",
      "<a href=\"/node/7021/pdf\" target=\"_blank\"><span class=\"file-icon widget-file--application-pdf\"></span></a>\n",
      "</div>\n",
      "</div>\n",
      "</td>\n",
      "</tr>\n",
      "<tr>\n",
      "<td class=\"views-field-field-nir-date\">\n",
      "    13 January 2020\n",
      "  </td>\n",
      "<td class=\"views-field-field-nir-title\">\n",
      "<a class=\"skip-me\" href=\"/news-releases/news-release-details/biontech-appoints-ryan-richardson-chief-strategy-officer-support\">BioNTech Appoints Ryan Richardson as Chief Strategy Officer to Support its Continued Global Expansion</a>\n",
      "</td>\n",
      "<td class=\"views-field-field-nir-document\">\n",
      "<div class=\"nir-widget--field nir-widget--news--addl-formats\">\n",
      "<div class=\"nir-widgets-file-link\">\n",
      "<a href=\"/node/6991/pdf\" target=\"_blank\"><span class=\"file-icon widget-file--application-pdf\"></span></a>\n",
      "</div>\n",
      "</div>\n",
      "</td>\n",
      "</tr>\n",
      "<tr>\n",
      "<td class=\"views-field-field-nir-date\">\n",
      "    2 January 2020\n",
      "  </td>\n",
      "<td class=\"views-field-field-nir-title\">\n",
      "<a class=\"skip-me\" href=\"/news-releases/news-release-details/biontech-announces-publication-preclinical-data-first-kind-car-t\">BioNTech Announces Publication of Preclinical Data for First-in-Kind CAR-T Cell Therapy Approach Targeting Solid Tumors in Science</a>\n",
      "</td>\n",
      "<td class=\"views-field-field-nir-document\">\n",
      "<div class=\"nir-widget--field nir-widget--news--addl-formats\">\n",
      "<div class=\"nir-widgets-file-link\">\n",
      "<a href=\"/node/6976/pdf\" target=\"_blank\"><span class=\"file-icon widget-file--application-pdf\"></span></a>\n",
      "</div>\n",
      "</div>\n",
      "</td>\n",
      "</tr>\n",
      "</tbody>\n",
      "</table>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "<div class=\"field field--name-field-nir-lp-block-node field--type-entity-reference field--label-hidden field__item\">\n",
      "<div class=\"clearfix text-formatted field field--name-field-nir-lp-block-body field--type-text-long field--label-hidden field__item\"><div class=\"block-nir-attribution-block\">\n",
      "<p>The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. BioNTech disavows any obligation to update the information contained in such press releases after the date of their issuance.</p>\n",
      "</div></div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "<!-- /.boxton -->\n",
      "</div>\n",
      "</article>\n",
      "</div>\n",
      "</div>\n",
      "<div class=\"col-xs-12 col-sm-12 col-md-12 col-lg-3 ir-side-bar\">\n",
      "<div class=\"side-nav\">\n",
      "<h2 class=\"visually-hidden\">IR Side Nav</h2>\n",
      "<ul class=\"side-nav-menu\">\n",
      "<li class=\"levelOneNoChildren\">\n",
      "<a href=\"/investors-media\" target=\"\">Overview</a>\n",
      "</li>\n",
      "<li class=\"levelOneNoChildren active active-levelOneNoChildren\">\n",
      "<a href=\"/press-releases\" target=\"\">Press Releases</a>\n",
      "</li>\n",
      "<li class=\"levelOneNoChildren\">\n",
      "<a href=\"/events-presentations\" target=\"\">Events &amp; Presentations</a>\n",
      "</li>\n",
      "<li class=\"levelOneNoChildren\">\n",
      "<a href=\"/media-materials\" target=\"\">Media Materials</a>\n",
      "</li>\n",
      "<li class=\"levelOneNoChildren\">\n",
      "<a href=\"/corporate-governance\" target=\"\">Corporate Governance</a>\n",
      "</li>\n",
      "<li class=\"levelOneNoChildren\">\n",
      "<a href=\"/agm\" target=\"\">Annual General Meeting</a>\n",
      "</li>\n",
      "<li class=\"levelOneNoChildren\">\n",
      "<a href=\"/hv\" target=\"\">Hauptversammlung</a>\n",
      "</li>\n",
      "<li class=\"levelOneNoChildren\">\n",
      "<a href=\"/stock-information\" target=\"\">Stock Information</a>\n",
      "</li>\n",
      "<li class=\"levelOneWithChildren has-submenu\">\n",
      "<a href=\"/financials/overview\" target=\"\">Financials</a>\n",
      "<ul class=\"side-nav-submenu\">\n",
      "<li class=\"levelTwoNoChildren\">\n",
      "<a href=\"/financials/overview\" target=\"\">Overview</a>\n",
      "</li>\n",
      "<li class=\"levelTwoNoChildren\">\n",
      "<a href=\"/financials/annual-reports\" target=\"\">Annual Reports (20-F)</a>\n",
      "</li>\n",
      "<li class=\"levelTwoNoChildren\">\n",
      "<a href=\"/quarterly-reports\" target=\"\">Quarterly Reports</a>\n",
      "</li>\n",
      "<li class=\"levelTwoNoChildren\">\n",
      "<a href=\"/sec-filings\" target=\"\">SEC Filings</a>\n",
      "</li>\n",
      "<li class=\"levelTwoNoChildren\">\n",
      "<a href=\"/organizational-actions-form-8937\" target=\"\">Organizational Actions Form 8937</a>\n",
      "</li>\n",
      "</ul>\n",
      "</li>\n",
      "<li class=\"levelOneNoChildren\">\n",
      "<a href=\"/analyst-coverage\" target=\"\">Analyst Coverage</a>\n",
      "</li>\n",
      "<li class=\"levelOneNoChildren\">\n",
      "<a href=\"/shareholder-services\" target=\"\">Shareholder Services</a>\n",
      "</li>\n",
      "</ul>\n",
      "</div>\n",
      "<div class=\"sidebar-toolkit rounded-corners\">\n",
      "<h2>Toolkit</h2>\n",
      "<nav class=\"recent module toolkit\">\n",
      "<a href=\"/shareholder-services/information-request\" target=\"\">Information Requests</a>\n",
      "<a href=\"/events-presentations\" target=\"\">Corporate Presentation</a>\n",
      "<a href=\"/shareholder-services/investor-alerts\" target=\"\">Sign up for Email Alerts</a>\n",
      "<a href=\"/shareholder-services/rss-feeds\" target=\"\">RSS Feeds</a>\n",
      "</nav>\n",
      "</div>\n",
      "<div class=\"sidebar-contacts rounded-corners\">\n",
      "<div class=\"clearfix text-formatted field field--name-field-nir-global-block-body field--type-text-long field--label-hidden field__item\"><div class=\"sidebar-contact\"><span class=\"sidebar-contact-title\">Media Contact</span> <span class=\"sidebar-contact-text\"> Jasmina Alatovic<br/>\n",
      "Senior Manager Global External Communications<br/><a href=\"mailto:Media@biontech.de\">Media@biontech.de</a><br/>\n",
      "+49 6131 9084-1513 </span></div>\n",
      "<div class=\"sidebar-contact\"><span class=\"sidebar-contact-title\">Investor Contact</span> <span class=\"sidebar-contact-text\"> Sylke Maas, Ph.D.<br/>\n",
      "VP Investor Relations &amp; Business Strategy<br/><a href=\"mailto:Investors@biontech.de\">Investors@biontech.de</a><br/>\n",
      "+49 6131 9084-074</span></div>\n",
      "<div class=\"sidebar-contact\">For U.S. Investors:<br/>\n",
      "Westwicke<br/>\n",
      "Victoria Meissner, M.D.<br/><a href=\"mailto:victoria.meissner@westwicke.com\">victoria.meissner@westwicke.com</a><br/>\n",
      "+1 646 677-1837</div>\n",
      "<div class=\"sidebar-contact\"><span class=\"sidebar-contact-title\">Whistleblower Hotline</span> <span class=\"sidebar-contact-text\"> BioNTech Hotline (anonymous)<br/>\n",
      "Germany: 0800 000-8972<br/>\n",
      "US: 844 901-0271<br/>\n",
      "Other: +1 757 278-0107<br/>\n",
      "Online Access to <a href=\"https://biontech.gan-compliance.com/caseReport\">Whistle Blowing Reporting</a><br/>\n",
      "Or by <a href=\"mailto:corporatecompliance@biontech.de\">Email</a></span></div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</article>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "<footer class=\"footer\" id=\"footer\">\n",
      "<div class=\"footer-center\">\n",
      "<div class=\"container\">\n",
      "<div class=\"row\">\n",
      "<div class=\"clearfix text-formatted field field--name-field-nir-global-block-body field--type-text-long field--label-hidden field__item\"><div class=\"footer-first col-lg-3 col-md-3 col-sm-12 col-xs-12 column global-block-content\">\n",
      "<div class=\"first-footer-block block block-block-content block-block-contentc0aa9d0c-7f31-41a2-8ffe-7a4a22c0e281 no-title\" id=\"block-firstfooterinfo\">\n",
      "<div class=\"content block-content\">\n",
      "<div class=\"field field--name-body field--type-text-with-summary field--label-hidden field__item\">\n",
      "<div class=\"generic marginBott20\">\n",
      "<a href=\"https://biontech.de/\" target=\"_blank\" title=\"Biontech\">\n",
      "<img alt=\"Logo\" class=\"logo-footer\" data-entity-type=\"file\" data-entity-uuid=\"80f17c39-69c9-4815-a1af-5fe54e34838d\" src=\"/system/files-encrypted/nasdaq_kms/inline-images/logo-footer_0.png\"/></a>\n",
      "</div>\n",
      "<p>\n",
      "\t\t\t\t\tAn der Goldgrube 12\n",
      "\t\t\t\t\t<br/>\n",
      "\t\t\t\t\t55131 Mainz\n",
      "\t\t\t\t\t<br/>\n",
      "\t\t\t\t\tGermany\n",
      "\t\t\t\t</p>\n",
      "<p> </p>\n",
      "<p>\n",
      "\t\t\t\t\tT: +49 6131 9084-0\n",
      "\t\t\t\t\t<br/>\n",
      "\t\t\t\t\tF: +49 6131 9084-390\n",
      "\t\t\t\t\t<br/>\n",
      "\t\t\t\t\tM:\n",
      "\t\t\t\t\t<a href=\"mailto:info@biontech.de\">info@biontech.de</a>\n",
      "</p>\n",
      "<p class=\"jsRestartAnimationx footerFingerPrint marginTop20\" onclick=\"location.href='http://biontech.de/?ra=yes'\">We aspire to individualize cancer medicine</p>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div></div>\n",
      "<h2 class=\"visually-hidden\">02. Footer Column2 Links</h2>\n",
      "<div class=\"footer-second col-lg-3 col-md-3 col-sm-12 col-xs-6 column\">\n",
      "<nav aria-labelledby=\"block-footermain-menu\" class=\"block block-menu navigation menu--footer-main\" id=\"block-footermain\" role=\"navigation\">\n",
      "<div class=\"block-content\">\n",
      "<ul class=\"gva_menu\">\n",
      "<li class=\"menu-item\">\n",
      "<a href=\"https://biontech.de/our-dna/vision\" target=\"\">Our DNA</a>\n",
      "</li>\n",
      "<li class=\"menu-item\">\n",
      "<a href=\"https://biontech.de/how-we-translate/biontech-approach\" target=\"\">How We Translate</a>\n",
      "</li>\n",
      "<li class=\"menu-item\">\n",
      "<a href=\"https://biontech.de/science/individualized-cancer-medicine\" target=\"\">Science</a>\n",
      "</li>\n",
      "<li class=\"menu-item\">\n",
      "<a href=\"https://biontech.de/for-patients/info-resources\" target=\"\">For Patients</a>\n",
      "</li>\n",
      "<li class=\"menu-item\">\n",
      "<a href=\"/investors-media\" target=\"\">Investors &amp; Media</a>\n",
      "</li>\n",
      "<li class=\"menu-item\">\n",
      "<a href=\"https://biontech.de/careers\" target=\"\">Careers</a>\n",
      "</li>\n",
      "</ul>\n",
      "</div>\n",
      "</nav>\n",
      "</div>\n",
      "<h2 class=\"visually-hidden\">03. Footer Column3 Links</h2>\n",
      "<div class=\"footer-third col-lg-3 col-md-3 col-sm-12 col-xs-6 column\">\n",
      "<nav aria-labelledby=\"block-gavias-tico-footer-menu\" class=\"block block-menu navigation menu--footer\" id=\"block-gavias-tico-footer\" role=\"navigation\">\n",
      "<div class=\"block-content\">\n",
      "<ul class=\"gva_menu\">\n",
      "<li class=\"menu-item\">\n",
      "<a href=\"https://biontech.de/connect\" target=\"\">Connect</a>\n",
      "</li>\n",
      "<li class=\"menu-item\">\n",
      "<a href=\"https://biontech.de/imprint\" target=\"\">Imprint</a>\n",
      "</li>\n",
      "<li class=\"menu-item\">\n",
      "<a href=\"https://biontech.de/terms-of-use\" target=\"\">Terms of use</a>\n",
      "</li>\n",
      "<li class=\"menu-item\">\n",
      "<a href=\"https://biontech.de/data-privacy-policy\" target=\"\">Data privacy policy</a>\n",
      "</li>\n",
      "</ul>\n",
      "</div>\n",
      "</nav>\n",
      "</div>\n",
      "<div class=\"clearfix text-formatted field field--name-field-nir-global-block-body field--type-text-long field--label-hidden field__item\"><div class=\"footer-four col-lg-3 col-md-3 col-sm-12 col-xs-12 column global-block-content\">\n",
      "<div class=\"social-block-footer block block-block-content block-block-content63672dd0-c676-4d97-9559-ef493a438fbe no-title\" id=\"block-socialblockfooter\">\n",
      "<div class=\"content block-content\">\n",
      "<div class=\"field field--name-body field--type-text-with-summary field--label-hidden field__item\">\n",
      "<div class=\"generic\">\n",
      "<p>Follow us</p>\n",
      "<p>\n",
      "<a class=\"fb\" href=\"https://www.linkedin.com/company/biontech-se\" target=\"_blank\" title=\"Facebook\"><i class=\"fa fa-linkedin\"><span style=\"display: none;\"> </span></i></a>\n",
      "<a class=\"twi\" href=\"https://twitter.com/BioNTech_Group\" target=\"_blank\" title=\"Twitter\"><i class=\"fab fa-twitter\"><span style=\"display: none;\"> </span></i></a>\n",
      "</p>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div></div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "<div class=\"copyright\">\n",
      "<div class=\"container\">\n",
      "<div class=\"copyright-inner\">\n",
      "<div>\n",
      "<div class=\"block block-system block-system-powered-by-block no-title\" id=\"block-gavias-tico-powered\" role=\"complementary\">\n",
      "<div class=\"content block-content\">\n",
      "<div class=\"clearfix text-formatted field field--name-field-nir-global-block-body field--type-text-long field--label-hidden field__item\"><span>© Copyright BioNTech SE <script>\n",
      "<!--//--><![CDATA[// ><!--\n",
      "document.write((new Date()).getFullYear());\n",
      "//--><!]]>\n",
      "</script>. All Rights Reserved.</span></div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</footer>\n",
      "<a class=\"scroll scroll-top\" href=\"#top\"> </a>\n",
      "<div style=\"display: none\">\n",
      "<div>\n",
      "<div class=\"views-element-container block block-views block-views-blocklist-post-menu-block-1 no-title\" id=\"block-views-block-list-post-menu-block-1\">\n",
      "<div class=\"content block-content\">\n",
      "<div>\n",
      "<div class=\"js-view-dom-id-bca57ddebb15c8b3f6bae044517079a922a4c7e780974af89056879438b047e6\">\n",
      "<div class=\"view-content-wrap\">\n",
      "<div class=\"box-article-1 box-article item\">\n",
      "<div class=\"views-field views-field-view-node-1\">\n",
      "<span class=\"field-content\">\n",
      "<a href=\"https://biontech.de/our-dna/vision\" urldocument=\"\" urlextern=\"\">\n",
      "<div class=\"post-block\">\n",
      "<div class=\"post-image\">\n",
      "<img alt=\"Our Vision\" src=\"/sites/g/files/knoqqb50866/themes/site/nir_pid3469/client/images/THUMB_internal_Vision.jpg\" typeof=\"Image\"/>\n",
      "</div>\n",
      "<div class=\"post-content text-left\">\n",
      "<div class=\"post-title\">Our vision: individualize cancer medicine</div>\n",
      "</div>\n",
      "</div>\n",
      "</a>\n",
      "</span>\n",
      "</div>\n",
      "</div>\n",
      "<div class=\"box-article-1 box-article item\">\n",
      "<div class=\"views-field views-field-view-node-1\">\n",
      "<span class=\"field-content\">\n",
      "<a href=\"https://biontech.de/create-article-42\" urldocument=\"\" urlextern=\"/our-dna/leadership\">\n",
      "<div class=\"post-block\">\n",
      "<div class=\"post-image\">\n",
      "<img alt=\"Leadership\" src=\"/sites/g/files/knoqqb50866/themes/site/nir_pid3469/client/images/THUMB_Meet-our-Leadership-Team.jpg\" typeof=\"Image\"/>\n",
      "</div>\n",
      "<div class=\"post-content text-left\">\n",
      "<div class=\"post-title\">Meet our leadership team</div>\n",
      "</div>\n",
      "</div>\n",
      "</a>\n",
      "</span>\n",
      "</div>\n",
      "</div>\n",
      "<div class=\"box-article-1 box-article item\">\n",
      "<div class=\"views-field views-field-view-node-1\">\n",
      "<span class=\"field-content\">\n",
      "<a href=\"https://biontech.de/our-dna/collaborators\" urldocument=\"\" urlextern=\"\">\n",
      "<div class=\"post-block\">\n",
      "<div class=\"post-image\">\n",
      "<img alt=\"Collaborators\" src=\"/sites/g/files/knoqqb50866/themes/site/nir_pid3469/client/images/THUMB_internal_Collaborators_0.jpg\" typeof=\"Image\"/>\n",
      "</div>\n",
      "<div class=\"post-content text-left\">\n",
      "<div class=\"post-title\">Get to know our partners</div>\n",
      "</div>\n",
      "</div>\n",
      "</a>\n",
      "</span>\n",
      "</div>\n",
      "</div>\n",
      "<div class=\"box-article-1 box-article item\">\n",
      "<div class=\"views-field views-field-view-node-1\">\n",
      "<span class=\"field-content\">\n",
      "<a href=\"https://biontech.de/our-dna/locations\" urldocument=\"\" urlextern=\"\">\n",
      "<div class=\"post-block\">\n",
      "<div class=\"post-image\">\n",
      "<img alt=\"Our Locations\" src=\"/sites/g/files/knoqqb50866/themes/site/nir_pid3469/client/images/THUMB_Learn_About_our_Services.jpg\" typeof=\"Image\"/>\n",
      "</div>\n",
      "<div class=\"post-content text-left\">\n",
      "<div class=\"post-title\">Learn about our services</div>\n",
      "</div>\n",
      "</div>\n",
      "</a>\n",
      "</span>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "<div class=\"views-element-container block block-views block-views-blocklist-post-menu-block-2 no-title\" id=\"block-views-block-list-post-menu-block-2\">\n",
      "<div class=\"content block-content\">\n",
      "<div>\n",
      "<div class=\"js-view-dom-id-130f7e89c1375ca77d5e92143bcfb8d900c469a21b19282f4a55b7a1a1fc6693\">\n",
      "<div class=\"view-content-wrap\">\n",
      "<div class=\"box-article-2 box-article item\">\n",
      "<div class=\"views-field views-field-view-node-1\">\n",
      "<span class=\"field-content\">\n",
      "<a href=\"https://biontech.de/how-we-translate/biontech-approach\" urldocument=\"\" urlextern=\"\">\n",
      "<div class=\"post-block\">\n",
      "<div class=\"post-image\">\n",
      "<img alt=\"The BioNTech approach\" src=\"/sites/g/files/knoqqb50866/themes/site/nir_pid3469/client/images/THUMB_internal_The-BioNTech-approach.jpg\" typeof=\"Image\"/>\n",
      "</div>\n",
      "<div class=\"post-content text-left\">\n",
      "<div class=\"post-title\">How we approach individualized cancer medicine</div>\n",
      "</div>\n",
      "</div>\n",
      "</a>\n",
      "</span>\n",
      "</div>\n",
      "</div>\n",
      "<div class=\"box-article-2 box-article item\">\n",
      "<div class=\"views-field views-field-view-node-1\">\n",
      "<span class=\"field-content\">\n",
      "<a href=\"https://biontech.de/how-we-translate/mrna-therapeutics\" urldocument=\"\" urlextern=\"\">\n",
      "<div class=\"post-block\">\n",
      "<div class=\"post-image\">\n",
      "<img alt=\"mRNA Therapeutics\" src=\"/sites/g/files/knoqqb50866/themes/site/nir_pid3469/client/images/THUMB_internal_mRNA-Therapeutics.jpg\" typeof=\"Image\"/>\n",
      "</div>\n",
      "<div class=\"post-content text-left\">\n",
      "<div class=\"post-title\">Why mRNA represents a disruptive new drug class</div>\n",
      "</div>\n",
      "</div>\n",
      "</a>\n",
      "</span>\n",
      "</div>\n",
      "</div>\n",
      "<div class=\"box-article-2 box-article item\">\n",
      "<div class=\"views-field views-field-view-node-1\">\n",
      "<span class=\"field-content\">\n",
      "<a href=\"https://biontech.de/how-we-translate/antibodies\" urldocument=\"\" urlextern=\"\">\n",
      "<div class=\"post-block\">\n",
      "<div class=\"post-image\">\n",
      "<img alt=\"Antibodies\" src=\"/sites/g/files/knoqqb50866/themes/site/nir_pid3469/client/images/THUMB_internal_Antibodies.jpg\" typeof=\"Image\"/>\n",
      "</div>\n",
      "<div class=\"post-content text-left\">\n",
      "<div class=\"post-title\">\n",
      "                                                            Beyond mRNA: Expanding therapeutics with our antibody discovery engines\n",
      "                                                        </div>\n",
      "</div>\n",
      "</div>\n",
      "</a>\n",
      "</span>\n",
      "</div>\n",
      "</div>\n",
      "<div class=\"box-article-2 box-article item\">\n",
      "<div class=\"views-field views-field-view-node-1\">\n",
      "<span class=\"field-content\">\n",
      "<a href=\"https://biontech.de/how-we-translate/manufacturing\" urldocument=\"\" urlextern=\"\">\n",
      "<div class=\"post-block\">\n",
      "<div class=\"post-image\">\n",
      "<img alt=\"Manufacturing\" src=\"/sites/g/files/knoqqb50866/themes/site/nir_pid3469/client/images/THUMB_internal_Manufacturing.jpg\" typeof=\"Image\"/>\n",
      "</div>\n",
      "<div class=\"post-content text-left\">\n",
      "<div class=\"post-title\">Manufacturing our own therapeutics</div>\n",
      "</div>\n",
      "</div>\n",
      "</a>\n",
      "</span>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "<div class=\"views-element-container block block-views block-views-blocklist-post-menu-block-3 no-title\" id=\"block-views-block-list-post-menu-block-3\">\n",
      "<div class=\"content block-content\">\n",
      "<div>\n",
      "<div class=\"js-view-dom-id-156f751b27e2443c53e6afdca3e8cbd84d97f58c15e347d8c5533fa5c216d64e\">\n",
      "<div class=\"view-content-wrap\">\n",
      "<div class=\"box-article-3 box-article item\">\n",
      "<div class=\"views-field views-field-view-node-1\">\n",
      "<span class=\"field-content\">\n",
      "<a href=\"https://biontech.de/node/125\" urldocument=\"\" urlextern=\"/science/pipeline\">\n",
      "<div class=\"post-block\">\n",
      "<div class=\"post-image\">\n",
      "<img alt=\"Pipeline\" src=\"/sites/g/files/knoqqb50866/themes/site/nir_pid3469/client/images/THUMB_internal_Pipeline.jpg\" typeof=\"Image\"/>\n",
      "</div>\n",
      "<div class=\"post-content text-left\">\n",
      "<div class=\"post-title\">Explore our individualized immunotherapy pipeline</div>\n",
      "</div>\n",
      "</div>\n",
      "</a>\n",
      "</span>\n",
      "</div>\n",
      "</div>\n",
      "<div class=\"box-article-3 box-article item\">\n",
      "<div class=\"views-field views-field-view-node-1\">\n",
      "<span class=\"field-content\">\n",
      "<a href=\"https://biontech.de/science/platforms\" urldocument=\"\" urlextern=\"\">\n",
      "<div class=\"post-block\">\n",
      "<div class=\"post-image\">\n",
      "<img alt=\"Platforms\" src=\"/sites/g/files/knoqqb50866/themes/site/nir_pid3469/client/images/THUMB_internal_Platforms.jpg\" typeof=\"Image\"/>\n",
      "</div>\n",
      "<div class=\"post-content text-left\">\n",
      "<div class=\"post-title\">\n",
      "                                                            Tour our platforms that produce individually-tailored therapeutics\n",
      "                                                        </div>\n",
      "</div>\n",
      "</div>\n",
      "</a>\n",
      "</span>\n",
      "</div>\n",
      "</div>\n",
      "<div class=\"box-article-3 box-article item\">\n",
      "<div class=\"views-field views-field-view-node-1\">\n",
      "<span class=\"field-content\">\n",
      "<a href=\"https://biontech.de/science/publications\" urldocument=\"\" urlextern=\"\">\n",
      "<div class=\"post-block\">\n",
      "<div class=\"post-image\">\n",
      "<img alt=\"Publications\" src=\"/sites/g/files/knoqqb50866/themes/site/nir_pid3469/client/images/THUMB_internal_Publications.jpg\" typeof=\"Image\"/>\n",
      "</div>\n",
      "<div class=\"post-content text-left\">\n",
      "<div class=\"post-title\">Browse our research publications</div>\n",
      "</div>\n",
      "</div>\n",
      "</a>\n",
      "</span>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "<div class=\"views-element-container block block-views block-views-blocklist-post-menu-block-4 no-title\" id=\"block-views-block-list-post-menu-block-4\">\n",
      "<div class=\"content block-content\">\n",
      "<div>\n",
      "<div class=\"js-view-dom-id-e42610d125b785c3ecab38b0085aafa2ba4aeb84f545704054cddb819828524c\">\n",
      "<div class=\"view-content-wrap\">\n",
      "<div class=\"box-article-4 box-article item\">\n",
      "<div class=\"views-field views-field-view-node-1\">\n",
      "<span class=\"field-content\">\n",
      "<a href=\"https://biontech.de/for-patients/info-resources\" urldocument=\"\" urlextern=\"\">\n",
      "<div class=\"post-block\">\n",
      "<div class=\"post-image\">\n",
      "<img alt=\"Info &amp; Resources\" src=\"/sites/g/files/knoqqb50866/themes/site/nir_pid3469/client/images/THUMB_internal_Patient-Info-Resources.jpg\" typeof=\"Image\"/>\n",
      "</div>\n",
      "<div class=\"post-content text-left\">\n",
      "<div class=\"post-title\">\n",
      "                                                            Our Mission: broaden the therapeutic universe to benefit patients\n",
      "                                                        </div>\n",
      "</div>\n",
      "</div>\n",
      "</a>\n",
      "</span>\n",
      "</div>\n",
      "</div>\n",
      "<div class=\"box-article-4 box-article item\">\n",
      "<div class=\"views-field views-field-view-node-1\">\n",
      "<span class=\"field-content\">\n",
      "<a href=\"https://biontech.de/for-patients/clinical-trials\" urldocument=\"\" urlextern=\"\">\n",
      "<div class=\"post-block\">\n",
      "<div class=\"post-image\">\n",
      "<img alt=\"Clinical trials\" src=\"/sites/g/files/knoqqb50866/themes/site/nir_pid3469/client/images/THUMB_internal_Clinical-Trials.jpg\" typeof=\"Image\"/>\n",
      "</div>\n",
      "<div class=\"post-content text-left\">\n",
      "<div class=\"post-title\">Clinical trials currently ongoing</div>\n",
      "</div>\n",
      "</div>\n",
      "</a>\n",
      "</span>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "</div>\n",
      "<div class=\"clearfix\"></div>\n",
      "</div>\n",
      "</div>\n",
      "<script type=\"text/javascript\">var s_CCSWebHostingAccount = \"trcgbiontechse\";</script>\n",
      "<script data-drupal-selector=\"drupal-settings-json\" type=\"application/json\">{\"path\":{\"baseUrl\":\"\\/\",\"scriptPath\":null,\"pathPrefix\":\"\",\"currentPath\":\"node\\/5816\",\"currentPathIsAdmin\":false,\"isFront\":false,\"currentLanguage\":\"en\",\"themeUrl\":\"sites\\/g\\/files\\/knoqqb50866\\/themes\\/site\\/nir_pid3469\"},\"pluralDelimiter\":\"\\u0003\",\"suppressDeprecationErrors\":true,\"ajaxPageState\":{\"libraries\":\"core\\/drupal.collapse,core\\/html5shiv,nir_base\\/adobe_omniture,nir_base\\/nir_icons,nir_base\\/nir_toolbar,nir_ckeditor_datatables\\/datatables,nir_market_data_block\\/nir_market_data_block.filterform,nir_multimedia\\/nir_multimedia,nir_pid3469\\/client-footer,nir_pid3469\\/client-header,nir_pid3469\\/override,nir_pid3469\\/vendor,nir_website_notices\\/nir_website_notices.notices,radix_layouts\\/radix_layouts,system\\/base\",\"theme\":\"nir_pid3469\",\"theme_token\":null},\"ajaxTrustedUrl\":{\"form_action_p_pvdeGsVG5zNF_XLGPTvYSKCf43t8qZYSwcfZl2uzM\":true},\"user\":{\"uid\":0,\"permissionsHash\":\"fe519247fa47c1457dd915fb9b8babdd1576f517aa658cc0a7a481d4c35737b1\"}}</script>\n",
      "<script src=\"/sites/g/files/knoqqb50866/files/js/js_xOIkO3CURy265jcW2FDWV5wmqgOJa-SoRzRCdU3JAeU.js\"></script>\n",
      "<script type=\"text/javascript\">window.NREUM||(NREUM={});NREUM.info={\"beacon\":\"bam.nr-data.net\",\"licenseKey\":\"761e715901\",\"applicationID\":\"32397309,24276188\",\"transactionName\":\"ZlVXYRcAW0ZRW0QKX18fdFYRCFpbH3xCFkBQXGl2ChNQaXZXQg5sd19HWCcUXFlUXUJODkNVW1EAE2VZUVtVC19dVFBHIw5HWHFbRApfXw==\",\"queueTime\":0,\"applicationTime\":853,\"atts\":\"ShJUF18aSEg=\",\"errorBeacon\":\"bam.nr-data.net\",\"agent\":\"\"}</script></body>\n"
     ]
    }
   ],
   "source": [
    "page = requests.get('https://investors.biontech.de/press-releases/').text\n",
    "soup = BeautifulSoup(page, 'html.parser')\n",
    "body = soup.find('body')\n",
    "print(body)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 77,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<a href=\"/node/8019/pdf\" target=\"_blank\"><span class=\"file-icon widget-file--application-pdf\"></span></a>\n",
      ": /node/8019/pdf \n",
      "\n",
      "<a class=\"skip-me\" href=\"/news-releases/news-release-details/independence-day-phase-test-positive\">Independence Day Phase Test Positive</a>\n",
      "Independence Day Phase Test Positive: /news-releases/news-release-details/independence-day-phase-test-positive \n",
      "\n"
     ]
    }
   ],
   "source": [
    "# Testing with local html files\n",
    "pg_original = '../datasets/original_webpage.html'\n",
    "pg_updated = '../datasets/updated_webpage.html'\n",
    "\n",
    "soup_original = BeautifulSoup(open(pg_original), 'html.parser')\n",
    "soup_updated = BeautifulSoup(open(pg_updated), 'html.parser')\n",
    "\n",
    "\n",
    "body_original = soup_original.find('body')\n",
    "body_updated = soup_updated.find('body')\n",
    "\n",
    "links_original = list(body_original.find_all('a'))\n",
    "links_updated = list(body_updated.find_all('a'))\n",
    "\n",
    "# print(f'Originally: {len(links_original)} links \\n\\\n",
    "# Href: {len(links_href)} links \\n')\n",
    "\n",
    "# Method from\n",
    "# https://stackoverflow.com/questions/41125909/python-find-elements-in-one-list-that-are-not-in-the-other\n",
    "links_diff = list(set(links_updated) - set(links_original))\n",
    "\n",
    "for link in links_diff:\n",
    "    print(link)\n",
    "    ref = link.get('href')\n",
    "    content = link.text\n",
    "    \n",
    "    print(f'{content}: {ref} \\n')\n",
    "    #print(f'{link.get('href')}\\n')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "metadata": {},
   "outputs": [],
   "source": [
    "def url_to_filename(base_url:str):\n",
    "    base_url = prune_url(base_url)\n",
    "    \n",
    "    forbidden_ascii = ['/', '\\\\', '\\|', ':', '?',\n",
    "                      '\\'', '\\\"', '?', '*', '>', '<']\n",
    "    \n",
    "    for ascii_char in forbidden_ascii:\n",
    "        base_url = base_url.replace(ascii_char, '-')\n",
    "    \n",
    "    base_url = base_url.replace('.', '_')\n",
    "    \n",
    "    return base_url\n",
    "    \n",
    "    \n",
    "def prune_url(full_url:str):\n",
    "    cut_chars = ['https://', 'http://', 'www.']\n",
    "    \n",
    "    for cut in cut_chars:\n",
    "        full_url = full_url.replace(cut, '')\n",
    "    \n",
    "    if full_url[-1] == '/':\n",
    "        pruned_url = full_url[0:-1]\n",
    "    else:\n",
    "        pruned_url = full_url\n",
    "    \n",
    "    return pruned_url\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "def load_cache(base_url, path='logs/'):\n",
    "    url_filename = url_to_filename(base_url)\n",
    "    filename = f'{path}CACHE-{url_filename}.html'\n",
    "    f=open(filename, 'r')\n",
    "    data_cache = f.read()\n",
    "    return data_cache\n",
    "\n",
    "\n",
    "def store_cache(base_url, data, path='logs/'):\n",
    "    url_filename = url_to_filename(base_url)\n",
    "    filename = f'{path}CACHE-{url_filename}.html'\n",
    "    f = open(filename, 'w')\n",
    "    f.write(data)\n",
    "    f.close()\n",
    "                      \n",
    "\n",
    "def cache_updated(base_url, data, path='logs/'):\n",
    "    # Check cache exists\n",
    "    url_filename = url_to_filename(base_url)\n",
    "    filename = f'{path}CACHE-{url_filename}.html'\n",
    "    cache_exists = os.path.isfile(filename)\n",
    "    \n",
    "    if cache_exists:\n",
    "        data_cache = load_cache(base_url, path=path)\n",
    "        f=open(filename, 'r')\n",
    "        data_cache = f.read()\n",
    "        \n",
    "        soup_cache = BeautifulSoup(data_cache, 'html.parser')\n",
    "        body_cache = soup_cache.find_all('body')\n",
    "        soup_data = BeautifulSoup(data, 'html.parser')\n",
    "        body_data = soup_data.find_all('body')\n",
    "        \n",
    "        hash_cache = hash(str(body_cache))\n",
    "        hash_data = hash(str(body_data))\n",
    "        \n",
    "        \n",
    "        if body_cache == body_data:\n",
    "            message = f'No update from {base_url} \\n'\n",
    "            write_log(message, base_url, path=path)\n",
    "            return False\n",
    "        else:\n",
    "            message = f'Update detected from {base_url} \\n'\n",
    "            write_log(message, base_url, path=path)\n",
    "            return True\n",
    "        \n",
    "    else:\n",
    "        message1 = f'No cached webpage found for {base_url} \\n'\n",
    "        message2 = f'Initializing page in {filename} \\n'\n",
    "        write_log(f'{message1}{message2}', base_url, path=path)\n",
    "        store_cache(base_url, data, path=path)\n",
    "        return False\n",
    "        \n",
    "        \n",
    "        \n",
    "        \n",
    "\n",
    "def load_scache(base_url, path='logs/'):\n",
    "    url_filename = url_to_filename(base_url)\n",
    "    filename = f'{path}CACHE-{url_filename}.pkl'\n",
    "    f=open(filename, 'rb')\n",
    "    serial_data = f.read()\n",
    "    data_cache1 = pickle.loads(serial_data)\n",
    "    data_cache = pickle.loads(data_cache1) # Need to revisit\n",
    "    return data_cache\n",
    "\n",
    "\n",
    "def store_scache(base_url, data, path='logs/'):\n",
    "    url_filename = url_to_filename(base_url)\n",
    "    filename = f'{path}CACHE-{url_filename}.pkl'\n",
    "    f = open(filename, 'wb')\n",
    "    serial_data = pickle.dumps(data)\n",
    "    pickle.dump(serial_data, f)\n",
    "    # f.write(data_ser)\n",
    "    f.close()\n",
    "                      \n",
    "\n",
    "def scache_updated(base_url, data, path='logs/'):\n",
    "    # Check cache exists\n",
    "    url_filename = url_to_filename(base_url)\n",
    "    filename = f'{path}CACHE-{url_filename}.pkl'\n",
    "    cache_exists = os.path.isfile(filename)\n",
    "    \n",
    "    if cache_exists:\n",
    "        data_cache = load_cache(base_url, path=path)\n",
    "        f=open(filename, 'rb')\n",
    "        serial_cache = f.read()\n",
    "        serial_data = pickle.dumps(data)\n",
    "        \n",
    "        if serial_data == serial_cache:\n",
    "            message = f'No update from {base_url} \\n'\n",
    "            write_log(message, base_url, path=path)\n",
    "            return False\n",
    "        else:\n",
    "            message = f'Update detected from {base_url} \\n'\n",
    "            write_log(message, base_url, path=path)\n",
    "            return True\n",
    "        \n",
    "    else:\n",
    "        message1 = f'No cached webpage found for {base_url} \\n'\n",
    "        message2 = f'Initializing page in {filename} \\n'\n",
    "        write_log(f'{message1}{message2}', base_url, path=path)\n",
    "        store_cache(base_url, data, path=path)\n",
    "        return False\n",
    "        \n",
    "\n",
    "def write_log(message:str, base_url, path='logs/'):\n",
    "    print(message)\n",
    "    url_filename = url_to_filename(base_url)\n",
    "    filename = f'{path}LOG-{url_filename}.txt'\n",
    "    f = open(filename, 'w')\n",
    "    f.write(message)\n",
    "    f.close()\n",
    "    \n",
    "def get_links(html_data):\n",
    "    anchors = get_anchors(html_data)\n",
    "    hrefs, content = parse_anchors(anchors)\n",
    "    \n",
    "    return hrefs, content, anchors\n",
    "    \n",
    "\n",
    "def get_anchors(html_data):\n",
    "    if html_data.find('body') == None:\n",
    "        html_body = html_data\n",
    "    else:\n",
    "        html_body = html_data.find('body')   \n",
    "        \n",
    "    anchors = list(html_body.find_all('a'))\n",
    "    \n",
    "    return anchors\n",
    "\n",
    "\n",
    "def parse_anchors(anchors):\n",
    "    hrefs = []\n",
    "    content = []\n",
    "    \n",
    "    for anchor in anchors:\n",
    "        hrefs.append(anchor.get('href'))\n",
    "        content.append(anchor.text)\n",
    "    \n",
    "    return hrefs, content\n",
    "\n",
    "def get_new_diff(new_data, old_data):\n",
    "    diff = list(set(new_data) - set(old_data))\n",
    "    return diff\n",
    "\n",
    "\n",
    "def is_na(subject):\n",
    "    if isinstance(subject, str):\n",
    "        na_versions = ['n/a', 'nan']\n",
    "        if subject.lower() in na_versions:\n",
    "            return True\n",
    "        else: \n",
    "            return False\n",
    "    elif isinstance(subject, float):\n",
    "        if math.isnan(subject):\n",
    "            return True\n",
    "    elif isinstance(subject, bool):\n",
    "        return subject\n",
    "    else:\n",
    "        return False\n",
    "        \n",
    "    \n",
    "        "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "No update from https://www.astrazeneca.com/media-centre/press-releases.html \n",
      "\n",
      "False\n",
      "\n",
      "\n",
      "\n",
      "----------------------------------\n",
      "Skipping CanSino Biological Inc.\n",
      "\n",
      "----------------------------------\n",
      "\n",
      "\n",
      "\n",
      "----------------------------------\n",
      "Skipping Beijing Institute of Biotechnology\n",
      "\n",
      "----------------------------------\n",
      "\n",
      "\n",
      "Update detected from https://investors.modernatx.com/news-releases/ \n",
      "\n",
      "True\n",
      "\n",
      "\n",
      "New links found: \n",
      "---------------\n",
      "/news-releases/news-release-details/moderna-highlights-opportunity-mrna-vaccines-its-first-vaccines  ::  Moderna Highlights Opportunity of mRNA Vaccines at its First Vaccines Day\n",
      "https://www.modernatx.com/mrna-technology/research-engine  ::  Research Engine\n",
      "/news-releases/news-release-details/moderna-provides-business-updates-and-reports-third-quarter-2019  ::  Moderna Provides Business Updates and Reports Third Quarter 2019 Financial Results\n",
      "/  ::  \n",
      "/news-releases/news-release-details/moderna-present-preclinical-data-2019-american-society-gene-cell  ::  Moderna to Present Preclinical Data at 2019 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting\n",
      "/news-releases/news-release-details/elizabeth-tallett-joins-modernas-board-directors  ::  Elizabeth Tallett Joins Moderna’s Board of Directors\n",
      "/news-releases/news-release-details/moderna-present-goldman-sachs-40th-annual-global-healthcare  ::  Moderna to Present at Goldman Sachs 40th Annual Global Healthcare Conference\n",
      "/news-releases/news-release-details/moderna-named-top-employer-science-fifth-consecutive-year  ::  Moderna Named Top Employer by Science for Fifth Consecutive Year\n",
      "/news-releases/news-release-details/moderna-present-upcoming-investor-conferences-1  ::  Moderna to Present at Upcoming Investor Conferences\n",
      "/news-releases/news-release-details/moderna-present-18th-annual-needham-healthcare-conference  ::  Moderna to Present at 18th Annual Needham Healthcare Conference\n",
      "https://investors.modernatx.com/shareholder-services/email-alerts  ::  Join our Mailing List\n",
      "/news-releases/news-release-details/moderna-present-19th-annual-needham-healthcare-conference  ::  Moderna to Present at 19th Annual Needham Healthcare Conference\n",
      "/shareholder-services/investor-faqs  ::  Shareholder Resources\n",
      "/news-releases/news-release-details/moderna-host-rd-day-september-12-2019  ::  Moderna to Host R&D Day on September 12, 2019\n",
      "/news-releases/news-release-details/moderna-host-manufacturing-digital-day-march-4-2020  ::  Moderna to Host Manufacturing & Digital Day on March 4, 2020\n",
      "/news-releases/news-release-details/moderna-announces-pricing-public-offering-shares-common-stock  ::  Moderna Announces Pricing of Public Offering of Shares of Common Stock\n",
      "/news-releases/news-release-details/moderna-announces-first-participant-dosed-nih-led-phase-1-study  ::  Moderna Announces First Participant Dosed in NIH-led Phase 1 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus\n",
      "/news-releases/news-release-details/moderna-present-upcoming-investor-conferences-march  ::  Moderna to Present at Upcoming Investor Conferences in March\n",
      "/news-releases/news-release-details/moderna-host-science-day-may-7-2019-and-report-first-quarter  ::  Moderna to Host Science Day on May 7, 2019 and Report First Quarter Financial Results on May 8, 2019\n",
      "/news-releases/news-release-details/moderna-announces-pricing-public-offering-shares-common-stock-0  ::  Moderna Announces Pricing of Public Offering of Shares of Common Stock\n",
      "/news-releases/news-release-details/moderna-announces-first-patient-enrolled-phase-12-study-mrna  ::  Moderna Announces First Patient Enrolled in Phase 1/2 Study of mRNA-3704 for Methylmalonic Acidemia\n",
      "/news-releases/news-release-details/moderna-builds-clinical-validation-systemic-delivery-two  ::  Moderna Builds on Clinical Validation of Systemic Delivery with Two Additional Development Candidates in New Autoimmune Therapeutic Area\n",
      "/news-releases/news-release-details/moderna-present-upcoming-investor-conferences  ::  Moderna to Present at Upcoming Investor Conferences\n",
      "/news-releases/news-release-details/moderna-reports-first-quarter-2020-financial-results-and  ::  Moderna Reports First Quarter 2020 Financial Results and Provides Business Updates\n",
      "/news-releases/news-release-details/sandra-horning-md-join-modernas-board-directors  ::  Sandra Horning, M.D. To Join Moderna’s Board of Directors\n",
      "https://www.linkedin.com/company/moderna-therapeutics  ::  LinkedIn\n",
      "/news-releases/news-release-details/moderna-announces-positive-interim-phase-1-data-first  ::  Moderna Announces Positive Interim Phase 1 Data for First Combination Vaccine Against the Respiratory Viruses hMPV and PIV3\n",
      "https://www.modernatx.com/ecosystem/strategic-collaborators  ::  Strategic Collaborators\n",
      "https://www.modernatx.com/mrna-technology/intellectual-property  ::  Intellectual Property\n",
      "/news-releases/news-release-details/moderna-present-bmo-2019-prescriptions-success-healthcare  ::  Moderna to Present at BMO 2019 Prescriptions for Success Healthcare Conference\n",
      "/news-releases/news-release-details/moderna-announces-presentation-interim-data-phase-1-study-mrna  ::  Moderna Announces Presentation of Interim Data from Phase 1 Study of mRNA Personalized Cancer Vaccine at 2019 ASCO Annual Meeting\n",
      "/news-releases/news-release-details/moderna-announces-first-participants-each-age-cohort-dosed-phase  ::  Moderna Announces First Participants in Each Age Cohort Dosed in Phase 2 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus\n",
      "/news-releases/news-release-details/moderna-announces-open-ind-propionic-acidemia-program-mrna-3927  ::  Moderna Announces Open IND for Propionic Acidemia Program (mRNA-3927)\n",
      "/news-releases/news-release-details/moderna-announces-recent-progress-its-immuno-oncology-and-rare  ::  Moderna Announces Recent Progress in Its Immuno-Oncology and Rare Disease Programs and Highlights Corporate Objectives\n",
      "/news-releases/news-release-details/moderna-announces-positive-interim-results-phase-1  ::  Moderna Announces Positive Interim Results from Phase 1 Cytomegalovirus (CMV) Vaccine (mRNA-1647) Study and Progress Toward Phase 2 and Pivotal Trials\n",
      "https://www.modernatx.com/about-us/quick-facts  ::  Quick Facts\n",
      "/news-releases/news-release-details/moderna-host-virtual-science-day-june-2-2020  ::  Moderna to Host Virtual Science Day on June 2, 2020\n",
      "https://investors.modernatx.com/archived-press-releases?b7b10998_year%5Bvalue%5D=2018&op=Filter&b7b10998_widget_id=b7b10998&form_build_id=form-THGxyJg-cfeL_6ATRZUgwQNoyerLqE0cIUYENvH8d8s&form_id=widget_form_base  ::  See Archived Press Releases \n",
      "/news-releases/news-release-details/moderna-announces-ind-submitted-us-fda-phase-2-study-mrna  ::  Moderna Announces IND Submitted to U.S. FDA for Phase 2 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus\n",
      "/stock-information/stock-quote-chart  ::  Stock Information\n",
      "https://www.facebook.com/modernatx  ::  Facebook\n",
      "/news-releases/news-release-details/moderna-provide-business-and-pipeline-updates-2020-jp-morgan  ::  Moderna to Provide Business and Pipeline Updates at the 2020 J.P. Morgan Healthcare Conference\n",
      "/news-releases/news-release-details/moderna-announces-updated-plans-its-march-4-manufacturing  ::  Moderna Announces Updated Plans for its March 4 Manufacturing & Digital Day Event\n",
      "/news-releases  ::  Press Releases\n",
      "/news-releases/news-release-details/moderna-provides-update-impact-covid-19-business-operations-and  ::  Moderna Provides Update on the Impact of COVID-19 on Business Operations and Clinical Program Development\n",
      "/news-releases/news-release-details/moderna-highlights-advances-platform-science-and-innovative  ::  Moderna Highlights Advances in Platform Science and Innovative Vaccine Research at Third Annual Science Day\n",
      "/news-releases/news-release-details/moderna-receives-fda-fast-track-designation-mrna-vaccine-mrna  ::  Moderna Receives FDA Fast Track Designation for mRNA Vaccine (mRNA-1273) Against Novel Coronavirus\n",
      "/news-releases/news-release-details/moderna-present-bmo-2020-prescriptions-success-healthcare  ::  Moderna to Present at BMO 2020 Prescriptions for Success Healthcare Conference\n",
      "/news-releases/news-release-details/moderna-present-upcoming-investor-conferences-3  ::  Moderna to Present at Upcoming Investor Conferences\n",
      "/news-releases/news-release-details/moderna-announces-award-us-government-agency-barda-483-million  ::  Moderna Announces Award from U.S. Government Agency BARDA for up to $483 Million to Accelerate Development of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus\n",
      "/news-releases/news-release-details/moderna-announces-publication-preclinical-data-chikungunya  ::  Moderna Announces Publication of Preclinical Data for Chikungunya Antibody Program\n",
      "/news-releases/news-release-details/moderna-present-data-two-its-prophylactic-mrna-vaccines-idweek  ::  Moderna to Present Data From Two of Its Prophylactic mRNA Vaccines at IDWeek 2019\n",
      "/news-releases  ::  Newsroom\n",
      "/news-releases/news-release-details/dr-john-mendlein-transition-advisory-role-moderna-and-join  ::  Dr. John Mendlein to Transition to an Advisory Role at Moderna and Join Flagship Pioneering as an Executive Partner\n",
      "/news-releases/news-release-details/moderna-announces-mrna-immunotherapy-research-collaboration  ::  Moderna Announces mRNA Immunotherapy Research Collaboration with Harvard University\n",
      "https://www.modernatx.com/mrna-technology  ::  mRNA Technology\n",
      "/news-releases/news-release-details/moderna-and-lonza-announce-worldwide-strategic-collaboration  ::  Moderna and Lonza Announce Worldwide Strategic Collaboration to Manufacture Moderna’s Vaccine (mRNA-1273) Against Novel Coronavirus\n",
      "/news-releases/news-release-details/moderna-receives-fda-fast-track-designation-propionic-acidemia  ::  Moderna Receives FDA Fast Track Designation for Propionic Acidemia Program (mRNA-3927)\n",
      "/news-releases/news-release-details/moderna-announces-publication-phase-1-data-mrna-vaccines-against  ::  Moderna Announces Publication of Phase 1 Data for mRNA Vaccines Against Two Potential Pandemic Influenza Strains\n",
      "/news-releases/news-release-details/moderna-announces-proposed-public-offering-shares-common-stock-0  ::  Moderna Announces Proposed Public Offering of Shares of Common Stock\n",
      "/news-releases/news-release-details/moderna-report-second-quarter-2019-financial-results-wednesday  ::  Moderna to Report Second Quarter 2019 Financial Results on Wednesday, August 7th, 2019\n",
      "/news-releases/news-release-details/moderna-report-first-quarter-2020-financial-results-thursday-may  ::  Moderna to Report First Quarter 2020 Financial Results on Thursday, May 7th, 2020\n",
      "https://www.modernatx.com/mrna-technology/early-development-engine  ::  Early Development Engine\n",
      "/news-releases/news-release-details/ray-jordan-joins-moderna-chief-corporate-affairs-officer  ::  Ray Jordan Joins Moderna as Chief Corporate Affairs Officer\n",
      "/news-releases/news-release-details/moderna-announces-funding-award-cepi-accelerate-development  ::  Moderna Announces Funding Award from CEPI to Accelerate Development of Messenger RNA (mRNA) Vaccine Against Novel Coronavirus\n",
      "/news-releases/news-release-details/moderna-announces-proposed-public-offering-shares-common-stock  ::  Moderna Announces Proposed Public Offering of Shares of Common Stock\n",
      "https://www.modernatx.com/careers  ::  Careers\n",
      "/news-releases/news-release-details/moderna-announces-key-2020-investor-and-analyst-events  ::  Moderna Announces Key 2020 Investor and Analyst Events\n",
      "https://www.youtube.com/user/ModernaTx  ::  Youtube\n",
      "/news-releases/news-release-details/moderna-ships-mrna-vaccine-against-novel-coronavirus-mrna-1273  ::  Moderna Ships mRNA Vaccine Against Novel Coronavirus (mRNA-1273) for Phase 1 Study\n",
      "/news-releases/news-release-details/moderna-announces-dosing-first-monoclonal-antibody-encoded-mrna  ::  Moderna Announces Dosing of the First Monoclonal Antibody Encoded by mRNA in a Clinical Trial\n",
      "/news-releases/news-release-details/moderna-reports-2018-fourth-quarter-and-full-year-financial  ::  Moderna Reports 2018 Fourth Quarter and Full Year Financial Results and Highlights Recent Pipeline Progress\n",
      "/events-and-presentations  ::  Events & Presentations\n",
      "https://www.modernatx.com/modalities  ::  Modalities\n",
      "/corporate-governance/governance-overview  ::  Corporate Governance\n",
      "https://www.modernatx.com/moderna-blog  ::  Blog\n",
      "  ::  Continue\n",
      "https://www.modernatx.com/pipeline  ::  Pipeline\n",
      "https://www.modernatx.com/contact-us  ::  Contact Us\n",
      "https://www.modernatx.com/about-us/key-milestones  ::  Key Milestones\n",
      "/news-releases/news-release-details/moderna-present-credit-suisse-28th-annual-healthcare-conference  ::  Moderna to Present at Credit Suisse 28th Annual Healthcare Conference\n",
      "None  ::  ×\n",
      "/news-releases/news-release-details/moderna-provides-business-updates-and-reports-second-quarter  ::  Moderna Provides Business Updates and Reports Second Quarter 2019 Financial Results\n",
      "/news-releases/news-release-details/francois-nader-md-joins-modernas-board-directors  ::  François Nader, M.D., Joins Moderna’s Board of Directors\n",
      "/news-releases/news-release-details/moderna-receives-fda-fast-track-designation-zika-vaccine-mrna  ::  Moderna Receives FDA Fast Track Designation for Zika Vaccine mRNA-1893\n",
      "/news-releases/news-release-details/moderna-provide-business-and-pipeline-updates-2019-jp-morgan  ::  Moderna to Provide Business and Pipeline Updates at the 2019 J.P. Morgan Healthcare Conference\n",
      "/news-releases/news-release-details/moderna-advances-late-stage-development-its-vaccine-mrna-1273  ::  Moderna Advances Late-Stage Development of its Vaccine (mRNA-1273) Against COVID-19\n",
      "/news-releases/news-release-details/newly-published-pre-clinical-data-show-intratumoral-injections  ::  Newly Published Pre-Clinical Data Show Intratumoral Injections of Messenger RNA Encoding Three Immune Modulators Stimulate Durable Anti-Cancer Responses in Treated and Distal Tumors\n",
      "/news-releases/news-release-details/moderna-congratulates-dr-moncef-slaoui-his-appointment-oversee  ::  Moderna Congratulates Dr. Moncef Slaoui on His Appointment to Oversee the White House’s Operation Warp Speed Initiative\n",
      "https://www.modernatx.com/pipeline/clinical-trials  ::  Clinical Trials\n",
      "/news-releases/news-release-details/moderna-present-upcoming-investor-conferences-2  ::  Moderna to Present at Upcoming Investor Conferences\n",
      "/news-releases/news-release-details/moderna-announces-positive-interim-phase-1-data-its-mrna-vaccine  ::  Moderna Announces Positive Interim Phase 1 Data for its mRNA Vaccine (mRNA-1273) Against Novel Coronavirus\n",
      "/news-releases/news-release-details/moderna-present-mit-lecture-series  ::  Moderna to Present at MIT Lecture Series\n",
      "https://www.modernatx.com/about-us  ::  About Us\n",
      "/news-releases/news-release-details/phase-1-data-published-nature-communications-show-potential-mrna  ::  Phase 1 Data Published in Nature Communications Show Potential of mRNA Encoding VEGF-A as a Regenerative Therapeutic\n",
      "/news-releases/news-release-details/moderna-announces-positive-phase-1-results-first-systemic  ::  Moderna Announces Positive Phase 1 Results for the First Systemic Messenger RNA Therapeutic Encoding a Secreted Protein (mRNA-1944)\n",
      "https://www.modernatx.com/ecosystem/therapeutic-areas  ::  Therapeutic Areas\n",
      "/news-releases/news-release-details/moderna-and-catalent-announce-collaboration-fill-finish  ::  Moderna and Catalent Announce Collaboration for Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate\n",
      "/news-releases/news-release-details/moderna-present-roth-rna-revolution-conference  ::  Moderna to Present at ROTH RNA Revolution Conference\n",
      "/news-releases/news-release-details/moderna-appoints-tracey-franklin-chief-human-resources-officer  ::  Moderna Appoints Tracey Franklin as Chief Human Resources Officer\n",
      "/news-releases/news-release-details/moderna-present-bank-america-merrill-lynch-2019-health-care  ::  Moderna to Present at Bank of America Merrill Lynch 2019 Health Care Conference\n",
      "/news-releases/news-release-details/moderna-reports-first-quarter-2019-financial-results-and  ::  Moderna Reports First Quarter 2019 Financial Results and Provides Business Updates\n",
      "https://www.modernatx.com/about-us/leadership  ::  Leadership\n",
      "/  ::  Investors\n",
      "/news-releases/news-release-details/david-meline-joins-moderna-chief-financial-officer  ::  David Meline Joins Moderna as Chief Financial Officer\n",
      "/news-releases/news-release-details/moderna-host-virtual-vaccines-day-april-14-2020  ::  Moderna to Host Virtual Vaccines Day on April 14, 2020\n",
      "/  ::  Overview\n",
      "https://www.modernatx.com/privacy-policy  ::  Privacy Policy\n",
      "https://www.modernatx.com  ::  \n",
      "/news-releases/news-release-details/moderna-announces-additional-positive-phase-1-data  ::  Moderna Announces Additional Positive Phase 1 Data from Cytomegalovirus (CMV) Vaccine (mRNA-1647) and First Participant Dosed in Phase 2 Study\n",
      "https://www.modernatx.com/terms-of-use  ::  Terms of Use\n",
      "/news-releases/news-release-details/moderna-report-fourth-quarter-and-full-year-2019-financial  ::  Moderna to Report Fourth Quarter and Full Year 2019 Financial Results on Wednesday, February 26th, 2020\n",
      "/news-releases/news-release-details/moderna-reports-2019-fourth-quarter-and-full-year-financial  ::  Moderna Reports 2019 Fourth Quarter and Full Year Financial Results and Highlights Advancements in Core Modalities\n",
      "https://www.modernatx.com/ecosystem/new-venture-labs  ::  New Venture Labs\n",
      "#main-menu  ::  \n",
      "        Skip to main navigation\n",
      "      \n",
      "/news-releases/news-release-details/moderna-report-fourth-quarter-and-full-year-2018-financial  ::  Moderna to Report Fourth Quarter and Full Year 2018 Financial Results on Wednesday, March 6, 2019\n",
      "https://twitter.com/moderna_tx  ::  Twitter\n",
      "https://www.modernatx.com/about-us/corporate-social-responsibility  ::  Corporate Responsibility\n",
      "https://www.modernatx.com/mrna-technology/our-mrna-platform  ::  Our mRNA Plaform\n",
      "/news-releases/news-release-details/moderna-announces-its-2020-annual-meeting-stockholders-will-be  ::  Moderna Announces that Its 2020 Annual Meeting of Stockholders Will be Held in Virtual Format\n",
      "/news-releases/news-release-details/moderna-completes-enrollment-cytomegalovirus-cmv-vaccine-mrna  ::  Moderna Completes Enrollment of Cytomegalovirus (CMV) Vaccine (mRNA-1647) Phase 2 Study\n",
      "/news-releases/news-release-details/melanie-ivarsson-phd-joins-moderna-chief-development-officer  ::  Melanie Ivarsson, Ph.D. Joins Moderna as Chief Development Officer\n",
      "https://www.modernatx.com/mrna-technology/science-mrna  ::  The Science of mRNA\n",
      "/news-releases/news-release-details/moderna-present-upcoming-investor-conferences-0  ::  Moderna to Present at Upcoming Investor Conferences\n",
      "/news-releases/news-release-details/moderna-present-31st-annual-piper-jaffray-healthcare-conference  ::  Moderna to Present at 31st Annual Piper Jaffray Healthcare Conference\n",
      "/news-releases/news-release-details/moderna-report-third-quarter-2019-financial-results-wednesday  ::  Moderna to Report Third Quarter 2019 Financial Results on Wednesday, November 6th, 2019\n",
      "https://www.modernatx.com/citizenship  ::  Citizenship \n",
      "/financial-information/sec-filings  ::  SEC Filings\n",
      "https://www.modernatx.com/newsroom/publications  ::  Publications\n",
      "/news-releases/news-release-details/moderna-announces-progress-prophylactic-vaccines-modality-cmv  ::  Moderna Announces Progress in Prophylactic Vaccines Modality with CMV Vaccine Phase 2 Study Data Now Expected in Third Quarter 2020 and Expands Investment in This Core Modality with Three New Development Candidates\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "----------------------------------\n",
      "Skipping NIAID\n",
      "\n",
      "----------------------------------\n",
      "\n",
      "\n",
      "\n",
      "----------------------------------\n",
      "Skipping Wuhan Institute of Biological Products\n",
      "\n",
      "----------------------------------\n",
      "\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "----------------------------------\n",
      "Skipping Beijing Institute of Biological Products\n",
      "\n",
      "----------------------------------\n",
      "\n",
      "\n",
      "No update from http://www.sinovacbio.com/?optionid=754 \n",
      "\n",
      "False\n",
      "\n",
      "\n",
      "Update detected from https://ir.novavax.com/press-releases \n",
      "\n",
      "True\n",
      "\n",
      "\n",
      "New links found: \n",
      "---------------\n",
      "/news-releases/news-release-details/novavax-present-ladenburg-thalmann-2019-healthcare-conference  ::  Novavax to Present at the Ladenburg Thalmann 2019 Healthcare Conference\n",
      "/news-releases/news-release-details/novavax-initiates-pre-clinical-testing-intranasal-influenza  ::  Novavax Initiates Pre-Clinical Testing of Intranasal Influenza Vaccine\n",
      "/news-releases/news-release-details/novavax-present-rodman-renshaw-techvest-7th-annual-healthcare  ::  Novavax to Present at Rodman & Renshaw Techvest 7th Annual Healthcare Conference\n",
      "/news-releases/news-release-details/novavax-initiates-phase-2-clinical-trial-rsv-vaccine-candidate  ::  Novavax Initiates Phase 2 Clinical Trial of RSV Vaccine Candidate\n",
      "/news-releases/news-release-details/change-directors-or-principal-officers-financial-statements-and  ::  Change in Directors or Principal Officers, Financial Statements and Exhibits\n",
      "/news-releases/news-release-details/novavax-announces-grant-89-million-support-development-rsv-f  ::  Novavax Announces Grant of Up to $89 Million to Support Development of RSV F Vaccine to Protect Infants Via Maternal Immunization\n",
      "/news-releases/news-release-details/long-time-novavax-board-member-jack-marsh-assumes-role-director  ::  Long-Time Novavax Board Member Jack Marsh Assumes Role of Director Emeritus\n",
      "/news-releases/news-release-details/novavax-preclinical-nanoflu-data-published-vaccines-details  ::  Novavax’ Preclinical NanoFlu Data Published in Vaccines; Details Structural Basis for Broadly Neutralizing Immunity\n",
      "/news-releases/news-release-details/novavax-announces-release-date-2006-fourth-quarter-full-year  ::  Novavax Announces Release Date of 2006 Fourth Quarter, Full Year Financial Results and Investor Conference Call\n",
      "/news-releases/news-release-details/novavax-host-conference-call-discuss-first-quarter-financial  ::  Novavax to Host Conference Call to Discuss First Quarter Financial Results on May 7, 2015\n",
      "/news-releases/news-release-details/novavaxs-seasonal-influenza-vlp-vaccine-candidate-shows-positive  ::  Novavax's Seasonal Influenza VLP Vaccine Candidate Shows Positive Results in a Phase II Clinical Trial in Older Adults\n",
      "/news-releases/news-release-details/novavax-executes-definitive-agreements-18-million-public  ::  Novavax Executes Definitive Agreements for $18 Million Public Offering\n",
      "/news-releases/news-release-details/novavax-identifies-coronavirus-vaccine-candidate-accelerates  ::  Novavax Identifies Coronavirus Vaccine Candidate; Accelerates Initiation of First-in-Human Trial to Mid-May\n",
      "/news-releases/news-release-details/novavax-host-conference-call-discuss-second-quarter-financial  ::  Novavax to Host Conference Call to Discuss Second Quarter Financial Results on August 10, 2015\n",
      "https://novavax.com/20200116-JPM-Presentation.pdf  ::  Investor Presentation\n",
      "/news-releases/news-release-details/novavax-reports-fourth-quarter-and-full-year-2019-financial  ::  Novavax Reports Fourth Quarter and Full Year 2019 Financial Results\n",
      "https://novavax.com/2019_02_27_ResVax_Draft.pdf  ::  Investor Presentation\n",
      "/news-releases/news-release-details/novavax-reports-second-quarter-2018-financial-results  ::  Novavax Reports Second Quarter 2018 Financial Results\n",
      "/news-releases/news-release-details/novavax-present-citi-2011-global-health-care-conference  ::  NOVAVAX to Present at Citi 2011 Global Health Care Conference\n",
      "/news-releases/news-release-details/novavax-confirms-accelerated-approval-pathway-available  ::  Novavax Confirms Accelerated Approval Pathway Available for Licensure of NanoFlu™\n",
      "/news-releases/news-release-details/novavax-host-3rd-annual-analyst-and-investor-meeting-0  ::  Novavax to Host 3rd Annual Analyst and Investor Meeting\n",
      "/news-releases/news-release-details/novavax-report-first-quarter-2012-financial-results-may-4-2012  ::  NOVAVAX to Report First Quarter 2012 Financial Results on May 4, 2012\n",
      "/news-releases/news-release-details/novavax-ceo-present-piper-jaffray-london-health-care-conference  ::  Novavax CEO to Present at Piper Jaffray London Health Care Conference\n",
      "/news-releases/news-release-details/novavax-appoints-new-vice-president-vaccine-research  ::  Novavax Appoints New Vice President of Vaccine Research\n",
      "/news-releases/news-release-details/novavax-present-26th-annual-piper-jaffray-healthcare-conference  ::  Novavax to Present at the 26th Annual Piper Jaffray Healthcare Conference\n",
      "/news-releases/news-release-details/novavax-present-35th-annual-jp-morgan-healthcare-conference  ::  Novavax to Present at the 35th Annual J.P. Morgan Healthcare Conference\n",
      "/news-releases/news-release-details/novavax-reports-positive-preclinical-results-its-novel-vaccine  ::  Novavax reports positive preclinical results on its novel vaccine for pandemic influenza\n",
      "/news-releases/news-release-details/novavax-reports-fourth-quarter-and-year-end-2012-financial  ::  Novavax Reports Fourth Quarter and Year-End 2012 Financial Results\n",
      "/news-releases/news-release-details/novavax-succeeds-making-vaccine-protect-against-new-mutation  ::  Novavax Succeeds in Making Vaccine to Protect Against New Mutation of Avian Influenza\n",
      "/news-releases/news-release-details/novavax-and-collaborators-make-multiple-presentations-9th  ::  Novavax and Collaborators Make Multiple Presentations at the 9th International Respiratory Syncytial Virus Symposium in South Africa, November 9-13, 2014\n",
      "/news-releases/news-release-details/novavax-report-third-quarter-2002-financial-results-tuesday  ::  Novavax to Report Third Quarter 2002 Financial Results on Tuesday, November 12, 2002\n",
      "https://novavax.com  ::  \n",
      "\n",
      "\n",
      "/news-releases/news-release-details/novavax-names-jeffrey-church-chief-financial-officer  ::  Novavax Names Jeffrey Church Chief Financial Officer\n",
      "/news-releases/news-release-details/novavaxs-estrasorb-product-referenced-nbcs-today-show  ::  Novavax's ESTRASORB Product Referenced on NBC's 'Today Show'\n",
      "/news-releases/news-release-details/novavax-appoints-brian-rosen-vice-president-government-affairs  ::  Novavax Appoints Brian Rosen as Vice President, Government Affairs\n",
      "/news-releases/news-release-details/novavax-announces-first-quarter-2006-financial-results  ::  Novavax Announces First Quarter 2006 Financial Results\n",
      "/news-releases/news-release-details/novavax-scientific-leadership-present-rsv-maternal-immunization  ::  Novavax Scientific Leadership to Present RSV Maternal Immunization Program Phase 3 Data and Participate in Panel on COPD at World Vaccine Congress\n",
      "/news-releases/news-release-details/novavax-announces-strategic-alliance-pandemic-influenza-vaccine  ::  Novavax Announces Strategic Alliance on Pandemic Influenza Vaccine Production Technologies\n",
      "/news-releases/news-release-details/new-england-journal-medicine-publishes-positive-data-clinical  ::  New England Journal of Medicine Publishes Positive Data From Clinical Trial of Novavax' Vaccine Against H7N9 Avian Flu\n",
      "/  ::  For Investors\n",
      "/news-releases/news-release-details/novavax-present-34th-annual-jp-morgan-healthcare-conference  ::  Novavax to Present at the 34th Annual J.P. Morgan Healthcare Conference\n",
      "https://novavax.com  ::  \n",
      "\n",
      "\n",
      "/news-releases/news-release-details/novavax-presents-rsv-f-protein-nanoparticle-vaccine-clinical  ::  Novavax Presents RSV F Protein Nanoparticle Vaccine Clinical Data at the 8th Vaccine & ISV Congress in Philadelphia on Sunday, October 26\n",
      "/news-releases/news-release-details/novavax-host-conference-call-discuss-third-quarter-2014  ::  Novavax to Host Conference Call to Discuss Third Quarter 2014 Financial Results on November 5, 2014\n",
      "/news-releases/news-release-details/novavax-appoints-james-robinson-vice-president-technical-and  ::  Novavax Appoints James Robinson Vice President of Technical and Quality Operations\n",
      "/news-releases/news-release-details/novavax-reports-third-quarter-2006-financial-results  ::  Novavax Reports Third Quarter 2006 Financial Results\n",
      "/press-releases?field_nir_news_date_value%5Bmin%5D=2015  ::  2015\n",
      "/news-releases/news-release-details/novavax-host-conference-call-discuss-third-quarter-2017  ::  Novavax to Host Conference Call to Discuss Third Quarter 2017 Financial Results on November 7, 2017\n",
      "/press-releases  ::  Press Releases\n",
      "/news-releases/news-release-details/novavax-announces-appointment-dr-mark-thornton-senior-vice  ::  Novavax Announces Appointment of Dr. Mark Thornton as Senior Vice President, Development and Chief Medical Officer\n",
      "/news-releases/news-release-details/novavax-review-recent-findings-vaccine-programs-world-vaccine  ::  Novavax to Review Recent Findings from Vaccine Programs at World Vaccine Congress and Expo in Washington, DC\n",
      "/news-releases/news-release-details/novavax-initiates-phase-2-clinical-trial-quadrivalent-seasonal  ::  Novavax Initiates Phase 2 Clinical Trial of Quadrivalent Seasonal Influenza VLP\n",
      "/news-releases/news-release-details/novavax-inc-present-ubs-warburg-global-specialty-pharmaceuticals  ::  Novavax, Inc. to Present at UBS Warburg Global Specialty Pharmaceuticals Conference\n",
      "/news-releases/news-release-details/novavax-elects-james-f-young-its-board-directors  ::  NOVAVAX Elects James F. Young to Its Board of Directors\n",
      "/news-releases/news-release-details/novavax-host-conference-call-discuss-second-quarter-2017  ::  Novavax to Host Conference Call to Discuss Second Quarter 2017 Financial Results on August 8, 2017\n",
      "/news-releases/news-release-details/novavax-present-14th-annual-needham-healthcare-conference  ::  Novavax to Present at the 14th Annual Needham Healthcare Conference\n",
      "/news-releases/news-release-details/novavax-announces-leadership-change  ::  Novavax Announces Leadership Change\n",
      "/news-releases/news-release-details/novavax-report-2012-fourth-quarter-and-year-end-financial  ::  Novavax to Report 2012 Fourth-Quarter and Year-End Financial Results on March 1, 2013\n",
      "/news-releases/news-release-details/novavax-initiate-seasonal-and-pandemic-influenza-trials  ::  Novavax to Initiate Seasonal and Pandemic Influenza Trials in Collaboration With BARDA\n",
      "/news-releases/news-release-details/novavax-inc-initiates-combination-study-androsorbtm-and  ::  Novavax, Inc. Initiates Combination Study of ANDROSORB(TM) and ESTRASORB(TM) In Hormone Deficient Women\n",
      "/news-releases/news-release-details/novavax-inc-present-bio-ceo-and-investor-conference-2004  ::  Novavax, Inc. to Present at BIO CEO and Investor Conference 2004\n",
      "/news-releases/news-release-details/novavax-announces-proposed-offering-200-million-convertible  ::  Novavax Announces Proposed Offering of $200 Million of Convertible Senior Notes Due 2023\n",
      "/news-releases/news-release-details/novavax-present-25th-annual-piper-jaffray-healthcare-conference  ::  Novavax to Present at the 25th Annual Piper Jaffray Healthcare Conference\n",
      "/news-releases/news-release-details/novavax-reports-third-quarter-2012-financial-results  ::  Novavax Reports Third-Quarter 2012 Financial Results\n",
      "/news-releases/news-release-details/novavax-announces-27-million-equity-offering  ::  Novavax Announces $27 Million Equity Offering\n",
      "/news-releases/news-release-details/novavax-present-ladenburg-thalmann-2017-healthcare-conference  ::  Novavax to Present at the Ladenburg Thalmann 2017 Healthcare Conference\n",
      "/news-releases/news-release-details/novavax-present-2012-wedbush-life-sciences-conference  ::  NOVAVAX to Present at the 2012 Wedbush Life Sciences Conference\n",
      "/news-releases/news-release-details/novavax-reports-positive-top-line-results-two-phase-1-trials  ::  Novavax Reports Positive Top-Line Results From Two Phase 1 Trials of Pandemic Influenza Vaccine\n",
      "/news-releases/news-release-details/novavax-present-interscience-conference-antimicrobial-agents-and  ::  NOVAVAX to Present at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)\n",
      "https://novavax.com/download/files/policy/NVAX_PO_Language_2016-12-01.pdf  ::  Purchase Order Terms and Conditions\n",
      "/news-releases/news-release-details/novavax-host-conference-call-discuss-fourth-quarter-and-full-0  ::  Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2015 Financial Results on February 29, 2016\n",
      "/news-releases/news-release-details/novavax-and-serum-institute-india-develop-and-commercialize  ::  Novavax and Serum Institute of India to Develop and Commercialize Malaria Vaccine Candidate\n",
      "https://www.youtube.com/channel/UCrNorBVidJqLcfgKPkMdQVQ  ::  \n",
      "\n",
      "\n",
      "/news-releases/news-release-details/novavax-receive-388-million-funding-cepi-covid-19-vaccine  ::  Novavax to Receive up to $388 Million Funding from CEPI for COVID-19 Vaccine Development and Manufacturing\n",
      "/news-releases/news-release-details/novavax-report-third-quarter-2010-financial-results-november-5  ::  Novavax to Report Third Quarter 2010 Financial Results on November 5, 2010\n",
      "/news-releases/news-release-details/novavax-present-38th-annual-jp-morgan-healthcare-conference  ::  Novavax to Present at the 38th Annual J.P. Morgan Healthcare Conference\n",
      "/news-releases/news-release-details/novavax-reports-third-quarter-2018-financial-results  ::  Novavax Reports Third Quarter 2018 Financial Results\n",
      "/news-releases/news-release-details/novavax-appoints-jeffrey-stoddard-md-vice-president-medical  ::  Novavax Appoints Jeffrey Stoddard, M.D., Vice President, Medical Affairs\n",
      "/news-releases/news-release-details/novavax-inc-announces-2002-fourth-quarter-and-year-end-results  ::  Novavax, Inc. Announces 2002 Fourth Quarter and Year End Results\n",
      "/news-releases/news-release-details/novavax-reports-fourth-quarter-and-2011-year-end-financial  ::  NOVAVAX Reports Fourth Quarter and 2011 Year-End Financial Results\n",
      "/news-releases/news-release-details/novavax-announces-second-quarter-financial-results  ::  Novavax Announces Second Quarter Financial Results\n",
      "/news-releases/news-release-details/novavax-host-2nd-annual-analyst-and-investor-meeting  ::  Novavax to Host 2nd Annual Analyst and Investor Meeting\n",
      "/news-releases/news-release-details/novavax-reports-first-quarter-2011-financial-results  ::  Novavax Reports First Quarter 2011 Financial Results\n",
      "/news-releases/news-release-details/novavax-reports-third-quarter-2011-financial-results  ::  NOVAVAX Reports Third Quarter 2011 Financial Results\n",
      "/news-releases/news-release-details/novavax-named-biotechnology-firm-year-tech-council-maryland  ::  Novavax Named Biotechnology Firm of the Year by Tech Council of Maryland\n",
      "/news-releases/news-release-details/novavax-announces-management-promotion-1  ::  Novavax Announces Management Promotion\n",
      "/news-releases/news-release-details/novavax-announces-senior-management-appointments  ::  Novavax Announces Senior Management Appointments\n",
      "/news-releases/news-release-details/novavax-reports-second-quarter-2017-financial-results  ::  Novavax Reports Second Quarter 2017 Financial Results\n",
      "/news-releases/news-release-details/novavax-details-advantages-portable-manufacturing-process-world  ::  Novavax Details Advantages of Portable Manufacturing Process at World Vaccine Congress\n",
      "/news-releases/news-release-details/novavax-announces-release-date-fourth-quarter-and-year-end-2005  ::  Novavax Announces Release Date of Fourth Quarter and Year-End 2005 Financial Results and Investor Conference Call\n",
      "/news-releases/news-release-details/novavax-board-appoints-current-director-audit-committee  ::  Novavax Board Appoints Current Director to Audit Committee\n",
      "/news-releases/news-release-details/novavax-prices-300-million-convertible-senior-notes-due-2023  ::  Novavax Prices $300 Million of Convertible Senior Notes Due 2023\n",
      "/news-releases/news-release-details/barda-continues-novavax-influenza-vaccine-programs-following  ::  BARDA Continues Novavax' Influenza Vaccine Programs Following In-Process Review\n",
      "/news-releases/news-release-details/novavax-announces-positive-top-line-data-phase-1-ebola-vaccine  ::  Novavax Announces Positive Top-Line Data From Phase 1 Ebola Vaccine Trial on WHO Teleconference\n",
      "/news-releases/news-release-details/novavax-announces-release-date-first-quarter-results  ::  Novavax announces release date of first quarter results\n",
      "/news-releases/news-release-details/novavax-inc-announces-extension-fda-review-time-estrasorbtm  ::  Novavax, Inc. Announces Extension of FDA Review Time for Estrasorb(TM)\n",
      "/news-releases/news-release-details/novavax-ceo-present-ubs-global-life-sciences-conference  ::  Novavax CEO to Present at UBS Global Life Sciences Conference\n",
      "/news-releases/news-release-details/novavax-president-rd-dr-gregory-glenn-discuss-development-covid  ::  Novavax President of R&D Dr. Gregory Glenn to Discuss the Development of COVID-19 Vaccines on Panel at 2020 BIO Digital\n",
      "/news-releases/news-release-details/novavax-and-catalent-biologics-enter-strategic-partnership  ::  Novavax and Catalent Biologics Enter Strategic Partnership: Allowing Catalent Biologics to Expand Gene Therapy Footprint with Acquisition of Novavax’ Manufacturing Assets and Capabilities\n",
      "/news-releases/news-release-details/novavax-appoints-sven-andreasson-senior-vice-president-corporate  ::  Novavax Appoints Sven Andreasson as Senior Vice President, Corporate Development\n",
      "/news-releases/news-release-details/novavax-incs-new-drug-application-estrasorbtm-novel-transdermal  ::  Novavax, Inc.'s New Drug Application for ESTRASORB(TM), a Novel Transdermal, Topical Estrogen Replacement Therapy, Accepted for Review by the FDA\n",
      "/news-releases/news-release-details/novavax-reports-third-quarter-2019-financial-results  ::  Novavax Reports Third Quarter 2019 Financial Results\n",
      "/news-releases/news-release-details/novavax-named-fast-companys-top-ten-most-innovative-biotech  ::  NOVAVAX Named to Fast Company's Top Ten Most Innovative Biotech Companies List\n",
      "/news-releases/news-release-details/novavax-host-analyst-and-investor-update-call-webcast  ::  Novavax to Host an Analyst and Investor Update Call With Webcast\n",
      "/news-releases/news-release-details/novavax-prices-public-offering-common-stock-1  ::  Novavax Prices Public Offering of Common Stock\n",
      "/news-releases/news-release-details/novavax-announces-new-president-ceo-and-board-member  ::  Novavax Announces New President, CEO and Board Member\n",
      "/news-releases/news-release-details/novavax-host-conference-call-discuss-first-quarter-2017  ::  Novavax to Host Conference Call to Discuss First Quarter 2017  Financial Results on May 8, 2017\n",
      "#  ::  Print Page\n",
      "/news-releases/news-release-details/novavax-presents-data-rsv-f-nanoparticle-vaccine-induced  ::  Novavax Presents Data on RSV F Nanoparticle Vaccine Induced Monoclonal Antibody at ICAAC\n",
      "/news-releases/news-release-details/stanley-erck-elected-executive-chairman  ::  Stanley Erck Elected as Executive Chairman\n",
      "/news-releases/news-release-details/novavax-present-noble-financial-7th-annual-equity-conference  ::  NOVAVAX to Present at the NOBLE FINANCIAL 7th Annual Equity Conference\n",
      "/news-releases/news-release-details/novavax-present-wedbush-pacgrow-healthcare-conference  ::  Novavax to Present at the Wedbush PacGrow Healthcare Conference\n",
      "/news-releases/news-release-details/novavax-comments-e-selectin-tolerogen-treatment-nih-prevents  ::  Novavax Comments that E-Selectin Tolerogen Treatment by NIH Prevents Strokes In Animals\n",
      "/news-releases/news-release-details/novavax-reports-second-quarter-2010-financial-results  ::  NOVAVAX Reports Second Quarter 2010 Financial Results\n",
      "/news-releases/news-release-details/novavax-and-esprit-pharma-co-develop-novel-medicine-female  ::  Novavax and Esprit Pharma to Co-develop Novel Medicine for Female Sexual Desire Disorder\n",
      "/news-releases/news-release-details/novavax-publishes-positive-preclinical-efficacy-data-against  ::  Novavax Publishes Positive Preclinical Efficacy Data Against Influenza A(H7N9)\n",
      "/news-releases/news-release-details/novavax-names-len-stigliano-chief-financial-officer  ::  Novavax Names Len Stigliano Chief Financial Officer\n",
      "/news-releases/news-release-details/novavax-present-2013-stifel-nicolaus-healthcare-conference  ::  Novavax to Present at the 2013 Stifel Nicolaus Healthcare Conference\n",
      "/news-releases/news-release-details/novavax-inc-present-salomon-smith-barney-2nd-annual-specialty  ::  Novavax, Inc. to Present at Salomon Smith Barney 2nd Annual Specialty Pharmaceuticals Conference\n",
      "/news-releases/news-release-details/novavax-announces-leadership-promotions  ::  Novavax Announces Leadership Promotions\n",
      "/news-releases/news-release-details/novavax-h7n9-vlp-influenza-vaccine-enters-animal-testing  ::  Novavax H7N9 VLP Influenza Vaccine Enters Animal Testing\n",
      "/news-releases/news-release-details/novavax-study-published-vaccine-rsv-f-protein-nanoparticle  ::  Novavax Study Published in Vaccine: RSV F-Protein Nanoparticle Vaccine Induces Antigenic Site II Antibodies\n",
      "/news-releases/news-release-details/novavax-report-first-quarter-2011-financial-results-may-9-2011  ::  Novavax to Report First Quarter 2011 Financial Results on May 9, 2011\n",
      "/news-releases/news-release-details/novavax-relocating-corporate-headquarters-maryland  ::  Novavax Relocating Corporate Headquarters to Maryland\n",
      "/news-releases/news-release-details/novavax-ceo-present-rodman-renshaws-annual-healthcare-conference  ::  Novavax CEO to Present at Rodman & Renshaw's Annual Healthcare Conference\n",
      "/news-releases/news-release-details/us-senator-rick-santorum-r-pa-will-tour-novavax-facility  ::  U.S. Senator Rick Santorum (R-PA) Will Tour Novavax Facility\n",
      "/news-releases/news-release-details/novavax-report-second-quarter-2002-financial-results-monday  ::  Novavax to Report Second Quarter 2002 Financial Results On Monday, August 12, 2002\n",
      "/news-releases/news-release-details/novavax-inc-announces-2003-first-quarter-results  ::  Novavax, Inc. Announces 2003 First Quarter Results\n",
      "/news-releases/news-release-details/novavax-licenses-wyeths-virus-particle-technology  ::  Novavax Licenses Wyeth's Virus-Like Particle Technology\n",
      "/news-releases/news-release-details/novavaxs-pandemic-influenza-vaccine-candidates-trigger-robust  ::  Novavax's Pandemic Influenza Vaccine Candidates Trigger Robust Immune Response In Pre-Clinical Models\n",
      "/news-releases/news-release-details/novavax-announces-topline-results-phase-3-preparetm-trial  ::  Novavax Announces Topline Results from Phase 3 PrepareTM Trial of ResVax™ for Prevention of RSV Disease in Infants via Maternal Immunization\n",
      "https://novavax.com/science-and-technology-overview  ::  Science and Technology\n",
      "/news-releases/news-release-details/novavax-and-catalent-announce-closing-strategic-partnership  ::  Novavax and Catalent Announce Closing of Strategic Partnership\n",
      "/news-releases/news-release-details/novavax-present-ladenburg-thalmann-2015-healthcare-conference  ::  Novavax to Present at the Ladenburg Thalmann 2015 Healthcare Conference\n",
      "/news-releases/news-release-details/novavax-present-rodman-renshaw-3rd-annual-global-healthcare  ::  Novavax to Present at the Rodman & Renshaw 3rd Annual Global Healthcare Conference\n",
      "/news-releases/news-release-details/novavax-reports-third-quarter-2013-financial-results  ::  Novavax Reports Third-Quarter 2013 Financial Results\n",
      "/news-releases/news-release-details/update-novavax-host-conference-call-discuss-third-quarter  ::  UPDATE -- Novavax to Host Conference Call to Discuss Third Quarter Financial Results on November 9, 2016\n",
      "/news-releases/news-release-details/novavax-present-33rd-annual-jp-morgan-healthcare-conference  ::  Novavax to Present at the 33rd Annual J.P. Morgan Healthcare Conference\n",
      "/news-releases/news-release-details/novavax-announces-manufacturing-management-appointments  ::  Novavax Announces Manufacturing Management Appointments\n",
      "https://novavax.com/privacy-policy  ::  Privacy Policy\n",
      "/news-releases/news-release-details/novavax-announces-agreement-reduce-estrasorb-manufacturing-costs  ::  Novavax announces agreement to reduce ESTRASORB manufacturing costs\n",
      "/news-releases/news-release-details/novavax-inc-clarifies-recent-form-s-3-registration-statement  ::  Novavax, Inc. Clarifies Recent Form S-3 Registration Statement Filings and Provides Update on ESTRASORB Prescription Data\n",
      "/news-releases/news-release-details/novavax-reports-progress-rsv-vaccine-new-international  ::  NOVAVAX Reports on Progress with RSV Vaccine at New International Conference on Modern Vaccines\n",
      "/news-releases/news-release-details/novavax-announces-co-promotion-agreement-ferndale-laboratories  ::  Novavax Announces Co-Promotion Agreement With Ferndale Laboratories, Inc.\n",
      "/news-releases/news-release-details/novavax-reports-second-quarter-2011-financial-results  ::  Novavax Reports Second Quarter 2011 Financial Results\n",
      "/news-releases/news-release-details/novavax-present-2005-bio-investorforum  ::  Novavax to Present at the 2005 Bio InvestorForum\n",
      "/news-releases/news-release-details/novavax-present-ubs-global-specialty-pharmaceuticals-conference  ::  Novavax to Present at UBS Global Specialty Pharmaceuticals Conference\n",
      "/news-releases/news-release-details/novavax-awarded-department-defense-contract-covid-19-vaccine  ::  Novavax Awarded Department of Defense Contract for COVID-19 Vaccine\n",
      "https://novavax.com/analyst-coverage  ::  Analyst Coverage\n",
      "/news-releases/news-release-details/novavax-and-mexican-social-security-institute-publish-results  ::  NOVAVAX and the Mexican Social Security Institute Publish Results From H1N1 Influenza Vaccine Trial in Mexico\n",
      "/news-releases/news-release-details/novavax-announces-20-million-common-stock-offering-kleiner  ::  Novavax Announces $20 Million Common Stock Offering to Kleiner Perkins Caufield & Byers and Prospect Venture Partners\n",
      "/news-releases/news-release-details/novavax-appoints-amy-b-fix-vice-president-regulatory-affairs  ::  Novavax Appoints Amy B. Fix Vice President of Regulatory Affairs\n",
      "/news-releases/news-release-details/novavax-closes-sale-non-core-product-assets  ::  Novavax Closes Sale of Non-Core Product Assets\n",
      "/news-releases/news-release-details/novavax-present-phacilitate-vaccine-forum-washington-2010  ::  NOVAVAX to Present at Phacilitate Vaccine Forum Washington 2010\n",
      "/news-releases/news-release-details/novavax-present-clinical-data-rsv-f-and-nanoflutm-vaccines-world  ::  Novavax to Present Clinical Data on RSV F and NanoFlu™ Vaccines at World Vaccine Congress\n",
      "/news-releases/news-release-details/novavax-reports-third-quarter-2015-financial-results  ::  Novavax Reports Third Quarter 2015 Financial Results\n",
      "/news-releases/news-release-details/novavax-present-piper-jaffray-22nd-annual-healthcare-conference  ::  NOVAVAX to Present at Piper Jaffray 22nd Annual Healthcare Conference\n",
      "/news-releases/news-release-details/novavax-host-conference-call-discuss-fourth-quarter-financial  ::  Novavax to Host Conference Call to Discuss Fourth Quarter Financial Results on March 11, 2020\n",
      "/news-releases/news-release-details/novavax-reports-first-quarter-2007-financial-results  ::  Novavax Reports First Quarter 2007 Financial Results\n",
      "/news-releases/news-release-details/novavax-host-conference-call-discuss-first-quarter-financial-2  ::  Novavax to Host Conference Call to Discuss First Quarter Financial Results on May 2, 2019\n",
      "/news-releases/news-release-details/novavax-reports-second-quarter-2014-financial-results  ::  Novavax Reports Second-Quarter 2014 Financial Results\n",
      "/news-releases/news-release-details/novavax-present-13th-annual-needham-healthcare-conference  ::  Novavax to Present at the 13th Annual Needham Healthcare Conference\n",
      "/news-releases/news-release-details/novavax-announces-release-date-2009-year-end-financial-results  ::  NOVAVAX Announces Release Date of 2009 Year-End Financial Results and Investor Conference Call\n",
      "/news-releases/news-release-details/novavax-present-ubs-global-pharmaceuticals-conference  ::  Novavax to present at the UBS Global Pharmaceuticals Conference\n",
      "/news-releases/news-release-details/novavax-pandemic-flu-vaccine-provided-protection-against-lethal  ::  Novavax Pandemic Flu Vaccine Provided Protection Against a Lethal Challenge of Live Virus, Pre-Clinical Data Show\n",
      "/news-releases/news-release-details/novavax-announces-publication-pre-clinical-study-its-pandemic  ::  Novavax Announces Publication of a Pre-clinical Study with its Pandemic 2009 H1N1 Influenza Virus-Like Particle (VLP) Vaccine\n",
      "/news-releases/news-release-details/novavax-enters-final-phase-its-commercial-launch-estrasorbr  ::  Novavax Enters Final Phase of Its Commercial Launch of ESTRASORB(R)\n",
      "/news-releases/news-release-details/novavax-completes-estrasorb-partnership  ::  Novavax Completes ESTRASORB Partnership\n",
      "/news-releases/news-release-details/new-england-journal-medicine-publishes-novavax-nanoflu-clinical  ::  New England Journal of Medicine Publishes Novavax’ NanoFlu Clinical Trial Data\n",
      "/news-releases/news-release-details/novavax-inc-board-directors-adopts-stockholder-rights-plan  ::  Novavax, Inc. Board Of Directors Adopts Stockholder Rights Plan\n",
      "/news-releases/news-release-details/novavax-announces-closing-public-offering  ::  Novavax Announces Closing of Public Offering\n",
      "/news-releases/news-release-details/novavax-added-nasdaq-biotech-index  ::  Novavax Added to NASDAQ Biotech Index\n",
      "/news-releases/news-release-details/novavax-present-hc-wainwright-21st-annual-global-investment  ::  Novavax to Present at the H.C. Wainwright 21st Annual Global Investment Conference\n",
      "/news-releases/news-release-details/novavax-appoints-rachel-king-board-directors  ::  Novavax Appoints Rachel King to Board of Directors\n",
      "/news-releases/news-release-details/icaac-presentation-immunization-pregnant-baboons-rsv-f  ::  ICAAC Presentation: Immunization of Pregnant Baboons With the RSV F Nanoparticle Vaccine Protects Infant Baboons Challenged With Respiratory Syncytial Virus in a Comparable Manner to Infants Prophylaxed With Palivizumab\n",
      "/news-releases/news-release-details/correcting-and-replacing-novavax-present-rsv-vaccine-preclinical  ::  CORRECTING and REPLACING -- Novavax to Present RSV Vaccine Preclinical Results at ICAAC\n",
      "/news-releases/news-release-details/novavax-present-stifel-2017-healthcare-conference  ::  Novavax to Present at the Stifel 2017 Healthcare Conference\n",
      "/news-releases/news-release-details/novavax-present-2013-wedbush-life-sciences-conference  ::  NOVAVAX to Present at the 2013 Wedbush Life Sciences Conference\n",
      "/news-releases/news-release-details/novavax-announces-positive-topline-data-phase-2-older-adult  ::  Novavax Announces Positive Topline Data from Phase 2 Older Adult Trial and Provides Path Forward for RSV F Vaccine Programs\n",
      "/news-releases/news-release-details/novavax-review-rsv-program-new-international-conference-modern  ::  Novavax to Review RSV Program at New International Conference on Modern Vaccines\n",
      "/news-releases/news-release-details/novavaxs-head-vaccine-research-participate-who-meeting-develop  ::  Novavax's Head Of Vaccine Research To Participate In WHO Meeting To Develop Global Action Plan For Pandemic Influenza\n",
      "/news-releases/news-release-details/novavax-appoints-dr-cindy-oliver-senior-vice-president-process  ::  Novavax Appoints Dr. Cindy Oliver as Senior Vice President, Process Development Operations\n",
      "/news-releases/news-release-details/novavax-announces-promotion-dr-james-f-cummings-vice-president  ::  Novavax Announces the Promotion of Dr. James F. Cummings to Vice President, Clinical Development and Translational Medicine\n",
      "/news-releases/news-release-details/novavax-announces-proposed-public-offering-common-stock-0  ::  Novavax Announces Proposed Public Offering of Common Stock\n",
      "https://www.linkedin.com/company/novavax  ::  \n",
      "\n",
      "\n",
      "/news-releases/news-release-details/novavax-presents-new-data-non-human-primate-ebola-challenge-7th  ::  Novavax Presents New Data From Non-Human Primate Ebola Challenge at the 7th International Symposium on Filoviruses\n",
      "/stock-information/stock-quote-chart  ::  Stock Information\n",
      "/news-releases/news-release-details/novavax-vaccine-provides-robust-immune-response-pre-clinical  ::  Novavax Vaccine Provides Robust Immune Response, Pre-Clinical Data Show\n",
      "/news-releases/news-release-details/novavax-present-bio-ceo-investor-conference  ::  Novavax to Present at BIO CEO & Investor Conference\n",
      "/news-releases/news-release-details/novavax-licenses-recombinant-vlp-influenza-vaccine-lg-life  ::  Novavax Licenses Recombinant VLP Influenza Vaccine to LG Life Sciences for South Korea and Other Countries\n",
      "/news-releases/news-release-details/novavax-files-100-million-shelf-registration-statement  ::  Novavax Files $100 Million Shelf Registration Statement\n",
      "/news-releases/news-release-details/novavax-reports-third-quarter-2010-financial-results  ::  NOVAVAX Reports Third Quarter 2010 Financial Results\n",
      "/news-releases/news-release-details/novavax-present-rodman-renshaw-14th-annual-healthcare-conference  ::  NOVAVAX to Present at the Rodman & Renshaw 14th Annual Healthcare Conference\n",
      "/news-releases/news-release-details/novavax-reaches-agreement-fda-pivotal-phase-3-trial-design  ::  Novavax Reaches Agreement with the FDA on Pivotal Phase 3 Trial Design for NanoFlu\n",
      "/news-releases/news-release-details/novavax-report-second-quarter-2004-financial-results-monday  ::  NOVAVAX To Report Second Quarter 2004 Financial Results On Monday, August 9, 2004\n",
      "https://twitter.com/novavax  ::  \n",
      "\n",
      "\n",
      "/news-releases/news-release-details/novavax-inc-present-cibc-world-markets-annual-biotechnology  ::  Novavax, Inc. to Present at CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference\n",
      "/news-releases/news-release-details/novavax-inc-announces-2001-fourth-quarter-and-year-end-financial  ::  Novavax, Inc. Announces 2001 Fourth Quarter and Year End Financial Results\n",
      "/news-releases/news-release-details/novavax-participate-multiple-investor-conferences-september  ::  Novavax to Participate in Multiple Investor Conferences in September\n",
      "/news-releases/news-release-details/novavax-host-3rd-annual-analyst-and-investor-meeting  ::  Novavax to Host 3rd Annual Analyst and Investor Meeting\n",
      "/news-releases/news-release-details/novavax-ceo-present-needhams-6th-annual-biotechnology-medical  ::  Novavax CEO to Present at Needham's 6th Annual Biotechnology & Medical Technology Conference\n",
      "/news-releases/news-release-details/novavax-present-immunotherapeutics-and-vaccine-imvac-summit  ::  NOVAVAX to Present at the Immunotherapeutics and Vaccine (IMVAC) Summit\n",
      "/news-releases/news-release-details/novavax-announces-positive-top-line-data-phase-2-clinical-trial  ::  Novavax Announces Positive Top-Line Data from Phase 2 Clinical Trial of RSV F Vaccine to Protect Infants via Maternal Immunization\n",
      "javascript;  ::  More\n",
      "/news-releases/news-release-details/novavax-appoints-new-vice-president-pharmaceutical-development-0  ::  Novavax Appoints New Vice President of Pharmaceutical Development\n",
      "/news-releases/news-release-details/novavax-announces-positive-pre-clinical-results  ::  Novavax Announces Positive Pre-Clinical Results\n",
      "/news-releases/news-release-details/us-fda-grants-fast-track-designation-novavax-rsv-f-vaccine-older  ::  U.S. FDA Grants Fast Track Designation to Novavax’ RSV F Vaccine for Older Adults\n",
      "/events  ::  Events\n",
      "/news-releases/news-release-details/novavax-appoints-john-j-trizzino-senior-vice-president  ::  Novavax Appoints John J. Trizzino as Senior Vice President, Commercial Operations\n",
      "/news-releases/news-release-details/novavax-present-lazard-7th-annual-healthcare-conference  ::  NOVAVAX to Present at Lazard 7th Annual Healthcare Conference\n",
      "/news-releases/news-release-details/novavax-announces-positive-top-line-data-phase-2-rsv-f-protein  ::  Novavax Announces Positive Top-Line Data from Phase 2 RSV F-Protein Vaccine Clinical Trial in Older Adults\n",
      "/news-releases/news-release-details/novavax-present-12th-annual-needham-healthcare-conference  ::  Novavax to Present at 12th Annual Needham Healthcare Conference\n",
      "/news-releases/news-release-details/novavax-presents-rsv-vaccine-data-8th-annual-international  ::  Novavax Presents RSV Vaccine Data at the 8th Annual International Respiratory Virus Symposium\n",
      "/news-releases/news-release-details/novavax-present-bio-2005-forum  ::  Novavax to present at BIO 2005 Forum\n",
      "/news-releases/news-release-details/novavax-present-rsv-vaccine-clinical-data-8th-vaccine-isv  ::  Novavax to Present RSV Vaccine Clinical Data at the 8th Vaccine & ISV Congress in Philadelphia on Sunday, October 26\n",
      "/news-releases/news-release-details/novavax-report-fourth-quarter-2003-financial-results-wednesday  ::  Novavax to Report Fourth Quarter 2003 Financial Results on Wednesday, March 10, 2004\n",
      "/  ::  For Investors\n",
      "/news-releases/news-release-details/novavax-present-rsv-vaccine-clinical-and-preclinical-results  ::  Novavax to Present RSV Vaccine Clinical and Preclinical Results at ICAAC\n",
      "/news-releases/news-release-details/novavax-present-rsv-vaccine-clinical-and-preclinical-results-0  ::  Novavax to Present RSV Vaccine Clinical and Preclinical Results at ICAAC\n",
      "/news-releases/news-release-details/novavax-recognized-one-washington-posts-top-workplaces  ::  Novavax Recognized as One of The Washington Post's Top Workplaces\n",
      "/news-releases/news-release-details/novavax-ceo-present-acumenbiofins-4th-annual-global-healthcare  ::  Novavax CEO to Present at ACUMENBioFin's 4th Annual Global Healthcare Conference\n",
      "/news-releases/news-release-details/novavax-report-fourth-quarter-and-year-end-2013-financial  ::  Novavax to Report Fourth Quarter and Year-End 2013 Financial Results on March 10, 2014\n",
      "/news-releases/news-release-details/novavax-appoints-biotechnology-veteran-david-mott-board  ::  Novavax Appoints Biotechnology Veteran David Mott to Board of Directors\n",
      "/news-releases/news-release-details/novavax-launches-additional-phase-i-clinical-trial-ah5n1  ::  NOVAVAX Launches Additional Phase I Clinical Trial of A/H5N1 Influenza Vaccine Candidate\n",
      "/news-releases/news-release-details/novavax-inc-files-sec-form-10-q-quarterly-report  ::  NOVAVAX INC Files SEC form 10-Q, Quarterly Report\n",
      "/news-releases/news-release-details/novavax-present-jefferies-2012-global-healthcare-conference  ::  NOVAVAX to Present at Jefferies 2012 Global Healthcare Conference\n",
      "/news-releases/news-release-details/novavax-launches-phase-i-clinical-trial-ah5n1-influenza-vaccine  ::  NOVAVAX Launches Phase I Clinical Trial of A/H5N1 Influenza Vaccine Candidate\n",
      "/news-releases/news-release-details/novavaxs-launch-estrasorbr-underway  ::  Novavax's Launch of ESTRASORB(R) Underway\n",
      "/news-releases/news-release-details/novavax-report-first-quarter-2004-financial-results-wednesday  ::  Novavax to Report First Quarter 2004 Financial Results on Wednesday, May 5, 2004\n",
      "/news-releases/news-release-details/novavax-reports-additional-positive-data-its-trivalent-seasonal  ::  NOVAVAX Reports Additional Positive Data from Its Trivalent Seasonal Influenza (VLP) Vaccine Clinical Study in Healthy Adults\n",
      "/news-releases/news-release-details/novavax-promotes-john-j-trizzino-expanded-role-chief-business  ::  Novavax Promotes John J. Trizzino to Expanded Role as Chief Business Officer and Chief Financial Officer\n",
      "/news-releases/news-release-details/novavax-report-third-quarter-2013-financial-results-november-7  ::  Novavax to Report Third Quarter 2013 Financial Results on November 7, 2013\n",
      "/news-releases/news-release-details/novavax-ceo-present-friedman-billings-ramsey-cos-2007-growth  ::  Novavax CEO to Present at Friedman, Billings, Ramsey & Co.'s 2007 Growth Conference\n",
      "/news-releases/news-release-details/novavax-preclinical-influenza-nanoparticle-study-published  ::  Novavax’ Preclinical Influenza Nanoparticle Study Published in Vaccine\n",
      "/news-releases/news-release-details/novavax-and-university-massachusetts-medical-school-publish  ::  NOVAVAX and University of Massachusetts Medical School Publish Preclinical Safety and Efficacy Study of a Respiratory Syncytial Virus (RSV) Virus-like Particle (VLP) Vaccine Candidate\n",
      "/news-releases/news-release-details/novavax-appoints-mark-twyman-vice-president-marketing  ::  Novavax Appoints Mark Twyman Vice President Marketing\n",
      "/news-releases/news-release-details/novavax-initiates-phase-12-clinical-trial-covid-19-vaccine  ::  Novavax Initiates Phase 1/2 Clinical Trial of COVID-19 Vaccine\n",
      "/news-releases/news-release-details/novavax-elects-richard-h-douglas-its-board-directors  ::  NOVAVAX Elects Richard H. Douglas to its Board of Directors\n",
      "https://ir.novavax.com/static-files/43420448-9e22-4a2d-8464-b51cfc363e49  ::  Download PDF\n",
      "/news-releases/news-release-details/novavax-present-11th-annual-needham-healthcare-conference  ::  NOVAVAX to Present at the 11th Annual Needham Healthcare Conference\n",
      "/news-releases/news-release-details/novavax-reports-first-quarter-2013-financial-results  ::  Novavax Reports First-Quarter 2013 Financial Results\n",
      "/news-releases/news-release-details/novavax-host-conference-call-discuss-third-quarter-financial-2  ::  Novavax to Host Conference Call to Discuss Third Quarter Financial Results on November 7, 2019\n",
      "/news-releases/news-release-details/novavax-initiates-pivotal-phase-3-trial-rsv-f-vaccine-older  ::  Novavax Initiates Pivotal Phase 3 Trial of the RSV F Vaccine in Older Adults\n",
      "/news-releases/news-release-details/novavax-inc-present-banc-america-securities-specialty  ::  Novavax, Inc. to Present at Banc of America Securities Specialty Pharmaceutical Conference\n",
      "/news-releases/news-release-details/novavax-present-22nd-annual-roth-oc-growth-stock-conference  ::  NOVAVAX to Present at 22nd Annual ROTH OC Growth Stock Conference\n",
      "/news-releases/news-release-details/novavax-inc-present-ubs-warburg-global-specialty-0  ::  Novavax, Inc. to Present at UBS Warburg Global Specialty Pharmaceuticals Conference\n",
      "/news-releases/news-release-details/novavax-president-and-ceo-nelson-m-sims-be-featured-guest  ::  Novavax President and CEO Nelson M. Sims to Be Featured Guest on Biotech Today Radio Program\n",
      "/news-releases/news-release-details/novavax-host-conference-call-discuss-fourth-quarter-and-year-end  ::  Novavax to Host Conference Call to Discuss Fourth Quarter and Year-End 2018 Financial Results on March 18, 2019\n",
      "/news-releases/news-release-details/novavax-initiates-phase-1-clinical-trial-rsv-f-vaccine-pediatric  ::  Novavax Initiates Phase 1 Clinical Trial of RSV F Vaccine in Pediatric Subjects\n",
      "/news-releases/news-release-details/novavax-ceo-present-world-vaccine-congress-2006  ::  Novavax CEO to Present at World Vaccine Congress 2006\n",
      "/news-releases/news-release-details/novavax-announces-conference-call-discuss-results-phase-i-trial  ::  NOVAVAX Announces Conference Call to Discuss Results From Phase I Trial of Respiratory Syncytial Virus Vaccine Candidate\n",
      "/news-releases/news-release-details/novavax-reaches-significant-enrollment-milestone-preparetm-phase  ::  Novavax Reaches Significant Enrollment Milestone in the Prepare(TM) Phase 3 Trial of its RSV F Vaccine\n",
      "/news-releases/news-release-details/novavax-appoints-john-herrmann-iii-vice-president-and-general  ::  NOVAVAX Appoints John A. Herrmann III, Vice President and General Counsel\n",
      "/news-releases/news-release-details/novavax-announces-reverse-stock-split-common-stock  ::  Novavax Announces Reverse Stock Split of Common Stock\n",
      "/news-releases/news-release-details/novavax-appoints-russell-rip-wilson-senior-vice-president  ::  NOVAVAX Appoints Russell \"Rip\" Wilson Senior Vice President of Business Development\n",
      "/news-releases/news-release-details/novavax-present-lazard-capital-markets-9th-annual-healthcare  ::  Novavax to Present at the Lazard Capital Markets 9th Annual Healthcare Conference\n",
      "/news-releases/news-release-details/novavax-reports-third-quarter-2016-financial-results  ::  Novavax Reports Third Quarter 2016 Financial Results\n",
      "/news-releases/news-release-details/novavax-reports-second-quarter-2016-financial-results  ::  Novavax Reports Second Quarter 2016 Financial Results\n",
      "/news-releases/news-release-details/novavax-and-idm-announce-manufacturing-agreement  ::  Novavax and IDM Announce Manufacturing Agreement\n",
      "/news-releases/news-release-details/novavax-announces-release-date-second-quarter-2006-financial  ::  Novavax Announces Release Date of Second Quarter 2006 Financial Results and Investor Conference Call\n",
      "/news-releases/news-release-details/novavax-inc-announces-first-quarter-2004-results  ::  Novavax, Inc. Announces First Quarter 2004 Results\n",
      "/news-releases/news-release-details/novavax-appoints-new-vice-president-pharmaceutical-development  ::  Novavax Appoints New Vice President of Pharmaceutical Development and Manufacturing Operations\n",
      "/news-releases/news-release-details/novavax-report-fourth-quarter-and-year-end-2002-financial  ::  Novavax to Report Fourth Quarter and Year End 2002 Financial Results On Wednesday, March 19, 2003\n",
      "/news-releases/news-release-details/novavax-reports-first-quarter-2015-financial-results  ::  Novavax Reports First Quarter 2015 Financial Results\n",
      "/news-releases/news-release-details/novavax-announces-release-date-first-quarter-2006-financial-0  ::  Novavax Announces Release Date of First Quarter 2006 Financial Results and Investor Conference Call\n",
      "/news-releases/news-release-details/novavax-completes-enrollment-pivotal-h1n1-influenza-vaccine  ::  NOVAVAX Completes Enrollment of Pivotal H1N1 Influenza Vaccine Clinical Trial in Mexico\n",
      "/news-releases/news-release-details/novavax-inc-hosts-conference-call-provide-corporate-update  ::  Novavax, Inc. Hosts Conference Call to Provide Corporate Update\n",
      "/news-releases/news-release-details/novavax-announces-closing-public-offering-0  ::  Novavax Announces Closing of Public Offering\n",
      "/press-releases?field_nir_news_date_value%5Bmin%5D=2018  ::  2018\n",
      "/news-releases/news-release-details/novavax-reports-progress-rsv-vaccine-xv-international-symposium  ::  Novavax Reports Progress on RSV Vaccine at the XV International Symposium on Respiratory Viral Infections\n",
      "/news-releases/news-release-details/novavax-ceo-present-bio-ceo-investor-conference  ::  Novavax CEO to Present at BIO CEO & Investor Conference\n",
      "/news-releases/news-release-details/novavax-reports-fourth-quarter-and-2010-year-end-financial  ::  NOVAVAX Reports Fourth Quarter and 2010 Year-End Financial Results\n",
      "/news-releases/news-release-details/novavax-expands-large-scale-global-manufacturing-capacity  ::  Novavax Expands Large-Scale Global Manufacturing Capacity\n",
      "/news-releases/news-release-details/novavax-report-first-quarter-2002-financial-results-thursday-may  ::  Novavax to Report First Quarter 2002 Financial Results on Thursday, May 9, 2002\n",
      "/news-releases/news-release-details/novavax-announces-third-quarter-2005-financial-results  ::  Novavax Announces Third Quarter 2005 Financial Results\n",
      "/news-releases/news-release-details/novavax-present-15th-annual-needham-healthcare-conference  ::  Novavax to Present at the 15th Annual Needham Healthcare Conference\n",
      "/news-releases/news-release-details/novavax-reports-first-quarter-2018-financial-results  ::  Novavax Reports First Quarter 2018 Financial Results\n",
      "#main-menu  ::  \n",
      "        Skip to main navigation\n",
      "      \n",
      "/news-releases/news-release-details/novavax-reports-third-quarter-2017-financial-results  ::  Novavax Reports Third Quarter 2017 Financial Results\n",
      "/news-releases/news-release-details/novavax-names-mariann-caprino-vice-president-corporate  ::  Novavax Names Mariann Caprino Vice President of Corporate Communications and Investor Relations\n",
      "/news-releases/news-release-details/novavax-inc-announces-2002-second-quarter-results  ::  Novavax, Inc. Announces 2002 Second Quarter Results\n",
      "https://novavax.com/about-us  ::  About Us\n",
      "/news-releases/news-release-details/novavax-prices-public-offering-common-stock-2  ::  Novavax Prices Public Offering of Common Stock\n",
      "/news-releases/news-release-details/us-fda-grants-fast-track-designation-novavax-h7n9-influenza  ::  U.S. FDA Grants Fast Track Designation to Novavax' H7N9 Influenza Virus-Like Particle Vaccine Candidate Adjuvanted With Matrix-M(TM)\n",
      "/news-releases/news-release-details/novavax-announces-public-offer-all-outstanding-shares-isconova  ::  Novavax Announces Public Offer for All Outstanding Shares of Isconova\n",
      "/news-releases/news-release-details/novavax-names-executive-director-biologic-product-discovery  ::  Novavax Names Executive Director of Biologic Product Discovery\n",
      "/press-releases?field_nir_news_date_value%5Bmin%5D=2020  ::  2020\n",
      "/news-releases/news-release-details/novavax-successfully-completes-additional-vaccine-milestone  ::  Novavax Successfully Completes Additional Vaccine Milestone\n",
      "/news-releases/news-release-details/novavax-announces-release-date-2007-first-quarter-financial  ::  Novavax Announces Release Date of 2007 First Quarter Financial Results and Investor Conference Call\n",
      "/news-releases/news-release-details/novavax-initiates-phase-12-trial-nanoflutm-vaccine-older-adults  ::  Novavax Initiates Phase 1/2 Trial of NanoFlu™ Vaccine in Older Adults\n",
      "/news-releases/news-release-details/novavax-added-merrill-lynch-nanotech-index  ::  Novavax Added to Merrill Lynch Nanotech Index\n",
      "http://novavax.com/contact-us  ::  Contact Us\n",
      "/news-releases/news-release-details/novavax-reports-fourth-quarter-and-2006-year-end-financial  ::  Novavax Reports Fourth Quarter and 2006 Year-End Financial Results\n",
      "/news-releases/news-release-details/novavax-announces-proposed-public-offering-common-stock-1  ::  Novavax Announces Proposed Public Offering of Common Stock\n",
      "/news-releases/news-release-details/novavax-present-jefferies-2014-global-healthcare-conference  ::  Novavax to Present at the Jefferies 2014 Global Healthcare Conference\n",
      "/news-releases/news-release-details/novavax-inc-comments-recent-hormone-replacement-therapy-study  ::  Novavax, Inc. Comments on Recent Hormone Replacement Therapy Study\n",
      "/news-releases/news-release-details/novavax-reports-fourth-quarter-and-year-end-2018-financial  ::  Novavax Reports Fourth Quarter and Year-End 2018 Financial Results\n",
      "/news-releases/news-release-details/novavax-announces-topline-rsv-f-vaccine-data-two-clinical-trials  ::  Novavax Announces Topline RSV F Vaccine Data from Two Clinical Trials in Older Adults\n",
      "/news-releases/news-release-details/pre-clinical-study-novavaxs-seasonal-influenza-vaccine-published  ::  Pre-Clinical Study of Novavax's Seasonal Influenza Vaccine Published in Journal 'Vaccine'\n",
      "/news-releases/news-release-details/novavax-host-conference-call-discuss-second-quarter-financial-1  ::  Novavax to Host Conference Call to Discuss Second Quarter Financial Results on August 8, 2018\n",
      "/news-releases/news-release-details/novavax-inc-present-ubs-warburg-global-specialty-1  ::  Novavax, Inc. to Present at UBS Warburg Global Specialty Pharmaceuticals Conference\n",
      "/news-releases/news-release-details/novavax-reports-fourth-quarter-and-year-end-2016-financial-0  ::  Novavax Reports Fourth Quarter and Year-End 2016 Financial Results\n",
      "/press-releases?field_nir_news_date_value%5Bmin%5D=2017  ::  2017\n",
      "/news-releases/news-release-details/novavax-present-jefferies-global-healthcare-conference  ::  Novavax to Present at the Jefferies Global Healthcare Conference\n",
      "/news-releases/news-release-details/novavax-announces-new-seasonal-combination-respiratory-vaccine  ::  Novavax Announces New Seasonal Combination Respiratory Vaccine Program\n",
      "/news-releases/news-release-details/novavax-board-directors-elect-john-lambert-executive-chairman  ::  Novavax Board of Directors Elect John Lambert as Executive Chairman\n",
      "/news-releases/news-release-details/novavax-participate-fbr-new-prescriptions-conference  ::  Novavax to Participate in the FBR New Prescriptions Conference\n",
      "/news-releases/news-release-details/novavax-inc-announces-2002-first-quarter-results  ::  Novavax, Inc. Announces 2002 First Quarter Results\n",
      "/news-releases/news-release-details/novavax-appoints-interim-cfo  ::  Novavax Appoints Interim CFO\n",
      "/news-releases/news-release-details/novavax-reports-fourth-quarter-and-2009-year-end-financial  ::  NOVAVAX Reports Fourth Quarter and 2009 Year-End Financial Results\n",
      "/news-releases/news-release-details/novavax-and-path-announce-partnership-rsv-vaccine  ::  NOVAVAX and PATH Announce Partnership on RSV Vaccine\n",
      "/news-releases/news-release-details/novavax-notified-department-health-and-human-services-its  ::  NOVAVAX Notified by Department of Health and Human Services that its Proposal for a Contract Award is in the Competitive Range for the Advanced Development of its Recombinant Influenza Vaccine\n",
      "/news-releases/news-release-details/novavax-h7n9-avian-influenza-vlp-vaccine-candidate-matrix-mtm  ::  Novavax' H7N9 Avian Influenza VLP Vaccine Candidate With Matrix-M(TM) Delivers Positive Phase 1/2 Clinical Data\n",
      "/news-releases/news-release-details/one-year-follow-rsv-f-protein-vaccine-candidate-phase-1-elderly  ::  One Year Follow-Up From RSV F-Protein Vaccine Candidate Phase 1 Elderly Trial Demonstrates Sustained Levels of Immune Response\n",
      "/news-releases/news-release-details/novavax-present-stifel-nicolaus-healthcare-conference  ::  NOVAVAX to Present at Stifel Nicolaus Healthcare Conference\n",
      "/news-releases/news-release-details/novavax-presents-final-results-h1n1-influenza-vaccine-trial  ::  NOVAVAX Presents Final Results from H1N1 Influenza Vaccine Trial at World Health Organization Meeting\n",
      "/news-releases/news-release-details/results-phase-iii-clinical-trial-reveal-estrasorbtm-estradiol  ::  Results of Phase III Clinical Trial Reveal Estrasorb(TM) (Estradiol Topical Emulsion) Is Effective in Reducing Vasomotor Symptoms in Post Menopausal Women\n",
      "/news-releases/news-release-details/novavax-present-university-maryland-avian-flu-what-can-we-do  ::  Novavax to Present at the University of Maryland 'Avian Flu: What Can We Do?' Symposium\n",
      "/news-releases/news-release-details/new-experimental-vaccine-produces-immune-response-against-middle  ::  New Experimental Vaccine Produces Immune Response Against Middle East Respiratory Syndrome Coronavirus (MERS-CoV)\n",
      "/news-releases/news-release-details/novavax-report-first-quarter-2010-financial-results-may-10-2010  ::  Novavax to Report First Quarter 2010 Financial Results on May 10, 2010\n",
      "/news-releases/news-release-details/novavax-inc-appoints-raymond-j-hage-jr-vice-president-marketing  ::  Novavax, Inc. Appoints Raymond J. Hage, Jr. as Vice President, Marketing\n",
      "/news-releases/news-release-details/novavax-announces-change-leadership  ::  Novavax Announces Change in Leadership\n",
      "/news-releases/news-release-details/novavax-reacquire-all-rights-estrasorbr-king-pharmaceuticals  ::  Novavax to Reacquire All Rights to ESTRASORB(R) From King Pharmaceuticals\n",
      "/news-releases/news-release-details/novavax-announces-closing-300-million-offering-convertible  ::  Novavax Announces Closing of $300 Million Offering of Convertible Senior Notes Due 2023\n",
      "/news-releases/news-release-details/novavax-present-13th-annual-bio-ceo-investor-conference  ::  NOVAVAX to Present at 13th Annual BIO CEO & Investor Conference\n",
      "/news-releases/news-release-details/novavax-announces-positive-phase-2-nanoflu-results-older-adults  ::  Novavax Announces Positive Phase 2 NanoFlu Results in Older Adults\n",
      "/news-releases/news-release-details/novavax-announces-adjustment-conversion-rate-its-375-convertible  ::  Novavax Announces Adjustment of Conversion Rate for its 3.75% Convertible Senior Notes due 2023\n",
      "/news-releases/news-release-details/novavax-announces-fourth-quarter-and-year-end-2005-financial  ::  Novavax Announces Fourth Quarter and Year-End 2005 Financial Results\n",
      "/news-releases/news-release-details/novavax-recognized-washington-post-top-workplace  ::  Novavax Recognized by Washington Post as Top Workplace\n",
      "/join-press-release-list  ::  Join the Press Release List\n",
      "/news-releases/news-release-details/novavax-phase-i-rsv-vaccine-data-published-vaccine  ::  Novavax' Phase I RSV Vaccine Data Published in Vaccine\n",
      "/news-releases/news-release-details/new-data-support-novavaxs-pandemic-flu-vaccines  ::  New Data Support Novavax's Pandemic Flu Vaccines\n",
      "/news-releases/news-release-details/novavax-reschedules-4th-annual-investor-and-analyst-meeting  ::  Novavax Reschedules 4th Annual Investor and Analyst Meeting\n",
      "/news-releases/news-release-details/novavax-announces-ebola-vaccine-development-program-8th-vaccine  ::  Novavax Announces Ebola Vaccine Development Program at the 8th Vaccine and ISV Conference in Philadelphia\n",
      "https://novavax.com/novavax-in-the-news  ::  Novavax in the News\n",
      "/news-releases/news-release-details/novavax-ceo-discuss-future-global-vaccine-business-part-panel  ::  Novavax CEO to Discuss Future of Global Vaccine Business as Part of Panel of Industry Leaders at 2018 BIO International Convention\n",
      "/news-releases/news-release-details/novavax-host-conference-call-discuss-fourth-quarter-and-full  ::  Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2014 Financial Results on February 26, 2015\n",
      "/news-releases/news-release-details/novavax-bond-holders-elect-convert-70-million-outstanding-notes  ::  Novavax Bond Holders Elect to Convert $7.0 Million of Outstanding Notes\n",
      "/news-releases/news-release-details/novavax-inc-comments-estrogen-alone-arm-womens-health-initiative  ::  Novavax, Inc. Comments on Estrogen-Alone Arm of Women's Health Initiative Study\n",
      "/news-releases/news-release-details/novavax-announces-positive-top-line-results-phase-1-clinical  ::  Novavax Announces Positive Top-Line Results From Phase 1 Clinical Trial of RSV Vaccine Candidate in Elderly\n",
      "/news-releases/news-release-details/novavax-reports-third-quarter-2014-financial-results  ::  Novavax Reports Third Quarter 2014 Financial Results\n",
      "/news-releases/news-release-details/novavax-launches-phase-i-clinical-trial-evaluate-its-novel  ::  NOVAVAX Launches Phase I Clinical Trial to Evaluate its Novel Vaccine Against Respiratory Syncytial Virus (RSV)\n",
      "/news-releases/news-release-details/novavax-initiates-first-phase-1-clinical-trial-its-ah7n9  ::  Novavax Initiates First Phase 1 Clinical Trial of Its A(H7N9) Influenza Vaccine Candidate\n",
      "/news-releases/news-release-details/novavax-announces-second-quarter-results  ::  Novavax announces second quarter results\n",
      "/news-releases/news-release-details/novavax-present-bio-investor-forum  ::  NOVAVAX to Present at BIO Investor Forum\n",
      "/news-releases/news-release-details/financial-statements-and-exhibits  ::  Financial Statements and Exhibits\n",
      "/news-releases/news-release-details/novavax-inc-present-cibc-world-markets-annual-biotechnology-0  ::  Novavax, Inc. to Present at CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference\n",
      "/news-releases/news-release-details/novavax-announces-positive-preclinical-results-its-respiratory  ::  NOVAVAX Announces Positive Preclinical Results for its Respiratory Syncytial Virus (RSV) Vaccine Candidate\n",
      "/news-releases/news-release-details/novavax-announces-exercise-option-purchase-additional-shares-and  ::  Novavax Announces Exercise of Option to Purchase Additional Shares and Closing of Public Offering\n",
      "https://novavax.com/our-pipeline  ::  Our Pipeline\n",
      "/news-releases/news-release-details/novavax-present-roth-23rd-annual-oc-growth-stock-conference  ::  NOVAVAX to Present at the ROTH 23rd Annual OC Growth Stock Conference\n",
      "/news-releases/news-release-details/novavax-appoints-dr-timothy-hahn-senior-vice-president  ::  Novavax Appoints Dr. Timothy Hahn Senior Vice President of Manufacturing\n",
      "/news-releases/news-release-details/novavax-appoints-erica-s-shane-phd-vice-president-process  ::  NOVAVAX Appoints Erica S. Shane, Ph.D., Vice President, Process Development\n",
      "/news-releases/news-release-details/novavax-inc-provides-update-hiv-vaccine-programs  ::  Novavax, Inc. Provides Update on HIV Vaccine Programs\n",
      "/news-releases/news-release-details/novavax-inc-announces-2002-third-quarter-results  ::  Novavax, Inc. Announces 2002 Third Quarter Results\n",
      "/news-releases/news-release-details/novavax-inc-announces-12-million-equity-offering  ::  NOVAVAX, Inc. Announces $12 Million Equity Offering\n",
      "/news-releases/news-release-details/novavax-present-14th-annual-bio-ceo-investor-conference  ::  NOVAVAX to Present at the 14th Annual Bio CEO & Investor Conference\n",
      "/news-releases/news-release-details/novavax-present-stifel-nicolaus-conference  ::  NOVAVAX to Present at Stifel Nicolaus Conference\n",
      "/news-releases/news-release-details/novavax-elects-dr-tom-monath-board-directors  ::  Novavax Elects Dr. Tom Monath to Board of Directors\n",
      "/news-releases/news-release-details/novavax-host-conference-call-discuss-first-quarter-financial-1  ::  Novavax to Host Conference Call to Discuss First Quarter Financial Results on May 9, 2018\n",
      "/news-releases/news-release-details/novavax-inc-present-ce-unterberg-towbin-specialty-pharmaceutical  ::  Novavax, Inc. to Present at C.E. Unterberg Towbin Specialty Pharmaceutical Conference  \n",
      "/news-releases/news-release-details/novavax-participate-2016-citi-midwest-healthcare-access-day  ::  Novavax to Participate in the 2016 Citi Midwest Healthcare Access Day\n",
      "/news-releases/news-release-details/novavax-and-collaborators-significantly-improve-vlp-vaccine  ::  Novavax and Collaborators Significantly Improve VLP Vaccine for HIV/AIDS\n",
      "/news-releases/news-release-details/novavax-reports-second-quarter-2012-financial-results  ::  NOVAVAX Reports Second Quarter 2012 Financial Results\n",
      "/news-releases/news-release-details/novavax-present-27th-annual-piper-jaffray-healthcare-conference  ::  Novavax to Present at the 27th Annual Piper Jaffray Healthcare Conference\n",
      "/news-releases/news-release-details/novavax-cfo-john-trizzino-discuss-future-influenza-vaccines  ::  Novavax CFO John Trizzino to Discuss Future of Influenza Vaccines on Industry Panel at 2019 BIO International Convention\n",
      "/news-releases/news-release-details/novavax-announces-extension-contract-advanced-development  ::  Novavax Announces Extension of Contract for Advanced Development of Recombinant Influenza Products and Pandemic Preparedness With HHS-BARDA\n",
      "/news-releases/news-release-details/novavax-bond-holders-elect-convert-6-million-outstanding-notes  ::  Novavax Bond Holders Elect to Convert $6 Million of Outstanding Notes\n",
      "/news-releases/news-release-details/novavax-report-third-quarter-2011-financial-results-november-4  ::  NOVAVAX to Report Third Quarter 2011 Financial Results on November 4, 2011\n",
      "/news-releases/news-release-details/novavax-reports-positive-results-pre-clinical-safety-study  ::  Novavax Reports Positive Results from Pre-Clinical Safety Study of Respiratory Syncytial Virus (RSV) Vaccine Candidate\n",
      "/news-releases/news-release-details/novavax-host-conference-call-discuss-second-quarter-financial-2  ::  Novavax to Host Conference Call to Discuss Second Quarter Financial Results on August 7, 2019\n",
      "/news-releases/news-release-details/novavax-participate-4th-annual-guggenheim-boston-healthcare  ::  Novavax to Participate in the 4th Annual Guggenheim Boston Healthcare Conference\n",
      "/news-releases/news-release-details/novavax-present-world-vaccine-congress-2005  ::  Novavax to present at the World Vaccine Congress 2005\n",
      "/news-releases/news-release-details/novavax-cplb-and-icgeb-collaboration-honored-malaria-vaccine  ::  Novavax, CPLB and ICGEB Collaboration Honored for Malaria Vaccine Progress at Vaccine World Summit India 2013\n",
      "/news-releases/news-release-details/novavax-appoints-susan-b-bayh-board-directors  ::  Novavax Appoints Susan B. Bayh to Board of Directors  \n",
      "/news-releases/news-release-details/novavax-appoints-gail-boudreaux-board  ::  Novavax Appoints Gail Boudreaux to Board\n",
      "/news-releases/news-release-details/novavax-moves-ahead-cost-rationalization-plan  ::  Novavax moves ahead with cost rationalization plan\n",
      "/news-releases/news-release-details/novavax-inc-receives-comments-fda  ::  Novavax, Inc. Receives Comments From The FDA\n",
      "/news-releases/news-release-details/novavax-present-24th-annual-roth-conference  ::  NOVAVAX to Present at the 24th Annual ROTH Conference\n",
      "/news-releases/news-release-details/novavax-announces-appointment-dr-gregory-glenn-chief-scientific  ::  Novavax Announces Appointment of Dr. Gregory Glenn as Chief Scientific Officer\n",
      "/news-releases/news-release-details/novavax-expands-leadership-several-key-management-promotions  ::  Novavax Expands Leadership with Several Key Management Promotions\n",
      "/news-releases/news-release-details/novavax-releases-final-results-its-trivalent-seasonal-influenza  ::  NOVAVAX Releases Final Results from its Trivalent Seasonal Influenza Vaccine Phase II Clinical Study in Healthy Adults\n",
      "/news-releases/news-release-details/novavax-participate-citi-12th-annual-biotech-conference  ::  Novavax to Participate in the Citi 12th Annual Biotech Conference\n",
      "/news-releases/news-release-details/novavax-announces-release-date-first-quarter-2006-financial  ::  Novavax Announces Release Date of First Quarter 2006 Financial Results and Investor Conference Call\n",
      "/news-releases/news-release-details/novavax-report-first-quarter-financial-results-may-7-2014  ::  Novavax to Report First Quarter Financial Results on May 7, 2014\n",
      "/news-releases/news-release-details/novavax-receives-additional-government-funding-hivaids-vaccine  ::  Novavax Receives Additional Government Funding for HIV/AIDS Vaccine Research\n",
      "/news-releases/news-release-details/novavax-expands-executive-leadership-and-announces-key  ::  Novavax Expands Executive Leadership and Announces Key Promotions\n",
      "/news-releases/news-release-details/novavax-rsv-f-vaccine-highly-immunogenic-robust-transplacental  ::  Novavax RSV F Vaccine is Highly Immunogenic With Robust Transplacental Antibody Transfer in Preclinical Maternal Immunization Model\n",
      "/news-releases/news-release-details/novavax-announces-management-promotions-support-expanded  ::  Novavax Announces Management Promotions to Support Expanded Clinical Activity in 2014\n",
      "/news-releases/news-release-details/novavax-awarded-hhs-barda-contract-valued-179-million-develop  ::  NOVAVAX Awarded HHS-BARDA Contract Valued at up to $179 Million to Develop Pandemic and Seasonal Influenza Vaccines for U.S. Government Using Recombinant VLP Technology\n",
      "/news-releases/news-release-details/novavax-announces-release-date-2010-year-end-financial-results  ::  NOVAVAX Announces Release Date of 2010 Year-End Financial Results and Investor Conference Call\n",
      "/news-releases/news-release-details/novavax-report-top-line-results-phase-i-respiratory-syncytial  ::  Novavax to Report Top-Line Results From Phase I Respiratory Syncytial Virus Vaccine Clinical Trial on October 3rd at 5th Vaccine and ISV Annual Global Conference\n",
      "/news-releases/news-release-details/novavax-reports-second-quarter-2013-financial-results  ::  Novavax Reports Second-Quarter 2013 Financial Results\n",
      "https://novavax.com/download/files/ar/NVAX_2019_Annual_Report_FINAL.pdf  ::  Annual Report\n",
      "/news-releases/news-release-details/novavax-host-conference-call-discuss-fourth-quarter-and-year-0  ::  Novavax to Host Conference Call to Discuss Fourth Quarter and Year-End 2016 Financial Results on February 27, 2017\n",
      "javascript:window.print();  ::  \n",
      "/news-releases/news-release-details/novavax-awarded-nearly-1-million-grants-irs-under-qualifying  ::  NOVAVAX Awarded Nearly $1 Million in Grants from IRS Under Qualifying Therapeutic Discovery Project\n",
      "/news-releases/news-release-details/novavax-reports-second-quarter-2015-financial-results  ::  Novavax Reports Second Quarter 2015 Financial Results\n",
      "/news-releases/news-release-details/novavax-licenses-new-vlp-technology-university-massachusetts  ::  Novavax Licenses New VLP Technology From University of Massachusetts Medical School\n",
      "https://novavax.com/download/files/policy/OFCCP_Pay_Transparency_Nondiscrimination_Provision.pdf  ::  Pay Transparency Nondiscrimination Provision\n",
      "/news-releases/news-release-details/novavax-announces-management-promotion-2  ::  Novavax Announces Management Promotion\n",
      "/news-releases/news-release-details/novavax-executive-receives-cdc-science-award  ::  Novavax Executive Receives CDC Science Award\n",
      "/news-releases/news-release-details/novavax-updates-2005-first-half-milestones  ::  Novavax Updates 2005 First Half Milestones\n",
      "/news-releases/news-release-details/novavax-initiates-phase-2-clinical-trial-rsv-f-protein  ::  Novavax Initiates Phase 2 Clinical Trial of RSV F-Protein Nanoparticle Vaccine Candidate in Healthy Third-Trimester Pregnant Women\n",
      "/news-releases/news-release-details/novavax-report-second-quarter-2010-financial-results-august-6  ::  Novavax to Report Second Quarter 2010 Financial Results on August 6, 2010\n",
      "/news-releases/news-release-details/novavax-files-100-million-shelf-registration-statement-0  ::  Novavax Files $100 Million Shelf Registration Statement\n",
      "/news-releases/news-release-details/novavax-announces-fourth-quarter-and-fiscal-2004-results  ::  Novavax announces fourth quarter and fiscal 2004 results\n",
      "/news-releases/news-release-details/novavax-ceo-present-bmo-nesbitt-burns-healthcare-conference  ::  Novavax CEO to Present at BMO Nesbitt Burns Healthcare Conference\n",
      "https://novavax.com/careers  ::  Careers\n",
      "/news-releases/news-release-details/novavax-reports-fourth-quarter-and-year-end-2015-financial  ::  Novavax Reports Fourth Quarter and Year-End 2015 Financial Results\n",
      "/news-releases/news-release-details/novavax-present-23rd-annual-piper-jaffray-health-care-conference  ::  NOVAVAX to Present at 23rd Annual Piper Jaffray Health Care Conference\n",
      "/news-releases/news-release-details/novavax-announces-contract-award-us-department-homeland-security  ::  NOVAVAX Announces Contract Award from U.S. Department of Homeland Security to Develop Foot-and-Mouth Disease Vaccine\n",
      "/news-releases/news-release-details/novavax-initiates-dose-confirmatory-phase-2-clinical-trial-its  ::  Novavax Initiates Dose-Confirmatory Phase 2 Clinical Trial of its RSV Vaccine Candidate\n",
      "/news-releases/news-release-details/form-8-ka-novavax-inc  ::  Form 8-K/A for NOVAVAX INC \n",
      "/news-releases/news-release-details/novavax-present-results-phase-i-rsv-study-xiv-international  ::  NOVAVAX to Present Results From Phase I RSV Study at XIV International Symposium on Respiratory Viral Infections\n",
      "/news-releases/news-release-details/novavax-initiates-phase-2-clinical-trial-nanoflutm-older-adults  ::  Novavax Initiates Phase 2 Clinical Trial of NanoFlu™ in Older Adults\n",
      "/news-releases/news-release-details/novavax-present-bit-life-sciences-3rd-world-congress-vaccine  ::  NOVAVAX to Present at BIT Life Science's 3rd World Congress of Vaccine\n",
      "/news-releases/news-release-details/novavax-host-conference-call-discuss-second-quarter-financial-0  ::  Novavax to Host Conference Call to Discuss Second Quarter Financial Results on August 9, 2016\n",
      "/news-releases/news-release-details/novavax-announces-exercise-over-allotment-option-purchase  ::  Novavax Announces Exercise of Over-Allotment Option to Purchase Additional Shares\n",
      "/news-releases/news-release-details/novavax-report-second-quarter-2012-financial-results-august-3  ::  NOVAVAX to Report Second Quarter 2012 Financial Results on August 3, 2012\n",
      "/news-releases/news-release-details/novavax-terminates-negotiations-rovi-pharmaceuticals-influenza  ::  Novavax Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration\n",
      "/news-releases/news-release-details/novavax-present-bio-2006-chicago-annual-international-convention  ::  Novavax to Present at BIO 2006 Chicago Annual International Convention\n",
      "/news-releases/news-release-details/novavax-receives-sars-vaccine-funding-nih  ::  Novavax Receives SARS Vaccine Funding From NIH\n",
      "/news-releases/news-release-details/novavax-presents-results-phase-iii-clinical-trial-using  ::  Novavax Presents Results of a Phase III Clinical Trial Using ESTRASORB(TM) At Society for Gynecologic Investigation Meeting\n",
      "None  ::  Social\n",
      "/news-releases/news-release-details/novavax-reports-fourth-quarter-and-year-end-2013-financial  ::  Novavax Reports Fourth-Quarter and Year-End 2013 Financial Results and Initiation of Phase 1/2 Clinical Trial of Its H7N9 Avian Influenza VLP Vaccine Candidate With Matrix-M(TM)\n",
      "/news-releases/news-release-details/novavax-reports-first-quarter-2012-financial-results  ::  NOVAVAX Reports First Quarter 2012 Financial Results\n",
      "/news-releases/news-release-details/novavax-completes-enrollment-pivotal-phase-3-trial-rsv-f-vaccine  ::  Novavax Completes Enrollment of Pivotal Phase 3 Trial of the RSV F Vaccine in Older Adults\n",
      "/news-releases/news-release-details/novavax-scientific-leadership-present-new-rsv-maternal  ::  Novavax Scientific Leadership to Present New RSV Maternal Immunization Program Phase 3 Data and Participate in Discussion on RSV at the 2019 IDSOG Annual Meeting\n",
      "/news-releases/news-release-details/novavax-head-pharmaceutical-development-present-micellar  ::  Novavax Head of Pharmaceutical Development to Present on Micellar Nanoparticle Technology at Particles 2006 Meeting\n",
      "/news-releases/news-release-details/novavax-reports-positive-pre-clinical-study-results-live-virus  ::  Novavax Reports Positive Pre-Clinical Study Results from Live Virus Challenge to Pandemic Flu Vaccine\n",
      "/news-releases/news-release-details/novavax-expands-pipeline-pre-clinical-results-two-new-compounds  ::  Novavax expands pipeline with pre-clinical results for two new compounds\n",
      "/news-releases/news-release-details/novavax-present-lazard-capital-markets-8th-annual-healthcare  ::  NOVAVAX to Present at the Lazard Capital Markets 8th Annual Healthcare Conference\n",
      "/news-releases/news-release-details/novavax-receives-fda-clearance-launch-phase-i-rsv-vaccine  ::  NOVAVAX Receives FDA Clearance to Launch Phase I RSV Vaccine Clinical Trial\n",
      "/news-releases/news-release-details/novavax-inc-announces-relocation-corporate-headquarters  ::  Novavax, Inc. Announces Relocation of Corporate Headquarters  \n",
      "/news-releases/news-release-details/novavax-reports-progress-under-joint-venture-india-cadila  ::  NOVAVAX Reports Progress Under Joint Venture in India With Cadila Pharmaceuticals\n",
      "/news-releases/news-release-details/novavax-report-first-quarter-2003-financial-results-wednesday  ::  Novavax to Report First Quarter 2003 Financial Results on Wednesday, May 14, 2003\n",
      "/news-releases/news-release-details/novavax-make-multiple-presentations-rsv-vaccines-world  ::  Novavax to Make Multiple Presentations at RSV Vaccines for the World\n",
      "/news-releases/news-release-details/novavax-endorses-new-us-initiatives-develop-medical  ::  NOVAVAX Endorses New U.S. Initiatives to Develop Medical Countermeasures\n",
      "/news-releases/news-release-details/novavax-announces-additions-executive-leadership  ::  Novavax Announces Additions to Executive Leadership\n",
      "/news-releases/news-release-details/novavax-board-elects-dr-james-b-tananbaum-director  ::  Novavax Board Elects Dr. James B. Tananbaum as Director\n",
      "/news-releases/news-release-details/novavax-reports-first-quarter-2016-financial-results  ::  Novavax Reports First Quarter 2016 Financial Results\n",
      "/news-releases/news-release-details/novavax-announces-research-collaboration-university-pittsburgh  ::  Novavax Announces Research Collaboration With the University of Pittsburgh School of Medicine\n",
      "/news-releases/news-release-details/novavax-present-ce-unterberg-towbin-life-sciences-conference  ::  Novavax to Present at the C.E. Unterberg, Towbin Life Sciences Conference\n",
      "/news-releases/news-release-details/novavax-participate-phacilitate-vaccine-forum  ::  Novavax to Participate in Phacilitate Vaccine Forum\n",
      "/news-releases/news-release-details/novavax-initiates-phase-2-clinical-trial-rsv-vaccine-elderly  ::  Novavax Initiates Phase 2 Clinical Trial of RSV Vaccine in Elderly Subjects\n",
      "/news-releases/news-release-details/novavax-strengthens-vaccine-development-team-two-new  ::  Novavax Strengthens Vaccine Development Team with Two New Appointments\n",
      "/news-releases/news-release-details/novavax-present-25th-annual-roth-conference  ::  Novavax to Present at the 25th Annual ROTH Conference\n",
      "/news-releases/news-release-details/novavax-announces-barda-exercise-contract-option  ::  Novavax Announces BARDA Exercise of Contract Option\n",
      "/news-releases/news-release-details/novavax-inc-completes-relocation-corporate-headquarters-malvern  ::  Novavax, Inc. Completes Relocation of Corporate Headquarters to Malvern, Pennsylvania\n",
      "/news-releases/news-release-details/novavax-host-conference-call-discuss-first-quarter-financial-3  ::  Novavax to Host Conference Call to Discuss First Quarter Financial Results on May 11, 2020\n",
      "/news-releases/news-release-details/novavax-inc-ranked-100th-fastest-growing-technology-company  ::  Novavax, Inc. Ranked 100th Fastest Growing Technology Company in North America on the 2002 Deloitte & Touche Technology Fast 500\n",
      "/sec-filings  ::  SEC Filings\n",
      "/news-releases/news-release-details/novavax-participate-guggenheim-securities-3rd-annual-boston  ::  Novavax to Participate in the Guggenheim Securities 3rd Annual Boston Healthcare Conference\n",
      "/news-releases/news-release-details/novavax-present-2012-stifel-nicolaus-healthcare-conference  ::  NOVAVAX to Present at the 2012 Stifel Nicolaus Healthcare Conference\n",
      "/news-releases/news-release-details/novavax-inc-announces-fourth-quarter-and-year-end-2003-results  ::  Novavax, Inc. Announces Fourth Quarter and Year End 2003 Results\n",
      "/news-releases/news-release-details/novavax-awarded-funding-cepi-covid-19-vaccine-development  ::  Novavax Awarded Funding from CEPI  for COVID-19 Vaccine Development\n",
      "/news-releases/news-release-details/novavax-appoints-barclay-buck-phillips-senior-vice-president-and  ::  Novavax Appoints Barclay \"Buck\" Phillips as Senior Vice President and Chief Financial Officer\n",
      "/news-releases/news-release-details/novavax-publishes-preclinical-efficacy-study-its-rsv-protein  ::  Novavax Publishes Preclinical Efficacy Study of its RSV Protein Nanoparticle Vaccine Candidate\n",
      "/press-releases  ::  More\n",
      "/news-releases/news-release-details/novavax-announces-release-date-second-quarter-financial-results  ::  Novavax announces release date of second quarter financial results\n",
      "/news-releases/news-release-details/novavax-inc-completes-166-million-financing  ::  Novavax, Inc. Completes $16.6 Million Financing\n",
      "/press-releases?field_nir_news_date_value%5Bmin%5D=2019  ::  2019\n",
      "/news-releases/news-release-details/novavax-announces-completion-construction-vaccine-production  ::  Novavax Announces Completion of Construction of Vaccine Production Facility in India\n",
      "/news-releases/news-release-details/novavax-partners-ranbaxy-evaluate-micellar-nanoparticle  ::  Novavax partners with Ranbaxy to evaluate micellar nanoparticle technology applications\n",
      "/news-releases/news-release-details/novavax-completes-100-million-public-offering-common-stock  ::  Novavax Completes $100 Million Public Offering of Common Stock\n",
      "/news-releases/news-release-details/novavax-recognized-washington-post-top-workplace-0  ::  Novavax Recognized by Washington Post as Top Workplace\n",
      "https://novavax.com/novavax-in-the-news  ::  News\n",
      "/news-releases/news-release-details/novavax-report-first-quarter-2013-financial-results-may-7-2013  ::  Novavax to Report First-Quarter 2013 Financial Results on May 7, 2013\n",
      "/news-releases/news-release-details/novavax-provides-corporate-update-and-report-fourth-quarter-and  ::  Novavax Provides Corporate Update and Report of Fourth Quarter and Year-End 2017 Financial Results\n",
      "/news-releases/news-release-details/novavax-host-conference-call-discuss-third-quarter-financial  ::  Novavax to Host Conference Call to Discuss Third Quarter Financial Results on November 9, 2015\n",
      "/news-releases/news-release-details/novavax-host-conference-call-and-webcast-provide-corporate  ::  Novavax to Host Conference Call and Webcast to Provide Corporate Update and Report of Fourth Quarter and Year-End 2017 Financial Results\n",
      "/news-releases/news-release-details/novavax-launches-phase-ii-clinical-trial-seasonal-influenza  ::  NOVAVAX Launches Phase II Clinical Trial of Seasonal Influenza Vaccine\n",
      "/news-releases/news-release-details/novavax-inc-present-deutsche-banc-alex-brown-health-care  ::  Novavax, Inc. to Present at Deutsche Banc Alex Brown Health Care Conference\n",
      "/news-releases/news-release-details/novavax-produces-mers-cov-vaccine-candidate  ::  Novavax Produces MERS-CoV Vaccine Candidate\n",
      "/news-releases/news-release-details/novavax-ceo-addresses-us-patent-and-trademark-office-uspto  ::  NOVAVAX CEO Addresses U.S. Patent and Trademark Office (USPTO) on Behalf of the Biotechnology Industry Organization (BIO)\n",
      "/news-releases/news-release-details/novavax-participate-two-upcoming-investor-conferences  ::  Novavax to Participate at Two Upcoming Investor Conferences\n",
      "/news-releases/news-release-details/novavax-host-rsv-f-vaccine-update-conference-call-and-webcast  ::  Novavax to Host an RSV F Vaccine Update Conference Call and Webcast on July 24, 2017 at 4:30 PM\n",
      "/news-releases/news-release-details/novavax-announces-positive-clinical-results-first-stage-pivotal  ::  NOVAVAX Announces Positive Clinical Results from First Stage of Pivotal Study of 2009 A/H1N1 VLP Pandemic Influenza Vaccine in Mexico\n",
      "/news-releases/news-release-details/novavax-inc-submits-new-drug-application-estrasorbtm-novel  ::  Novavax, Inc. Submits New Drug Application for ESTRASORB(TM), a Novel Transdermal, Topical Estrogen Replacement Therapy\n",
      "/news-releases/news-release-details/novavax-executes-definitive-agreement-38-million-public-offering  ::  Novavax Executes Definitive Agreement for $38 Million Public Offering\n",
      "/news-releases/news-release-details/novavax-announces-alternate-slate-directors-has-been-rescinded  ::  Novavax Announces Alternate Slate of Directors Has Been Rescinded\n",
      "/news-releases/news-release-details/novavax-granted-fast-track-designation-nanoflu-older-adults  ::  Novavax Granted Fast Track Designation for NanoFlu in Older Adults\n",
      "/news-releases/news-release-details/novavax-appoints-mervyn-l-hamer-vice-president-manufacturing  ::  NOVAVAX Appoints Mervyn L. Hamer, Vice President of Manufacturing\n",
      "/news-releases/news-release-details/novavax-initiates-pivotal-phase-3-clinical-trial-nanoflu  ::  Novavax Initiates Pivotal Phase 3 Clinical Trial of NanoFlu Influenza Vaccine in Older Adults\n",
      "/news-releases/news-release-details/novavax-present-covid-19-vaccine-candidate-progress-world  ::  Novavax to Present COVID-19 Vaccine Candidate Progress in World Vaccine Congress Webinar Series\n",
      "/news-releases/news-release-details/novavax-present-two-upcoming-investor-conferences  ::  Novavax to Present at Two Upcoming Investor Conferences\n",
      "/news-releases/news-release-details/us-fda-grants-fast-track-designation-novavax-rsv-f-protein  ::  U.S. FDA Grants Fast Track Designation to Novavax' RSV F-Protein Nanoparticle Vaccine for Protection of Infants Via Maternal Immunization\n",
      "/news-releases/news-release-details/novavax-announces-positive-top-line-data-dose-confirmatory-phase  ::  Novavax Announces Positive Top-Line Data from Dose-Confirmatory Phase 2 Clinical Trial of its RSV Vaccine Candidate in Women of Childbearing Age\n",
      "/news-releases/news-release-details/novavax-receives-80-million-cash-payment-estrasorbr  ::  Novavax Receives $8.0 Million Cash Payment on ESTRASORB(R)\n",
      "/news-releases/news-release-details/novavax-inc-files-sec-form-8-k-other-events  ::  NOVAVAX INC Files SEC form 8-K, Other Events\n",
      "https://novavax.com/privacy-policy  ::  Privacy Policy\n",
      "/news-releases/news-release-details/novavax-inc-receives-nasdaq-non-compliance-letter  ::  NOVAVAX, Inc. Receives NASDAQ Non-Compliance Letter\n",
      "/news-releases/news-release-details/novavax-announces-first-quarter-results  ::  Novavax announces first quarter results\n",
      "/news-releases/news-release-details/novavax-present-stifel-2015-healthcare-conference  ::  Novavax to Present at the Stifel 2015 Healthcare Conference\n",
      "/news-releases/news-release-details/novavax-present-12th-annual-bio-ceo-investor-conference  ::  NOVAVAX to Present at the 12th Annual BIO CEO & Investor Conference\n",
      "/news-releases/news-release-details/maryland-governor-martin-omalley-visit-novavax-celebration-hhs  ::  Maryland Governor Martin O'Malley to Visit Novavax in Celebration of HHS-BARDA Contract Award\n",
      "/news-releases/news-release-details/novavax-announces-release-date-third-quarter-2005-financial  ::  Novavax Announces Release Date of Third Quarter 2005 Financial Results\n",
      "/news-releases/news-release-details/novavax-announces-issuance-key-us-patent-influenza-virus  ::  NOVAVAX Announces Issuance of Key U.S. Patent for Influenza Virus-Like Particle (VLP) Vaccines\n",
      "https://novavax.com/terms-and-conditions  ::  Terms and Conditions\n",
      "/news-releases/news-release-details/novavax-provides-update-influenza-programs  ::  NOVAVAX Provides Update on Influenza Programs\n",
      "/news-releases/news-release-details/novavax-continues-phase-3-trial-rsv-f-vaccine-infants-maternal  ::  Novavax Continues Phase 3 Trial of the RSV F Vaccine for Infants via Maternal Immunization and Provides Update on Phase 1/2 Trial of the NanoFlu™ Vaccine\n",
      "https://novavax.com/contact-us  ::  Contact Us\n",
      "/news-releases/news-release-details/novavax-rsv-f-vaccine-phase-2-clinical-trial-data-women-child  ::  Novavax RSV F Vaccine Phase 2 Clinical Trial Data in Women of Child Bearing Age Published in Vaccine\n",
      "/news-releases/news-release-details/novavax-report-third-quarter-2012-financial-results-november-2  ::  Novavax to Report Third Quarter 2012 Financial Results on November 2, 2012\n",
      "/news-releases/news-release-details/novavax-raises-4000000-equity-offering  ::  Novavax raises $4,000,000 in equity offering\n",
      "/news-releases/news-release-details/novavax-announces-management-promotion  ::  Novavax Announces Management Promotion\n",
      "/news-releases/news-release-details/novavax-prices-public-offering-common-stock  ::  Novavax Prices Public Offering of Common Stock\n",
      "/news-releases/news-release-details/novavax-report-second-quarter-2011-financial-results-august-5  ::  Novavax to Report Second Quarter 2011 Financial Results on August 5, 2011\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "/news-releases/news-release-details/novavax-presents-positive-clinical-results-world-health  ::  NOVAVAX Presents Positive Clinical Results at The World Health Organization Conference, Geneva, Switzerland\n",
      "/news-releases/news-release-details/novavax-reports-positive-results-phase-i-trial-respiratory  ::  NOVAVAX Reports Positive Results From Phase I Trial of Respiratory Syncytial Virus Vaccine Candidate\n",
      "/news-releases/news-release-details/novavax-highlight-rsv-program-data-two-upcoming-meetings  ::  Novavax to Highlight RSV Program Data at Two Upcoming Meetings\n",
      "/news-releases/news-release-details/novavax-provides-updates-global-pathways-licensure-resvaxtm  ::  Novavax Provides Updates on the Global Pathways to Licensure for ResVax™\n",
      "/news-releases/news-release-details/icaac-presentations-highlight-potential-protective-effects  ::  ICAAC Presentations Highlight Potential Protective Effects of Novavax' RSV Vaccine Candidate\n",
      "/news-releases/news-release-details/novavax-announces-management-promotion-0  ::  Novavax Announces Management Promotion\n",
      "None  ::  Contact Us\n",
      "/news-releases/news-release-details/novavax-reports-first-quarter-2017-financial-results  ::  Novavax Reports First Quarter 2017 Financial Results\n",
      "/news-releases/news-release-details/novavax-host-4th-annual-investor-and-analyst-meeting-0  ::  Novavax to Host 4th Annual Investor and Analyst Meeting\n",
      "/news-releases/news-release-details/novavax-announces-initiation-ebola-vaccine-phase-1-clinical  ::  Novavax Announces Initiation of Ebola Vaccine Phase 1 Clinical Trial Supported by Non-Human Primate Challenge Data and Documented Rapid Manufacturing Capabilities\n",
      "/news-releases/news-release-details/novavax-present-wedbush-securities-life-sciences-management  ::  Novavax to Present at the Wedbush Securities Life Sciences Management Access Conference\n",
      "/news-releases/news-release-details/novavax-host-conference-call-discuss-second-quarter-2014  ::  Novavax to Host Conference Call to Discuss Second Quarter 2014 Financial Results on August 6, 2014\n",
      "/news-releases/news-release-details/novavax-nanoflutm-vaccine-demonstrates-improved-immune-responses  ::  Novavax NanoFlu™ Vaccine Demonstrates Improved Immune Responses Compared to Egg-Based, High-Dose Flu Vaccine\n",
      "/news-releases/news-release-details/novavaxs-dr-gale-smith-chair-scientific-congress  ::  Novavax's Dr. Gale Smith to Chair Scientific Congress\n",
      "/news-releases/news-release-details/novavax-participate-citi-2016-global-healthcare-conference  ::  Novavax to Participate in the Citi 2016 Global Healthcare Conference\n",
      "/news-releases/news-release-details/novavax-present-37th-annual-jp-morgan-healthcare-conference  ::  Novavax to Present at the 37th Annual J.P. Morgan Healthcare Conference\n",
      "/news-releases/news-release-details/novavax-present-stephens-nanotechnology-conference  ::  Novavax to present at the Stephens Nanotechnology conference\n",
      "/news-releases/news-release-details/novavax-announces-restructuring-existing-convertible-debt  ::  Novavax Announces Restructuring of Existing Convertible Debt\n",
      "/news-releases/news-release-details/novavax-receives-positive-results-pre-clinical-studies-influenza  ::  Novavax Receives Positive Results From Pre-Clinical Studies of Influenza Vaccines\n",
      "https://novavax.com/novavax-in-the-news  ::  News\n",
      "/news-releases/news-release-details/novavax-reports-first-quarter-2014-financial-results  ::  Novavax Reports First-Quarter 2014 Financial Results\n",
      "/news-releases/news-release-details/novavax-prices-public-offering-common-stock-0  ::  Novavax Prices Public Offering of Common Stock\n",
      "/email-alerts  ::  Join Our E-mail Alert List\n",
      "/news-releases/news-release-details/novavax-nanoflu-achieves-all-primary-endpoints-phase-3-clinical  ::  Novavax’ NanoFlu Achieves All Primary Endpoints In Phase 3 Clinical Trial\n",
      "/news-releases/news-release-details/novavax-announces-management-promotions  ::  Novavax Announces Management Promotions\n",
      "/news-releases/news-release-details/novavax-report-second-quarter-2013-financial-results-august-8  ::  Novavax to Report Second Quarter 2013 Financial Results on August 8, 2013\n",
      "/news-releases/news-release-details/novavax-announces-publication-results-h5n1-influenza-virus  ::  NOVAVAX Announces Publication of Results From H5N1 Influenza Virus-Like Particle Vaccine Phase I/IIa Clinical Trial\n",
      "/news-releases/news-release-details/new-data-novavax-phase-3-preparetm-trial-resvaxtm-presented-0  ::  New Data from Novavax Phase 3 Prepare™ Trial of ResVax™ Presented at 2019 IDSOG Annual Meeting\n",
      "/news-releases/news-release-details/novavax-reports-positive-top-line-results-phase-ii-clinical  ::  Novavax Reports Positive Top-Line Results From Phase II Clinical Trial of RSV Vaccine Candidate in Women of Childbearing Age\n",
      "https://novavax.com/resources  ::  Resources\n",
      "/news-releases/news-release-details/novavax-receives-tech-council-marylands-chairmans-award  ::  Novavax Receives the Tech Council of Maryland’s Chairman’s Award\n",
      "/news-releases/news-release-details/novavax-announces-strategic-alliance-pacificgmp-pandemic  ::  Novavax Announces Strategic Alliance With PacificGMP on Pandemic Influenza Vaccine Production Technologies\n",
      "/news-releases/news-release-details/novavax-appoints-bob-darius-senior-vice-president-quality  ::  Novavax Appoints Bob Darius Senior Vice President, Quality Operations\n",
      "/press-releases?field_nir_news_date_value%5Bmin%5D=2016  ::  2016\n",
      "/news-releases/news-release-details/novavax-announces-conference-call  ::  Novavax Announces Conference Call\n",
      "/news-releases/news-release-details/novavax-participate-hc-wainwright-fireside-chat-series  ::  Novavax to Participate in H.C. Wainwright Fireside Chat Series\n",
      "https://novavax.com/investor-relations-contact  ::  Investor Relations Contact\n",
      "/news-releases/news-release-details/results-phase-iii-clinical-trail-using-estrasorbtm-estradiol  ::  Results of a Phase III Clinical Trail Using Estrasorb(TM) (Estradiol Topical Emulsion) Reported at SGI\n",
      "/news-releases/news-release-details/novavax-rsv-f-vaccine-clinical-trial-data-women-child-bearing  ::  Novavax RSV F Vaccine Clinical Trial Data in Women of Child Bearing Age Published in the Journal of Infectious Disease\n",
      "/news-releases/news-release-details/novavax-announces-positive-top-line-data-rsv-f-vaccine-phase-1  ::  Novavax Announces Positive Top-Line Data From RSV F Vaccine  Phase 1 Clinical Trial in Pediatrics\n",
      "/news-releases/news-release-details/novavax-highlights-positive-results-partners-clinical-trial  ::  Novavax Highlights Positive Results From Partner's Clinical Trial of Vaccine Using Matrix-M(TM)\n",
      "/news-releases/news-release-details/novavax-present-15th-annual-bio-ceo-investor-conference  ::  NOVAVAX to Present at the 15th Annual Bio CEO & Investor Conference\n",
      "/news-releases/news-release-details/novavax-inc-present-suntrust-robinson-humphreys-31st-annual  ::  Novavax, Inc. To Present At Suntrust Robinson Humphrey's 31st Annual Institutional Conference\n",
      "/news-releases/news-release-details/novavax-inc-present-cibc-world-markets-thirteenth-annual-health  ::  Novavax, Inc. to Present at CIBC World Markets Thirteenth Annual Health Care Conference\n",
      "None  ::   \n",
      "/news-releases/news-release-details/novavax-reports-first-quarter-2019-financial-results  ::  Novavax Reports First Quarter 2019 Financial Results\n",
      "/news-releases/news-release-details/novavax-host-conference-call-discuss-third-quarter-financial-0  ::  Novavax to Host Conference Call to Discuss Third Quarter Financial Results on November 9, 2016\n",
      "/news-releases/news-release-details/novavaxs-vlp-influenza-vaccine-named-one-top-100-drugs  ::  Novavax's VLP Influenza Vaccine Named One of Top 100 Drugs in Development Today\n",
      "/news-releases/news-release-details/novavax-names-dr-penny-heaton-chief-medical-officer  ::  Novavax Names Dr. Penny Heaton Chief Medical Officer\n",
      "/news-releases/news-release-details/novavax-reports-first-quarter-2010-financial-results  ::  NOVAVAX Reports First Quarter 2010 Financial Results\n",
      "/news-releases/news-release-details/novavax-updates-clinical-strategy-testosterone-therapy-androsorb  ::  Novavax Updates Clinical Strategy for Testosterone Therapy ANDROSORB  \n",
      "/news-releases/news-release-details/novavax-host-conference-call-discuss-first-quarter-financial-0  ::  Novavax to Host Conference Call to Discuss First Quarter Financial Results on May 4, 2016\n",
      "/news-releases/news-release-details/novavax-cpl-biologicals-and-international-centre-genetic  ::  NOVAVAX, CPL Biologicals and the International Centre for Genetic Engineering and Biotechnology Announce Collaboration to Develop New Malaria Vaccine With Funding From Government of India\n",
      "/news-releases/news-release-details/novavax-initiates-phase-2-safety-and-immunogenicity-trial-rsv-f  ::  Novavax Initiates Phase 2 Safety and Immunogenicity Trial of the RSV F Vaccine in Older Adults\n",
      "/news-releases/news-release-details/novavax-announces-positive-data-phase-2-trial-quadrivalent  ::  Novavax Announces Positive Data From Phase 2 Trial of Quadrivalent Seasonal Influenza VLP\n",
      "/news-releases/news-release-details/novavax-announces-proposed-public-offering-common-stock  ::  Novavax Announces Proposed Public Offering of Common Stock\n",
      "/news-releases/news-release-details/novavax-inc-appoints-gale-e-smith-phd-vice-president-vaccine  ::  Novavax, Inc. Appoints Gale E. Smith, Ph.D. as Vice President, Vaccine Development\n",
      "/news-releases/news-release-details/novavax-announces-presentation-phase-3-data-rsv-maternal  ::  Novavax Announces Presentation of Phase 3 Data from RSV Maternal Immunization Program at 37th Annual Meeting of the European Society for Pediatric Infectious Diseases\n",
      "/news-releases/news-release-details/novavax-present-cowen-and-companys-30th-annual-health-care  ::  NOVAVAX to Present at Cowen and Company's 30th Annual Health Care Conference\n",
      "/news-releases/news-release-details/novavax-present-24th-annual-piper-jaffray-healthcare-conference  ::  Novavax to Present at the 24th Annual Piper Jaffray Healthcare Conference\n",
      "/news-releases/news-release-details/novavax-initiates-global-pivotal-phase-3-trial-rsv-f-vaccine  ::  Novavax Initiates Global Pivotal Phase 3 Trial of the RSV F Vaccine to Protect Infants via Maternal Immunization\n",
      "/news-releases/news-release-details/novavax-board-directors-elects-gary-c-evans-chairman-and  ::  Novavax Board of Directors Elects Gary C. Evans Chairman and Promotes Rahul Singhvi to Senior Vice-President and Chief Operating Officer\n",
      "https://novavax.com/about-us#corporate-governance  ::  Corporate Governance\n",
      "/news-releases/news-release-details/novavax-inc-closes-10-million-convertible-note-financing  ::  Novavax, Inc. Closes $10 Million Convertible Note Financing\n",
      "/news-releases/news-release-details/reminder-novavax-inc-report-third-quarter-2004-results-november  ::  Reminder: Novavax, Inc. to Report Third Quarter 2004 Results on November 3, 2004 and Host November 4 Webcast to Provide Update on Drug Delivery Product Development and Vaccine Pipeline  \n",
      "/news-releases/news-release-details/novavax-inc-announces-recent-management-appointments  ::  Novavax, Inc. Announces Recent Management Appointments\n",
      "/news-releases/news-release-details/novavax-reports-first-quarter-2020-financial-results  ::  Novavax Reports First Quarter 2020 Financial Results\n",
      "/news-releases/news-release-details/novavax-report-2011-fourth-quarter-and-year-end-financial  ::  NOVAVAX to Report 2011 Fourth-Quarter and Year-End Financial Results on March 9, 2012\n",
      "/news-releases/news-release-details/reminder-novavax-host-rsv-f-vaccine-update-conference-call-and  ::  Reminder: Novavax to Host an RSV F Vaccine Update Conference Call and Webcast on July 24, 2017 at 4:30 PM\n",
      "/news-releases/news-release-details/novavax-raise-200-million-private-placement-ra-capital  ::  Novavax to Raise $200 Million from Private Placement with RA Capital\n",
      "/news-releases/news-release-details/novavax-announces-release-date-third-quarter-2006-financial  ::  Novavax Announces Release Date of Third Quarter 2006 Financial Results and Investor Conference Call\n",
      "/news-releases/news-release-details/novavax-inc-announces-second-quarter-2004-results  ::  Novavax, Inc. Announces Second Quarter 2004 Results\n",
      "http://novavax.com/careers  ::  Careers\n",
      "/news-releases/news-release-details/novavax-inc-files-sec-form-8-ka-change-directors-or-principal  ::  NOVAVAX INC Files SEC form 8-K/A, Change in Directors or Principal Officers\n",
      "/news-releases/news-release-details/cdc-evaluate-novavaxs-pandemic-influenza-vaccine-candidate  ::  CDC TO EVALUATE NOVAVAX'S PANDEMIC INFLUENZA VACCINE CANDIDATE\n",
      "/news-releases/news-release-details/novavax-announces-release-date-fourth-quarter-and-2004-year-end  ::  Novavax Announces Release Date of Fourth Quarter and 2004 Year End Financial Results\n",
      "/news-releases/news-release-details/novavax-present-h1n1-vlp-influenza-vaccine-clinical-data-7th  ::  NOVAVAX to Present H1N1 VLP Influenza Vaccine Clinical Data at 7th World Health Organization (WHO) Meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials\n",
      "/news-releases/news-release-details/novavax-host-conference-call-discuss-third-quarter-financial-1  ::  Novavax to Host Conference Call to Discuss Third Quarter Financial Results on November 7, 2018\n",
      "/news-releases/news-release-details/novavax-present-2011-wedbush-life-sciences-conference  ::  Novavax to Present at the 2011 Wedbush Life Sciences Conference\n",
      "/news-releases/news-release-details/novavax-advances-development-novel-covid-19-vaccine  ::  Novavax Advances Development of Novel COVID-19 Vaccine\n",
      "/news-releases/news-release-details/novavax-initiates-phase-1-clinical-trial-rsv-vaccine-candidate  ::  Novavax Initiates Phase 1 Clinical Trial of RSV Vaccine Candidate in Elderly Adults\n",
      "/news-releases/news-release-details/novavax-and-bharat-biotech-announce-strategic-alliance-pandemic  ::  Novavax and Bharat Biotech Announce Strategic Alliance for Pandemic Influenza Vaccine Development\n",
      "/news-releases/news-release-details/novavax-ceo-present-phacilitate-vaccine-forum-barcelona-2010  ::  Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2010\n",
      "/news-releases/news-release-details/novavax-present-28th-annual-piper-jaffray-healthcare-conference  ::  Novavax to Present at the 28th Annual Piper Jaffray Healthcare Conference\n",
      "/news-releases/news-release-details/novavax-inc-present-lehman-brothers-5th-annual-global-healthcare  ::  Novavax, Inc. to Present at Lehman Brothers 5th Annual Global Healthcare Conference\n",
      "/news-releases/news-release-details/novavax-initiates-phase-2-safety-and-immunogenicity-trial  ::  Novavax Initiates Phase 2 Safety and Immunogenicity Trial to Evaluate Annual Re-Dosing of the RSV F Vaccine in Older Adults\n",
      "/news-releases/news-release-details/novavax-reports-fourth-quarter-and-year-end-2014-financial  ::  Novavax Reports Fourth Quarter and Year-End 2014 Financial Results\n",
      "/news-releases/news-release-details/novavax-acquires-new-manufacturing-and-office-facilities  ::  NOVAVAX Acquires New Manufacturing and Office Facilities in Gaithersburg, MD\n",
      "/news-releases/news-release-details/novavax-host-4th-annual-investor-and-analyst-meeting  ::  Novavax to Host 4th Annual Investor and Analyst Meeting\n",
      "/news-releases/news-release-details/novavax-announces-continuation-rsv-vaccine-partnership-path  ::  Novavax Announces Continuation of RSV Vaccine Partnership With PATH\n",
      "/news-releases/news-release-details/novavax-announces-updates-leadership-team  ::  Novavax Announces Updates to Leadership Team\n",
      "/news-releases/news-release-details/novavax-reports-second-quarter-2019-financial-results  ::  Novavax Reports Second Quarter 2019 Financial Results\n",
      "\n",
      "\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "No update from https://investors.biontech.de/press-releases/ \n",
      "\n",
      "False\n",
      "\n",
      "\n",
      "\n",
      "CONNECTION FAILED! - Status Code: 200\n",
      "\n",
      "CONNECTION FAILED! - Status Code: 200\n",
      "\n",
      "No cached webpage found for https://www.pfizer.com/news/press-release/press-releases-archive \n",
      "Initializing page in logs/CACHE-pfizer_com-news-press-release-press-releases-archive.html \n",
      "\n",
      "False\n",
      "\n",
      "\n",
      "No cached webpage found for http://ir.inovio.com/news-releases/default.aspx \n",
      "Initializing page in logs/CACHE-ir_inovio_com-news-releases-default_aspx.html \n",
      "\n",
      "False\n",
      "\n",
      "\n",
      "\n",
      "----------------------------------\n",
      "Skipping Genexine Consortium\n",
      "\n",
      "----------------------------------\n",
      "\n",
      "\n",
      "\n",
      "----------------------------------\n",
      "Skipping Gamaleya Research Institute\n",
      "\n",
      "----------------------------------\n",
      "\n",
      "\n",
      "\n",
      "----------------------------------\n",
      "Skipping Clover Biopharmaceuticals Inc.\n",
      "\n",
      "----------------------------------\n",
      "\n",
      "\n",
      "No cached webpage found for https://www.gsk.com/en-gb/media/press-releases/ \n",
      "Initializing page in logs/CACHE-gsk_com-en-gb-media-press-releases.html \n",
      "\n",
      "False\n",
      "\n",
      "\n",
      "No cached webpage found for http://investors.dynavax.com/press-releases \n",
      "Initializing page in logs/CACHE-investors_dynavax_com-press-releases.html \n",
      "\n",
      "False\n",
      "\n",
      "\n",
      "\n",
      "----------------------------------\n",
      "Skipping Anhui Zhifei Longcom Biopharmaceutical\n",
      "\n",
      "----------------------------------\n",
      "\n",
      "\n",
      "\n",
      "----------------------------------\n",
      "Skipping Curevac\n",
      "\n",
      "----------------------------------\n",
      "\n",
      "\n",
      "\n",
      "----------------------------------\n",
      "Skipping Walvax Biotech.\n",
      "\n",
      "----------------------------------\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "headers = {'User-Agent': 'Mozilla/5.0 (Macintosh; Intel Mac OS X 10_11_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/50.0.2661.102 Safari/537.36'}\n",
    "\n",
    "for ii in range(len(df)): \n",
    "    co, yco, sym, exch, mkcap, size, am, url_home, url_pr = \\\n",
    "    df.iloc[ii].T.values\n",
    "    \n",
    "    if not is_na(url_pr):\n",
    "        try:\n",
    "            r = requests.get(url_pr, headers=headers)\n",
    "        except:\n",
    "            message = f'CONNECTION FAILED! - Status Code: {r.status_code}\\n'\n",
    "            print(f'\\n{message}')\n",
    "            write_log(message, url_pr)\n",
    "            continue\n",
    "            \n",
    "        page = r.text\n",
    "        soup = BeautifulSoup(page, 'html.parser')\n",
    "        body = soup.find('body')\n",
    "        \n",
    "        if not body:\n",
    "            continue\n",
    "            \n",
    "        anchors = get_anchors(body)\n",
    "        \n",
    "        has_update = cache_updated(url_pr, page)\n",
    "        print(has_update)\n",
    "        print('\\n')\n",
    "     \n",
    "        if has_update:\n",
    "            old_anchors = load_cache(url_pr)\n",
    "            # old_anchors = get_anchors(old_body)\n",
    "            # new_anchors = get_anchors(body)\n",
    "            diff_anchors = get_new_diff(anchors, old_anchors)\n",
    "            diff_hrefs, diff_contents = parse_anchors(diff_anchors)\n",
    "            \n",
    "            if len(diff_anchors) > 0:\n",
    "                message = f'New links found: \\n---------------'\n",
    "                write_log(message, url_pr)\n",
    "                \n",
    "                for diff_href, diff_content in zip(diff_hrefs, diff_contents):\n",
    "                    message = f'{diff_href}  ::  {diff_content}'\n",
    "                    write_log(message, url_pr)\n",
    "                    \n",
    "            else:\n",
    "                message = 'Updated detected but no new anchors'\n",
    "                write_log(message, url_pr)\n",
    "                \n",
    "            \n",
    "            store_cache(url_pr, page)\n",
    "            print('\\n\\n')\n",
    "    \n",
    "    else:\n",
    "        print('\\n----------------------------------')\n",
    "        print(f'Skipping {co}')\n",
    "        print('\\n----------------------------------\\n\\n')\n",
    "            "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "https://investors.modernatx.com/news-releases/\n"
     ]
    }
   ],
   "source": [
    "# print(url_pr)\n",
    "#page = requests.get(url_pr, headers=headers)\n",
    "#print(page.text)\n",
    "# print(body)\n",
    "# print(len(body.find_all('a')))\n",
    "# store_cache(url_pr, page)\n",
    "\n",
    "# soup_ = BeautifulSoup(page, 'html.parser')\n",
    "# body_ = soup_.find_all('a')\n",
    "# print(hash(str(body_)))\n",
    "\n",
    "\n",
    "# headers = {'User-Agent': 'Mozilla/5.0 (Macintosh; Intel Mac OS X 10_11_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/50.0.2661.102 Safari/537.36'}\n",
    "# page = requests.get(url_pr, headers = headers)\n",
    "# print(page)\n",
    "# soup = BeautifulSoup(page.text, 'html.parser')\n",
    "# body = soup.find_all('body')\n",
    "# print(body)\n",
    "\n",
    "# print(soup.prettify())\n",
    "# cached = load_cache(url_pr)\n",
    "# print(cached)\n",
    "\n",
    "# url_filename = url_to_filename(url_pr)\n",
    "# filename = f'logs/CACHE-{url_filename}.pkl'\n",
    "# f=open(filename, 'rb')\n",
    "# serial_data = f.read()\n",
    "# data_cached = pickle.loads(serial_data)\n",
    "# cached = pickle.loads(data_cached)\n",
    "# print(data_cached)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.8.2"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
